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Multiparametric MR imaging and MR guided biopsy:
prostate cancer diagnosis and risk-stratification
Caroline M.A. Hoeks
The cover of this thesis depicts Janus, who in Roman religion was a god of transitions,
of beginnings, of endings and of time. Janus is usually depicted with two faces: the past 
and the future.
Prostate cancer has been described as “a disease with the two faces of Janus: having one 
benevolent face of small, indolent tumours, abundant among middle-aged and elderly 
men, it also has the grim face of a great killer. This constitutes a veritable dilemma for 
urologists and oncologists when counseling patients with localised prostate cancer. For 
which patient will Janus show his benevolent smile throughout life and for which patient 
will he turn around and show the ruthless face of painful skeletal metastases and death?” 
(Ola Bratt European Urology, 2006).
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Prostate cancer diagnosis
The first question a man with recently diagnosed prostate cancer is advised to 
ask his urologist is ‘What type of cancer do I have?’ (www.cancer.org), while the 
first questions most patients have is ‘Will I survive?’ And ‘What are my chances 
of losing my sexual potency?’ (www.prostate-cancer.com). All these questions 
pertain to aspects of prostate cancer diagnosis. This thesis focuses on the value 
of multiparametric magnetic resonance (MR) imaging and MR guided biopsy in 
prostate cancer diagnosis and its corresponding risk stratification.
(a)
(b)
Figure 1. Global cancer 5-year prevalence (a) and mortality rates (b) in men in 2008. Prostate 
cancer is depicted in green. Age-standardized rates and proportions per 100.000. Prostate 
cancer prevalence: Bray F, Ren JS, Masuyer E, Ferlay J. Estimates of global cancer prevalence for 
27 sites in the adult population in 2008. Int J Cancer. 2012. Jul 3. doi: 10.1002/ijc.27711. [Epub 
ahead of print]. Prostate cancer mortality: Ferlay J, Shin HR, Bray F, Forman D, Mathers C and 
Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase 
No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. Available from: 
http://globocan.iarc.fr, accessed on 30/10/2012.
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1On a global level, prostate cancer is, after skin cancer, the most frequently diagnosed cancer of men and the fifth most common overall cancer. Nearly seventy-five 
percent of the global prostate cancer incidence is registered in developed countries 
due to the use of prostate specific antigen (PSA) (1). Based on data from the United 
States 1 out of every 6 men will be diagnosed with prostate cancer during his lifetime, 
while 1 out of every 35 men will eventually die from it (2). These numbers imply a high 
disease burden for society due to high prostate cancer prevalence. Also worldwide, 
prostate cancer prevalence highly exceeds mortality rates as depicted in Figure 1.
When considering prostate cancer diagnosis, there are two important questions to 
ask. Firstly “how accurate can prostate cancer be detected using current diagnostic 
tools?” and, secondly “is this prostate cancer diagnosis relevant for this particular 
patient?”.
Prostate cancer is diagnosed based on a combination of PSA blood serum 
concentrations, digital rectal examination and random systematic transrectal 
ultrasound (TRUS) biopsies. Prostate cancer detection using these tools is subject to 
false-positive as well as false-negative results. False positive results are mainly caused 
by the PSA test. The blood-PSA level is often false-positively elevated due to benign 
conditions, such as i.a. prostatitis or benign prostatic hyperplasia, its specificity is 
therefore only 36% (3). However, false-negative PSA results also occur, even in the 
lower PSA ranges (2.0-3.9 ng/mL), where prostate cancer detection rates are 21%, with 
24% of cancers containing a Gleason score equal or higher than 7 (4). False-negative 
results are also caused by prostate cancer undersampling in random systematic 
TRUS biopsies. Around 25% of cancers are missed in the first TRUS biopsy session (5). 
All men
Prostate cancer at autopsy*
Prostate cancer diagnosed
Prostate cancer deaths
Figure 2. Relation between prevalence of prostate cancer at autopsy, clinically diagnosed 
prostate cancer, and prostate cancer deaths as presented by Damber, Lancet 2008.
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When prostate cancer has been diagnosed in a patient, the next question to ask 
is whether this prostate cancer diagnosis is clinically relevant for this particular 
patient. A diagnosis of prostate cancer in a patient, who would have never 
developed clinical symptoms during his life-time is defined as overdiagnosis (6). 
The ‘life-time’ part of this definition is influenced by patient factors like age and 
co-morbidities. Overdiagnosis has negative psychological, socio-economical and 
physical (overtreatment) effects (7).
Another clinical term for overdiagnosed low-risk cancer is clinically insignificant 
cancer. A cancer diagnosed during autopsy, which did not cause symptoms during 
a patient’s life, is called indolent cancer. Figure 2 shows the iceberg of indolent 
cancer in relation to the amount of currently clinically diagnosed prostate cancer. 
This figure illustrates the high prevalence of indolent prostate cancer in men. A 
consequence of the widespread use of PSA testing, is the unwanted diagnosis of 
parts of this “indolent cancer iceberg” (8).
Active surveillance of low-risk prostate cancer
In order to prevent harmful side-effects due to “whole gland” treatment of clinically 
insignificant cancers, studies that investigate whether radical treatment can be 
delayed without a simultaneous decrease of curability, were performed (9,10). These 
studies showed that risks to the patient by delaying surgical intervention (up to a 
median of 26.5 months) were minimal. In a recent study from 2012, 731 men with 
clinically stage T1-T2NxM0 cancer were randomly assigned to radical prostatectomy 
or to observation (11). It was found that radical prostatectomy did not significantly 
reduce all-cause or cancer-specific mortality during a median follow-up of 10 years. 
These results suggest that well-differentiated early-stage tumours do not progress 
rapidly and that patient outcome is unchanged by deferring radical treatment.
These findings have led to the increasing popularity of active surveillance of low-risk 
prostate cancer as an alternative treatment to “whole gland” treatments like radical 
surgery and radiotherapy. Patients are selected upon clinical and histopathological 
criteria for low-risk prostate cancer which may vary across studies. In general, a 
prostate specific antigen ≤10 ng/mL with a density <0.20 ng/mL/mL, a clinical 
stage ≤T1c or T2, a maximum of 2 cancer-positive TRUS biopsy cores with a Gleason 
score ≤3+3 to in some studies 3+4 (12,13). Subsequently, surveillance is performed 
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1by repeated PSA measurements, digital rectal examinations and repeated random systematic TRUS or transperineal saturation biopsies (14,15).
During median follow-up ranging from 24 months to 6.8 years, 20-30% of active 
surveillance patients develop progressive disease which needs radical treatment 
(15-17). Recent results indicate that most “progression” in active surveillance occurs 
within 1-2 years after diagnosis as a result of prostate cancer undersampling 
with subsequent undergrading or “understaging” by initial TRUS biopsy rather 
than the actual progression of clinically insignificant cancer (18). Suboptimal active 
surveillance patient selection due to inaccurate initial prostate cancer risk-
stratification is also expressed in high biochemical recurrence rates after delayed 
treatment in active surveillance (50.4%) (15).
Multiparametric MR imaging of the prostate
During the last three decades, prostate MR imaging techniques have improved 
significantly. In the eighties, prostate anatomy was visualized using 0.5-1.5 tesla MR 
imaging, which was a promising technique thanks to its high spatial resolution and 
soft tissue contrast (19). Current state-of-the-art prostate MR imaging examination 
includes a multiparametric approach, in which combinations of anatomical T2-
weighted MR imaging and functional MR imaging techniques, like diffusion 
weighted MR imaging, dynamic contrast-enhanced MR imaging and proton MR 
spectroscopy, are used. Using multiparametric MR imaging, a higher accuracy for 
detection, localization and staging of prostate cancer is achieved compared to 
T2-weighted anatomic imaging alone. These functional MR imaging techniques 
allow for visualization of cellular and/or molecular changes, and thus identify tissue 
characteristics, which can be used to determine prostate cancer aggressiveness. 
With diffusion-weighted MR imaging tissue cellular density is indirectly shown 
using the restricted motion range of hydrogen protons due to increased cellular 
density in prostate cancer (20). In dynamic contrast-enhanced MR imaging, prostate 
cancer neo-angiogenesis is evaluated by observing the behaviour of intravascular 
administered contrast (21). Finally, proton MR spectroscopy allows for evaluation of 
changes in metabolite concentrations due to prostate cancer (22).
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MR guided prostate biopsies
Multiparametric MR imaging prostate cancer localization accuracies range from 70-
90% (23-25). MR guided biopsy uses accurate multiparametric MR imaging prostate 
cancer localization to direct the biopsy needle towards (the most aggressive part 
of) the prostate cancer. MR guided biopsy has resulted in prostate cancer detection 
rates ranging from 38-59% using far less cores (median 4) compared to random 
systematic TRUS biopsies (8-12 cores) (26-30).
Multiparametric MR imaging and MR guided biopsy 
as diagnostic tests for prostate cancer and prostate 
cancer risk-stratification
Assessment of multiparametric MR imaging and MR guided biopsy as diagnostic 
tests for prostate cancer diagnosis and risk-stratification is performed by their 
evaluation on six levels of evidence in a hierarchical model of Fryback and 
Thornbury, as is depicted in Table 1 (31,32).
Table 1. One-way hierarchical model for diagnostic tests by Fryback and Thornbury as quoted 
by Sardanelli et al. Evidence-based radiology: why and how? Eur. Radiol. 2010; 20(1):1-15. With 
kind permission of Springer Science Business Media.
Level Parameters under investigation
6. Societal impact Benefit–cost and cost-effectiveness analysis from a social perspective
5. Patient outcomes Fraction of patients improved with the test compared with that of those 
improved without the test; difference in morbidity between the patients 
with the test and those without the test; gain in quality-adjusted life 
years (QALYs) obtained by the patients with the test compared with those 
without the test
4. Therapeutic impact Fraction of patients for whom the test is judged useful for treatment 
planning or for whom the treatment planning is modified on the basis of 
the information supplied by the test
3. Diagnostic impact Fraction of patients for whom the test is judged useful for rendering the 
diagnosis or for whom the diagnosis is substantially modified after the test; 
positive and negative likelihood ratios
2. Diagnostic performance Sensitivity, specificity, accuracy, positive predictive value, negative 
predictive value and receiver operator characteristic (ROC) analysis; 
intraobserver, interobserver and interstudy reproducibility
1. Technical performance Grey-scale range; modulation transfer function; sharpness; spatial 
resolution, in-plane (line pairs per mm, pixel size) and through-the-plane 
(slicet hickness), integrated in voxel size; signal-to-noise ratio; contrast 
resolution (contrast-to-noise ratio); time resolution (images/s) etc.
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1Most scientific evidence on MR imaging and MR guided biopsy in prostate cancer diagnosis and risk-stratification has been acquired on levels 2-4.
In the prostate peripheral zone, multiparametric MR imaging, including T2-weighted 
MR imaging, diffusion-weighted MR imaging and dynamic contrast-enhanced MR 
imaging improved sensitivity for prostate cancer detection to 79-81% versus 63% 
for T2-weighted MR imaging (level 2) (25). In the transition zone, multiparametric 
MR imaging improved prostate cancer detection accuracy from 64% to 79% (level 
2) (33). As mentioned, targeting cancer suspicious regions on multiparametric MR 
imaging with MR guided prostate biopsy results in prostate cancer detection rates 
varying from 38-59% (level 1-2) (26-30).
Once prostate cancer is diagnosed, patient risk re-stratification can be performed 
according to the d’Amico risk stratification criteria (PSA level, Gleason score and 
clinical stage) (34).
Prostate cancer staging using T2-weighted MR imaging with and without 
endorectal coil had accuracies of 72%-94% and 83-85% to predict extracapsular 
extension at 3T (level 2) (35-38). For seminal vesicle invasion accuracies were 94% 
and 98% respectively (level 2) (35-38). One study reported a change in surgery in 
44% of patients scheduled for radical prostatectomy by pre-surgery endorectal 
multiparametric MR imaging (39). The MR imaging findings led to preservation 
of the neurovascular bundle in 67% of patients with a high clinical probability of 
extracapsular extension, and prevented neurovascular bundle preservation in 33% 
of patients with a low clinical probability of extracapsular extension (level 4).
Another parameter in risk stratification of prostate cancer patients is determination 
of the prostate cancer Gleason score. With random transrectal ultrasound biopsy 
techniques, the most aggressive part of the prostate cancer is not being targeted, 
and this can lead to under-assessment of the aggressiveness and risk category of a 
particular tumour. A recent study presented upgrading from a Gleason score 6 in 
the initial TRUS biopsy specimen to a Gleason score ≥7 in the radical prostatectomy 
specimen in 201 out of 298 patients (67.4%) (40). Diagnostic accuracy for MR imaging 
techniques to determine prostate cancer Gleason score has mainly been evaluated 
in the prostate peripheral zone. Diagnostic accuracies for apparent diffusion 
coefficient values of diffusion weighted MR imaging, expressed as areas under the 
receiver operating characteristic curve (AUC), ranged from 0.78-0.80 to differentiate 
prostate cancers with Gleason grades ≤3 from cancers with Gleason grades ≥4 in 
the prostate peripheral zone (level 2) (41-43). MR spectroscopy choline-to creatine 
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ratios had an AUC of 0.67 and 0.90 for a similar differentiation in the prostate 
peripheral and transition zone respectively (level 2) (43).
Finally, tumour volume is a prognostic parameter for prostate cancer risk 
stratification (44,45). Although correlation coefficients of MR imaging tumour 
volume to histopathology tumour volume vary from 0.60-0.94, under- or over-
estimation of tumour volume by MR imaging is present in 23% and 47% (level 2) 
(46-48). Inaccuracy of MR imaging tumour volume estimations are mainly caused 
by inaccurate tumour delineation due to false-positive MR imaging conditions like 
prostatitis or benign prostatic hyperplasia and due to irregular tumour shape (49). 
Furthermore, decreased detection of lower tumour Gleason grade components 
may result in underestimation of tumour volume on MR imaging (50).
In conclusion, most of the current evidence on MR imaging and MR guided biopsy 
in prostate cancer diagnosis and risk-stratification was acquired on levels 2-4. The 
studies, which are presented in this thesis were also performed on levels 2-4.
Aims of this thesis
Current prostate cancer epidemiology comprises a high prevalence of clinically 
insignificant prostate cancers, which behave as a chronic disease rather than as a 
lethal cancer. It is a recognized fact that most patients will rather die with than of 
their prostate cancer.
The high prevalence of low-risk prostate cancer requires accurate diagnostic 
tools, which involve accurate patient risk-stratification as part of a prostate cancer 
diagnosis. Random systematic TRUS biopsies undersample (the most aggressive 
part of a) prostate cancer and may therefore fall short in prostate cancer diagnosis 
and/or may result in an incorrect patient risk stratification, once prostate cancer is 
diagnosed.
This thesis aims to evaluate multiparametric MR imaging and MR guided biopsy for 
prostate cancer diagnosis and risk-stratification.
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1Outline of this thesis
In chapter 2 a State-of-the-Art review on multiparametric MR imaging for detection, 
localization, characterization, staging, biopsy guidance and active surveillance of 
prostate cancer is presented. Technical requirements and clinical indications are 
discussed.
Results of a multireader study on the added value of multiparametric MR imaging 
to T2-weighted MR imaging for the detection and localization of transition zone 
prostate cancers are described in chapter 3.
In chapter 4, diffusion-weighted MR imaging apparent diffusion coefficient values 
of the prostate transition zone are related to histopathology outcomes using MR 
guided biopsy specimens as a reference standard.
Chapter 5 describes MR guided biopsy prostate cancer detection rates in a large 
prospective population of patients with an elevated PSA and one or more previous 
negative TRUS biopsy session(s).
Chapter 6 compares radical prostatectomy specimen Gleason grade concordance 
of the highest Gleason grade in MR guided biopsies versus the highest Gleason 
grade in random systematic 10 core TRUS biopsies.
Advantages of MR guided biopsy as discussed in chapters 5 and 6 are clinically 
applied in chapter 7. This chapter describes the value of three-tesla multiparametric 
MR imaging and MR guided biopsy in early risk-re-stratification of prostate cancer 
patients on active surveillance.
Using the design of the latter study, a quantitative parametric analysis was 
performed to evaluate median apparent diffusion coefficient values of diffusion 
weighted MR imaging for differentiation of prostate cancer in patients on active 
surveillance in chapter 8.
In chapter 9 the main findings of this thesis are discussed. Clinical implications and 
recommendations for future research are provided.
CHAPTeR 1
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Abstract
This review presents the current state of the art regarding multiparametric magnetic 
resonance (MR) imaging of prostate cancer. Technical requirements and clinical 
indications for the use of multiparametric MR imaging in detection, localization, 
characterization, staging, biopsy guidance, and active surveillance of prostate 
cancer are discussed. Although reported accuracies of the separate and combined 
multiparametric MR imaging techniques vary for diverse clinical prostate cancer 
indications, multiparametric MR imaging of the prostate has shown promising 
results and may be of additional value in prostate cancer localization and local 
staging. Consensus on which technical approaches (field strengths, sequences, use 
of an endorectal coil) and combination of multiparametric MR imaging techniques 
should be used for specific clinical indications remains a challenge. Because 
guidelines are currently lacking, suggestions for a general minimal protocol 
for multiparametric MR imaging of the prostate based on the literature and the 
authors’ experience are presented. Computer programs that allow evaluation of 
the various components of a multiparametric MR imaging examination in one view 
should be developed. In this way, an integrated interpretation of anatomic and 
functional MR imaging techniques in a multiparametric MR imaging examination 
is possible. Education and experience of specialist radiologists are essential for 
correct interpretation of multiparametric prostate MR imaging findings. Supportive 
techniques, such as computer-aided diagnosis are needed to obtain a fast, cost-
effective, easy, and more reproducible prostate cancer diagnosis out of more and 
more complex multiparametric MR imaging data.
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Introduction
The most recent estimation by the International Agency for Research on Cancer 
revealed 679 000 new cases of and 221 000 deaths related to prostate cancer on a 
global level in 2002 (1). With an estimated 5-year prevalence of 2.3 million patients 
in the world, prostate cancer is a major global health problem.
Prostate cancer diagnostics are initiated on the basis of prostate-specific antigen 
(PSA) measurements and determination of clinical stage by means of digital 
rectal examination. Definite diagnosis is usually obtained by means of transrectal 
ultrasonography (US)-guided systematic random prostate biopsies. Histopathologic 
analysis of these biopsy samples provides the clinician with information on the 
Gleason score. This is a histopathologic score that correlates with prostate cancer 
prognosis (2,3).
Nomograms (4) based on the combination of PSA level, digital rectal examination 
findings, and systematic random biopsy–based Gleason score are used to 
determine the choice of therapy and prognosis. However, each of these tests has its 
shortcomings: Digital rectal examination has a low overall sensitivity (37%) and low 
positive predictive value when lower PSA ranges of 0–3 ng/mL are encountered 
(5). PSA measurement has yielded higher detection rates than has digital rectal 
examination (6), but its specificity is low (36%) owing to false-positive PSA elevation 
under benign circumstances, such as inflammation or benign prostatic hyperplasia 
(BPH) (7). When digital rectal examination results are positive or when the PSA level 
is elevated, systematic random sextant biopsy with acquisition of a minimum of 
four extra cores from lateral peripheral zones or from a region that is suspicious for 
cancer is generally recommended to be performed initially (8). Systematic random 
biopsy is prone to undersampling (35% cancers missed on first biopsy (9)] and 
underestimation Gleason grade in 46% of cases (10). These inaccurate tools often 
lead to incorrect diagnoses, inaccurate risk assessments, and less optimal therapy 
choices. Because these diagnostic methods all have their limitations, there is a need 
for improved prostate cancer diagnosis with improved detection, localization, and 
sampling.
In the mid 1980s, the first prostate magnetic resonance (MR) imaging examinations 
were performed. Since then, MR imaging has evolved from a promising technique 
into a mature prostate imaging modality (11,12). MR imaging can provide functional 
tissue information along with anatomic information. To increase the accuracy, 
anatomic T2-weighted MR imaging and functional MR imaging techniques such as 
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dynamic contrast agent–enhanced MR imaging, diffusion-weighted (DW) imaging, 
and hydrogen 1 MR spectroscopic imaging should be combined in an integrated 
multiparametric MR imaging examination. These multiparametric MR techniques 
will contribute to prostate cancer diagnostics, although results for detection, 
localization, and local staging of prostate cancer vary greatly among the studies 
performed.
This article will describe the fundamentals of multiparametric MR imaging of 
prostate cancer. We will provide an overview of the individual MR imaging 
techniques with their combined merits and limitations for clinical challenges such 
as detection, localization, local staging, and active surveillance of prostate cancer.
MR imaging techniques
Anatomic T2-weighted MR Imaging
T2-weighted MR imaging is the workhorse of prostate MR imaging. T2-weighted 
MR images have high spatial resolution and, thus, can clearly differentiate the 
normal intermediate- to high-signal-intensity peripheral zone from the low-signal-
intensity central and transition zones in young male subjects (13). In the aging man, 
owing to variable extension of the transition zone due to BPH, the size and signal 
intensity of the prostate transition zone may vary. BPH itself is a round, well-defined, 
inhomogeneous area with (variable) intermediate signal intensity and a low signal-
intensity rim that surrounds the expanded transition zone (12). Because of transition 
zone expansion, the remainder of the compressed central zone is often indefinable 
on MR images.
High-spatial-resolution T2-weighted rapid acquisition with refocused echo 
sequences with a small field of view, performed with endorectal and/or external 
body phased-array coils, are generally used to depict prostate anatomy. T1-
weighted contrast in the prostate is very low. Therefore, it is not possible to 
appreciate the different anatomic zones on T1-weighted images. On T2-weighted 
images, prostate cancer can appear as an area of low signal intensity within the 
high signal intensity of a normal peripheral zone. An example of this finding is 
shown In Figure 1a. The degree of signal intensity decrease may differ with the 
Gleason score: Higher Gleason score components 4 or 5 have shown lower signal 
intensities than do lower Gleason score components 2 and 3 (14). The density and 
the growth pattern of the cancer may also influence T2- weighted signal intensity. 
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Cancers in the peripheral zone, which grow thinly scattered into the surrounding 
normal tissue, have shown no significant difference in quantitative T2 values with 
normal peripheral zone. On the other hand, densely growing cancers do show 
lower quantitative T2 values (15).
A limitation of T2-weighted imaging is that focal areas of low signal intensity in 
the peripheral zone do not always represent cancer. Benign abnormalities such 
as chronic prostatitis, atrophy, scars, postirradiation or hormonal treatment effects, 
hyperplasia, and postbiopsy hemorrhage may mimic tumor tissue (16). Low-signal-
intensity lesions with a wedge shape and a diffuse extension without mass may be 
reliable signs of benignity (17). Hemorrhage may be differentiated on the basis of 
its high signal intensity on T1-weighted images. When methemoglobin is present 
in hemorrhagic regions, its paramagnetic characteristics result in high signal 
intensity on T1-weighted MR images. Preferably, MR imaging of patients suspected 
of having prostate cancer should be avoided for 8 weeks after prostate biopsy to 
allow reduction of artifacts due to postbiopsy hemorrhage (18).
  
(a) (b)
Figure 1. Axial T2-weighted turbo spin-echo MR images (repetition time msec/echo time msec, 
4260/99; flip angle 120°) of prostate cancer. (a) At level of midprostate to apex, a low-signal-
intensity lesion is present on the right side of the prostate, within the high signal intensity of 
the peripheral zone (outline), with signs of minimal capsular invasion (arrow). At prostatectomy, 
this lesion, which was suspicious for prostate cancer, corresponded to stage T3a (extracapsular 
extension of 5 mm), Gleason score 7 (4+3) prostate cancer. (b) At midprostate level, a 
homogeneous low signal intensity area in the ventral transition zone is seen (outline), with loss 
of visibility of healthy BPH structures (“charcoal sign”). Invasion of anterior fibromuscular stroma 
at the ventral prostate can be seen (arrows). This lesion was suspicious for transition zone cancer. 
At prostatectomy, stage T2c, Gleason score 6 (2+4) prostate cancer was found.
Owing to the presence of BPH, cancer in central and transition zones is more 
difficult to discern. BPH may have signal intensity similar to that of prostate cancer 
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on T2-weighted images. However, it has been reported that features such as 
homogeneously low T2-weighted signal intensity (Fig 1b), ill-defined irregular 
edges of the suspicious lesion, invasion into the urethra or the anterior fibromuscular 
stroma (Fig 1b), and lenticular shape are helpful signs for detection of malignancy 
in the transition zone (19).
Combined T1-weighted and T2-weighted MR imaging should be used for all 
clinical prostate cancer indications to evaluate anatomy and possible postbiopsy 
hematoma artifacts.
Dynamic Contrast-enhanced MR Imaging
Angiogenesis in prostate cancer tissue is induced by secretion of vascular growth 
factors in reaction to the presence of local hypoxia or lack of nutrients ( 20 ). 
Resultant changes in vascular characteristics can be studied well with dynamic 
contrast-enhanced MR imaging (Fig 2). This technique exploits the dynamic uptake 
and rapid washout of a gadolinium chelate contrast agent to show the typical 
pharmacokinetics of cancerous tissue. Because the prostate as a whole is highly 
vascularized, a simple comparison of pre- and postgadolinium images is usually 
insufficient to discern prostate cancer (21,22).
A fast and direct method to characterize prostatic vascular pharmacokinetic 
features is high-temporal-resolution dynamic contrast-enhanced MR imaging. 
Dynamic contrast-enhanced MR imaging consists of a series of fast T1-weighted 
sequences covering the entire prostate before and after rapid injection (2–4 mL/
sec) of a bolus of a low-molecular-weight gadolinium chelate such as gadoterate 
meglumine or gadopentetate dimeglumine (concentration, 0.1–0.2 mmol/kg) 
(23,24). In addition to the most frequently used fast sequences, which have a high 
temporal resolution (a short period of 1–4 seconds between measurements), slow 
sequences (temporal resolution, 30 seconds with higher spatial resolution) have 
also been used. Depending on the area of anatomic coverage, the acquisition 
times, potential susceptibility artifacts, and desired T1 sensitivity, a choice for a 
faster or slower sequence must be made (25). On one hand, fast sequences may 
improve tissue characterization because the prostate enhances quickly with T1-
weighted dynamic contrast-enhanced MR sequences. With fast sequences, 
accurate quantification of different pharmacokinetic enhancement parameters is 
possible. On the other hand, fast T1-weighted sequences have trade-offs, including 
reduced spatial resolution and/or anatomic coverage. Optimal spatial and temporal 
resolutions based on clinical indications remain subjects of future research.
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(a) (b)
(c)
Figure 2. Dynamic contrast-enhanced MR imaging of prostate cancer in 65-year-old man with 
PSA level of 8.3 ng/mL, clinical stage T2c cancer, and Gleason score of 7 (3+4) in 80% of the 
volume of systematic random biopsy specimens. (This patient is also in Fig 7). (a, b) Axial dynamic 
contrast-enhanced T2-weighted MR images (38/1.35; flip angle, 14°) obtained at midprostate 
level, with superimposed Ktrans (volume transfer constant) parametric map on a and washout 
parametric map on b.
(a) Right peripheral zone (outline) shows contrast enhancement (red) that is suspicious for 
prostate cancer.
(b) In addition to the transition zone (arrow), right peripheral zone (outline) shows increased 
washout.
(c) Relative gadolinium concentration (y-axis)-time (x-axis) curve of tumor shows a type 3 curve 
with fast increase, fast time to peak, and washout, which are suspicious for cancer.
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Prior to post-processing of dynamic contrast-enhanced MR imaging data, 
estimation of the arterial input function can be performed. In the Tofts model, the 
arterial input function can be calculated with a formula that uses values of plasma 
concentration after administration of a bolus in healthy subjects (26). In addition to 
the Tofts model, automatic derivation of the arterial input function from reference 
tissues can be performed (27). The latter method has the advantages that it needs 
only T1-weighted MR images and that the arterial input function is estimated 
accurately in a large reference tissue volume.
Assessment of signal intensity changes on T1-weighted dynamic contrast-
enhanced MR images in order to estimate contrast agent uptake in vivo can be 
performed qualitatively, semi-quantitatively or quantitatively. Qualitative analysis 
of signal intensity changes can be achieved by assessing the shape of the signal 
intensity–time curve. Quantification of signal intensity changes, which are generally 
represented by gadolinium concentration– time curves, requires semi-quantitative 
assessment of contrast agent concentration or calculation of different quantitative 
physiologic parameters by using pharmacokinetic compartmental modelling. 
Washout is a semi-quantitative parameter that captures the curve pattern after the 
first peak of enhancement. Other semi-quantitative parameters are (a) integral area 
under the gadolinium-concentration–time curves, (b) wash-in gradient (upward 
slope of first pass), maximum signal intensity, (c) time-to-peak enhancement, and 
(d) start of enhancement. Semi-quantitative parameters have the advantages of 
being fast, relatively simple to calculate, and of being available on current MR 
systems. They may, however, be influenced by MR unit settings (22).
In quantitative pharmacokinetic analysis, the behavior of a volume of contrast 
agent in the intravascular space versus that in the extravascular extracellular space 
is estimated in volume units for a certain period of time. The return of the contrast 
agent to the extracellular extravascular space can be limited by flow, by permeability 
of the endothelium, or by a combination of flow and endothelium permeability. 
The flow-limited Kety model (28), the permeability-limited Tofts model (29) and 
mixed models (30,31) are applicable under these respective circumstances. Tofts et 
al (32) suggested the following standard pharmacokinetic quantitative parameters: 
Ve which represents the volume fraction of extravascular extracellular leakage 
space and k
ep
 which represents the exchange rate constant of contrast agent 
between the extracellular extravascular leakage space and the blood plasma (in 
units per minute). V
e
 and k
ep
 are related with the following equation in the Tofts 
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model: k
ep
 = Ktrans / V
e
. When flow is limited, the volume transfer constant Ktrans 
equals the blood plasma flow per unit volume of tissue. Under permeability-
limited, conditions, Ktrans equals the permeability surface area product per unit 
volume of tissue, which is the case in prostate cancer. Prostate cancer tends to 
enhance earlier, faster, and to a greater extent and shows earlier contrast agent 
washout, as compared with healthy prostate tissue (23,33). This characteristic makes 
dynamic contrast-enhanced MR imaging a sensitive technique for prostate cancer 
localization. Estimated quantitative parameters can be presented to the radiologist 
as color-overlay maps on anatomic T2-weighted MR images to relate dynamic 
contrast-enhanced MR images to prostate anatomy. Prostate cancer diagnostics for 
clinical indications such as local staging can then be improved by better prostate 
cancer localization characteristics obtained with dynamic contrast-enhanced MR 
imaging. This advantage will be addressed in the Clinical Questions section.
One of the limitations of dynamic contrast-enhanced MR imaging is related to 
discrimination of cancer from prostatitis in the peripheral zone and from highly 
vascularized BPH nodules in the transition zone (34). Other shortcomings are a 
limited use of standardized approaches for calibration and analysis, the shortage of 
uniform commercially available tools for pharmacokinetic analysis, and the lack of 
consensus in acquisition protocols.
Correlation of dynamic contrast-enhanced MR images with prognostic histopathologic 
markers of prostate cancer angiogenesis has rarely been performed. This remains 
an important area for future research (35).
Dynamic contrast-enhanced MR imaging is an accurate functional MR imaging 
technique that can be used for all clinical indications discussed in this article. In a 
multiparametric MR imaging examination, the high sensitivity of dynamic contrast-
enhanced MR may be used for initial evaluation of potential tumor locations. 
Other functional MR imaging techniques may subsequently be added to increase 
specificity for prostate cancer localization, because sensitivity of dynamic contrast-
enhanced MR imaging is low. Little standardization exists in acquisition protocols 
and analytic models for dynamic contrast-enhanced MR imaging.
DW Imaging
In DW imaging, proton diffusion properties in water are used to produce image 
contrast. Images that reflect proton diffusion are acquired by applying motion 
encoding gradients, which cause phase shifts in moving protons, depending on 
the direction and quantity of their movement (36). The attenuation of the MR signal 
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in DW imaging is expressed with the Stejskal-Tanner equation (36). The b value and 
the apparent diffusion coefficient (ADC) are components in this equation. While the 
b value expresses the amount of diffusion weighting, ADC reflects the movement 
of the water molecules within the interpulse-time. Because ADC quantifies the flow 
as well as the distance a water molecule has moved, it represents both capillary 
perfusion and diffusion characteristics (37). Fitting the Stejskal-Tanner equation for 
every pixel on two or more DW images acquired with different b values results in 
an ADC map. For prostate cancer, DW imaging b values between 500 and 800 sec/
mm2 are typically used (38). b Values of 1000 and even 2000 sec/mm2 may increase 
the accuracy of prostate cancer detection (39). Especially within the transition zone, 
high b values may help improve differentiation of BPH from prostate cancer (40).
Healthy prostate tissue in the peripheral zone, which is rich in tubular structures, 
allows extensive diffusion of water molecules within the gland tubules. Consequently, 
ADCs in healthy peripheral zone tissues can be high. Prostate cancer tissue destroys 
the normal glandular structure of the prostate and replaces ducts. It also has a higher 
cellular density than does healthy prostate peripheral zone tissue (38). On ADC maps, 
therefore, prostate cancer often shows lower ADCs in comparison to surrounding 
healthy peripheral zone prostate tissue (41). Examples of this are presented in Figure 3. 
Recently, 3 T DW imaging ADCs were shown to correlate significantly with the 
cellular density of prostate cancer in radical prostatectomy specimens (42).
Because the acquired ADC depend on the specific pulse sequence parameters 
(especially the b values), the specific MR systems used, and the magnetic field 
strength, the ADCs of healthy and cancerous tissue have varied among reported 
studies. Furthermore, there is an overlap in the ADCs of healthy tissue and those of 
prostate cancer, within and between subjects, which limits the determination of a 
single threshold ADC for malignancy (4).
Mean ADCs for prostate cancer versus those for healthy prostate tissue obtained at 
different field strengths, with or without the use of an endorectal coil in different 
anatomic regions are shown in Table 1. Owing to variation in ADCs of benign 
prostate tissue in the peripheral and transition zones, the area under the receiver 
operating characteristic curve (AUC) for differentiation of prostate cancer from 
benign tissue can vary by anatomic location within the prostate gland and are 
found to be lower in the prostatic base (AUC of 0.725 in prostate base vs 0.952 and 
0.906 for overall peripheral and transition zones, respectively) (44). The reported 
differences in detection accuracies with DW imaging might be explained by the 
different tissue composition in different anatomic zones of the prostate. It has been 
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hypothesized that a higher degree of proton motion in the extracellular water 
compartment occurs as opposed to that in intracellular water, where movement 
is restricted by cell membranes or other intracellular structures (38). As a result of 
variation in glandular tissue within a healthy peripheral zone to muscular or fibrous 
tissue within the transition zone, the ratio of intracellular versus extracellular water 
also differs. This variation might also explain the variability of ADCs in healthy 
prostate tissue that have been reported. Relative ADC thresholds calibrated to an 
individual gray-scale value may be a way to overcome intra- and inter-individual 
variation and overlap of ADCs of cancer and healthy prostate tissue (45).
DW imaging is a fast, simple, and readily available MR imaging technique for 
prostate cancer. Nevertheless, DW imaging of the prostate has the limitation of low 
in-plane spatial resolution, even at 3 T. Consequently, DW imaging is not a preferred 
technique for prostate cancer staging. However, DW imaging does reflect cellular 
density, which makes the technique potentially suitable to determine tumor 
aggressiveness. DW imaging, being a technique for measuring proton motion, is 
very sensitive to motion artifacts. Single-shot echo-planar MR imaging is used to 
decrease motion artifacts by acquiring images in less than 1 second. Because the 
phase-encoding bandwidth per pixel is very small, echo-planar imaging is very 
sensitive to magnetic field inhomogeneities. As a result, artifacts occur in areas with 
large variations in magnetic susceptibility, such as in tissue-air interfaces (air in the 
rectum or endorectal coil) or in chemical shift in areas with water-fat interfaces. 
Parallel imaging and short-imaging-time protocols are used to overcome these off-
resonance artifacts (46).
Correlation of DW imaging results and histopathologic findings as well as to 
prognostic histologic prostate cancer markers such hypoxia-inducible factors, 
should be another area for future research. Of all functional MR imaging techniques 
DW imaging is the most practical and simple in its use. Within a multiparametric MR 
imaging examination DW imaging may be used for all clinical indications discussed 
in this article. DW imaging has the disadavantages of being susceptible to motion 
and to magnetic field inhomogeneities.
Proton MR Spectroscopic Imaging
In MR spectroscopic imaging, spectral profiles are measured in two or three spatial 
dimensions. These spectral profiles reflect resonance frequencies that are unique 
for protons in different metabolites present at the sampled location. The specific 
resonance frequencies or chemical shifts are given relative to a reference frequency 
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in parts per million (ppm). In human prostate examinations, MR spectroscopic 
imaging is usually performed in a volume that covers the whole prostate, which is 
subdivided up into a three-dimensional grid of multiple voxels. With the introduction 
of the endorectal coil for prostate MR examinations, it became possible to obtain 
in vivo MR spectroscopic imaging spectra of small voxels in the prostate (less than 
1 cm3) with sufficient signal to noise (47–49). The dominant peaks observed in these 
spectra are from protons in citrate (approximately 2.60 ppm), creatine (3.04 ppm) 
and choline compounds (approximately 3.20 ppm).
  
(a) (b)
Figure 3. DW imaging of prostate cancer. Axial ADC maps (2400/81; b = 0, 50, 500 and 800 sec/
mm2) obtained at midprostate level in same patients as in Figure 1a (a) and 1b (b).
(a) Lesion with low DC (mean ADC = 0.8×10-3 mm2/sec), is suspicious for cancer in right peripheral 
zone (arrows). This indicates intermediate to high cancer aggressiveness. At prostatectomy, the 
lesion was determined to be stage T3a, Gleason score 7 (4+3) prostate cancer.
(b) Comma-shaped area with low ADC (mean ADC = 0.6×10-3 mm2/sec) is seen in ventral transition 
zone (arrows). This indicates intermediate to high cancer aggressiveness. At prostatectomy, 
lesion was determined to be stage T2c, Gleason score 6 (2+4) prostate cancer.
Polyamine signals (mostly from spermine) also may be observed (approximately 
3.15 ppm) at various relative intensities, depending on the acquisition conditions. 
Compared with healthy peripheral tissue or BPH tissue, citrate signals are reduced 
and those of choline compounds are often increased in prostate cancer tissue 
(Fig 4) (50). Citrate is produced in epithelial cells as an intermediate product in the 
Krebs cycle due to aconitase inhibition. It then accumulates in the luminal space 
of the prostate. The lower citrate peak in cancer tissue may thus be caused by 
altered metabolism, as well as by a reduction of luminal space, which commonly 
occur in prostate cancer. Choline compounds are involved in the biosynthesis and 
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degradation of phospholipids, which are required for the build-up and maintenance 
of cell membranes. An increased cell-turnover in prostate cancer results in an 
increased concentration of free choline-containing molecules within the cytosol 
and the prostate interstitial tissue.
Table 1. Mean ADCs for Prostate Zones at Different Field Strengths with or without an 
Endorectal Coil
Magnetic Field Strength
(T)
Peripheral zone ADC Transition zone ADC
Healthy Tissue
(x 10-3 mm2/sec)
Prostate cancer
(x 10-3 mm2/sec)
Healthy Tissue
(x 10-3 mm2/sec)
Prostate cancer
(x 10-3 mm2/sec)
1.5
          without ERC 1.72-1,85
(19,133,135)
0.96-1,02 1.34-1,85 0.93-0,96
           with ERC 1.51-1 69
(136,137)
1.39
(136)
1.31
(137)
-
3.0 1.86-2.61
(39,138, 139)
1.19-1138
(39,138, 139)
1.77
(39,138,139)
1.21
(39)
Numbers in parentheses are reference numbers. ERC = endorectal coil.
Because differentiation of choline peaks from creatine peaks on spectra obtained 
at common clinical field strengths is often hampered by their bandwidths and 
by weaker signals from polyamines between them, the choline plus creatine–to-
citrate ratio is mostly used as a metabolic biomarker for prostate cancer. An example 
of this is presented in Figure 4. In the analysis of patient data, it should be taken 
into account that different anatomic zones of the healthy prostate have different 
amplitudes for citrate, creatine, and choline, which are reflected in different choline 
plus creatine–to-citrate ratios. High citrate concentrations are found in the glandular 
tissues of the prostate such as the peripheral zone, which contains epithelial cells 
and secretory ducts. Therefore, citrate concentrations are highest in the peripheral 
zone and lower in the central zone. In the transition zone, the citrate concentration 
may be higher in case of glandular proliferation and lower in the case of stromal 
proliferation (51). Furthermore, because of the sensitivity profile of the surface coil, 
the spectral signal intensity will drop the farther away the tissue is from the ERC. 
Since the prostate is relatively small and embedded in adipose tissue, much effort 
has been put into suppressing spectral contamination, not only of the high water 
signal, but also of strong lipid signals. Therefore, radiofrequency pulse schemes that 
selectively invert and dephase water and lipid signals have been developed (52,53). 
Frequency selective suppression methods, such as Mescher-Garwood (or MEGA) 
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pulses (52) or later band selective inversion with gradient dephasing (or BASING) 
are generally applicable because no high-performance gradients are necessary. 
Spectral-spatial pulses have the advantage of increased bandwidth, which results 
in decreased chemical shift–dependent localization errors. Three-dimensional MR 
spectroscopic imaging sequences are currently preferred over two-dimensional 
sequences because of the possibility of complete coverage of the entire prostate 
gland (47,54). Three-dimensional acquisitions can be performed in approximately 
10–15 minutes with a resolution as low as 0.4 cm3 with sufficient signal-to-noise 
ratio at 1.5 T (54).
MR spectroscopic imaging has several limitations. Spectral quality depends 
on magnetic field homogeneity, which must be optimized for each patient 
by shimming. Considerable local magnetic field distortions may occur due to 
hemorrhage, which is why the examination should be performed with sufficient 
delay from the time of biopsy. The clinical performance of MR spectroscopic 
imaging of the prostate can be improved by optimizing field shimming or by 
means of correction procedures, in addition to better signal-to-noise ratio and 
chemical shift dispersion, by using stronger magnetic fields (55). Currently, the 
interpretation of MR spectroscopic imaging results requires special expertise 
and is time consuming. Automated measurement procedures, rapid display of 
examination results, and proper training of clinical users are important to transform 
MR spectroscopic imaging into a practical and widespread clinical tool. To this day, 
these requirements are generally not met.
MR spectroscopic imaging is an accurate technique that may be used for all clinical 
indications mentioned in this article. MR spectroscopic imaging needs, however, 
relatively more time and expertise than do other functional MR imaging techniques, 
which limits its clinical applicability.
Because the functional MR imaging techniques we have discussed all have their 
strengths and shortcomings, they are combined in a multiparametric MR imaging 
prostate examination to increase accuracy. A multiparametric MR imaging prostate 
examination consists of T1- and T2-weighted imaging combined with one or more 
functional MR imaging techniques.
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Combined Multiparametric MR Imaging
Within the variety of possible MR imaging protocols and combinations of different 
techniques, consensus guidelines are needed to increase accuracy and unity 
in the field (56). Because formal practice guidelines for multiparametric prostate 
imaging are currently unavailable, the following suggestions for possible prostate 
multiparametric MR imaging protocols for different clinical indications can be 
recommended. Patients with a clinical indication of prostate cancer detection, who 
often have previously undergone one or more systematic random biopsies with 
negative results, may have a high a priori risk for transition zone cancer (57). In these 
patients, it is essential not only to use techniques such as T2-weighted and dynamic 
contrast-enhanced MR imaging, which may yield false-positive or false-negative 
results within the transition zone, but also DW imaging (with a high b value), which 
may be a valuable technique in difficult detection cases. In patients referred for 
pre-treatment staging, it is important to use an endorectal coil in combination with 
anatomic T2-weighted MR imaging. Because accurate localization may improve
accurate staging it may be important to add at least one multiparametric MR 
imaging technique (Fig 5). Patients with a clinical indication for active surveillance 
or focal therapy need evaluation of the stage of the cancer and its aggressiveness. 
Preferably, an endorectal coil could be used in combination with more than one 
multiparametric technique that yields findings related to prostate cancer Gleason 
score (DW imaging and/or MR spectroscopic imaging) (Fig 6).
The optimal strength of multiparametric MR imaging is achieved by combining 
the information obtained with the various techniques. Computer programs, which 
allow evaluation of two or more multiparametric images in one view, need to be 
developed for the integrated interpretation of anatomic and functional findings. An 
example of how this could be accomplished is presented in Figure 7. Development 
of supportive techniques like computer aided diagnosis (58–60) is needed to 
achieve fast and reproducible diagnostics from large quantities of complex 
data. Furthermore, the education, experience, and dedication of radiologists are 
essential for correct interpretation of findings from multiparametric MR imaging of 
the prostate (61). Minimal requirements for a multiparametric MR imaging protocol 
include a combination of T1- and T2-weighted MR imaging with DW and dynamic 
contrast-enhanced MR imaging. For detection and localization indications, the use 
of a phased-array coil is sufficient; for staging indications, combination with an 
endorectal coil may be preferred.
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(b) (c)
Figure 4. MR spectroscopic imaging in a 70-year-old man (same as in Fig 11) with a PSA level 
of 12 ng/mL and well-differentiated prostate cancer. (a) Axial T2-weighted turbo spin-echo 
MR image (4260/99; flip angle, 120°) shows stage T3a prostate cancer. Radical prostatectomy 
revealed a solitary Gleason score 7 (3+4) adenocarcinoma with extraprostatic extension. Red 
voxel has been placed in low-signal-intensity lesion in left peripheral zone, which is suspicious 
for cancer; blue voxel has been placed in benign-appearing region in right peripheral zone. 
(b) MR spectrum (750/145; flip angle, 90°) from red voxel shows choline peak that is increased 
relative to citrate peak. The choline plus creatine–to-citrate ratio, calculated from the integrals 
of the spectral peaks from choline, creatine, and citrate, is 0.80, which is suspicious for prostate 
cancer. (c) MR spectrum (750/145; flip angle, 90°) from blue voxel demonstrates low choline peak 
and high citrate peak, consistent with benign peripheral zone tissue. The choline plus creatine–
to-citrate ratio is 0.32.
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Figure 5. Multiparametric MR imaging for prostate cancer localization in the transition zone in 
a 67-year old man with a PSA level of 17.6 ng/mL and Gleason score 7 prostate cancer shows 
the added value of multiparametric MR imaging for localization. While T2-weighted images 
yielded indeterminate findings for localization, and dynamic contrast-enhanced images yielded 
false-positive findings in another area, DW images were used to correctly localize this high-
grade prostate cancer. (a) Axial T2-weighted turbo spin-echo image (4260/99; flip angle, 120°) 
obtained at the level of the base of the prostate shows area of lower signal in the right ventral 
prostate (outline), which is suspicious for prostate cancer. Bulging is present as a sign of stage T3 
disease (arrows). (b) Axial MR image with superimposed Ktrans parametric map (38/1.35; flip angle, 
14°) at same level as a. Mediodorsal part of the prostate shows early enhancement (outline) 
but no increased Ktrans at low-signal-intensity area in a. (c) On axial ADC map (2400/81; b = 0, 50, 
500, 800 sec/mm2) obtained at same level as a, the right ventral transition zone (outline) shows 
restriction (mean ADC = 606×10-6 mm2/sec), which suggests highly aggressive cancer. (d) Axial 
whole-mount histopathologic slice from level corresponding to a–c shows stage T3b (Gleason 
score, 9 [4+5]) prostate cancer in right ventral prostate (outline).
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Figure 6. Multiparametric MR imaging in a 69-year-old man undergoing active surveillance of 
Gleason score 6 (3+3) prostate cancer, found in 5% of the volume of one (left-sided) of nine 
systematic random biopsy core specimens. The patient had a PSA level of 6.7 ng/mL, PSA 
density of 0.9 ng/mL/mL, and clinical stage T2 disease. Multiparametric MR imaging findings 
obtained with an endorectal coil were suspect for stage T3a cancer in the left peripheral zone at 
the midprostate level. DW imaging findings indicated tumor intermediate to highly aggressive 
tumor at the same location. Subsequent MR-guided biopsy of this patient is depicted in Figure 
8. (a) Axial T2-weighted turbo spin-echo MR image obtained with endorectal coil (4260/99; flip 
angle, 120°) at midprostate level shows small area of lower signal intensity in left peripheral zone 
(outline) with signs of extracapsular extension (arrows). (b) Axial MR image with superimposed 
Ktrans parametric map (38/1.35; flip angle, 14°; same level as a and b) at the same level as a. Early 
enhancement occurs in multiple areas. The region suspicious for tumor is also enhanced 
(outline). (c) ADC map (2400/81; b = 800 sec/mm2) shows restriction at the suspicious region in 
the left peripheral zone (outlined), indicating intermediate to highly aggressive tumor. Analysis 
of MR-guided biopsy specimen from the suspicious lesion resulted in Gleason score of 8 (3+5) in 
80% of the specimen volume, with extension into periprostatic fat (stage T3a).
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Figure 7. 
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Figure 7. Multiparametric MR imaging of the prostate (same patient as in Fig 2: 65-year-old man, 
PSA level of 8.3 ng/mL, clinical stage T2c, Gleason score of 7 [3+4]) in screenshot generated 
by a computer-program, which can be used for image interpretation in multiparametric MR 
imaging. In addition to related views of multiplanar multiparametric images (A–E), quantitative 
information (F) is also displayed. A–E show tumor with bulging, suspicious for minimal stage 
T3A disease, in right peripheral zone at level of midprostate to apex (arrow). A, Axial Ktrans map 
from dynamic contrast-enhanced MR imaging projected over T2-weighted image (see Fig 2 for 
parameters). B, Sagittal T2-weighted image (4290/98; flip angle, 120°) with color overlay showing 
washout (from dynamic contrast-enhanced MR imaging). C, Axial ADC map (2900/81; flip angle, 
90°). D, Axial DW trace image (b = 800 sec/mm2 ; 2900/81; flip angle, 90°). E, Axial T2-weighted 
image. F, Relative gadolinium concentration–time curve (left) and MR spectrum (right) from 
chosen point of interest in tumor (+). In MR spectrum, choline (chol) and citrate (cit) peaks can 
be evaluated. The low-signal-intensity lesion on E shows increased Ktrans (on A), restriction on C, 
high signal intensity on D, gadolinium concentration–time curve type 3 and high choline peak 
on F. On a five-point scale, this can be scored 5/5 on T2-w, dynamic contrast-enhanced, DW, and 
MR spectroscopic images, for total score of 20/20, indicating intermediate to highly aggressive 
tumor.
MR Imaging–guided Biopsy
As mentioned earlier, systematic random biopsy is prone to sampling error, which 
often results in inaccurate prostate cancer detection and Gleason score grading 
(10). MR-guided prostate biopsy can potentially improve prostate cancer detection, 
because multiparametric MR imaging–guided biopsy can be targeted toward 
previously determined regions that are suspicious for cancer. MR-guided biopsy is 
technically feasible and be performed on a routine basis (Fig 8). Owing to its limited 
availability and long examination time, this technique is typically used in patients 
with one or more previous negative systematic random biopsy sessions. Transrectal 
MR guided biopsy performed at 1.5 T has shown promising cancer detection rates 
of 38%–59% (57,62–64). These detection rates are promising in comparison to 
those of systematic random biopsy rates of 22%–29% (9,65) after one session and 
10%–17% after two sessions (9,65).
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Figure 8. (a, b) Sagittal and (c) axial gradient-echo MR images (4.48/2.24; flip angle, 70°) of MR-
guided biopsy in a case of active surveillance of prostate cancer in a 69-year old man (same 
patient as in Fig 6) with Gleason score 6 (3+3) disease. Multiparametric staging MR imaging (not 
shown) with an endorectal coil resulted in suspicion of stage T3A cancer in left peripheral zone 
at midprostate. DW imaging (not shown) findings indicated intermediate to highly aggressive 
tumor in left peripheral zone. (a) Needle guide (arrows) is positioned toward target in left 
peripheral zone at midprostate (outline). To accurately hit the target, the needle guide should 
be moved slightly caudal in sagittal plane; in position shown (red line), needle will miss the 
target. (b, c) Needle guide (arrows) is now accurately positioned and biopsy needle (line) has 
been inserted. MR guided biopsy of this suspicious lesion resulted in a Gleason score of 8 (3+5) 
for a volume percentage of 80% with extension into periprostatic fat (stage T3A). This patient 
was subsequently excluded from the active surveillance protocol.
Use of multiparametric MR imaging in MR-guided biopsy planning has been 
studied by Franiel et al ( 66 ) in a prospective study of 1.5-T MR imaging in 54 
patients with a median of two previous negative random systematic transrectal US-
guided biopsies. Their ground truth was based on MR-guided biopsy of suspicious 
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identifiable lesions from at least one multiparametric MR imaging technique 
only. They concluded that a combination of T2-weighted with DW MR imaging 
and either dynamic contrast-enhanced MR imaging or MR spectroscopic imaging 
reduced the number of areas that need to be subject to biopsy by 13%–15% while 
only missing 6% of cancers, in comparison to multiparametric MR imaging with all 
three techniques.
A limitation of MR-guided biopsy is that a multiparametric MR imaging and the 
MR-guided biopsy need to be performed in separate sessions because image post-
processing and exact tumor localization demand time. Another disadvantage is 
movement of the prostate during the biopsy procedure (67). MR imaging findings 
have also been used to help direct biopsies under transrectal US guidance with 
reasonable to good detection rates of 25%–55% (68,69). Moreover, Gleason score 
concordance with radical prostatectomy findings may be improved with MR image 
guidance of transrectal US-guided prostate biopsy (70). Experimental fusion of MR 
and transrectal US data (71), in which distances between corresponding data points 
for each technique are rendered as small as possible by means of registration, is 
used to obtain more accurate MR-guided transrectal US prostate biopsy results (72).
Transrectal MR-guided biopsy improves prostate cancer detection; however, its 
availability is limited, and examination times are long. MR guidance of prostate 
biopsy is a very promising method to improve determination of the true pre-
treatment Gleason score.
Clinical questions
Detection
As stated earlier, clinical prostate cancer detection is currently performed by using 
tools with limited accuracy. Because the specificity of PSA measurement is low, it 
is often the case that many unnecessary repeat systematic random biopsies are 
required to establish a diagnosis (9).
Individual multiparametric MR imaging techniques such dynamic contrast-
enhanced, DW and MR spectroscopic imaging have been shown (73–75) to be of 
possible additional value in prostate cancer detection (Fig 9). Because these MR 
techniques have a relatively high specificity in comparison with PSA measurement, 
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they could prevent the unnecessary performance of systematic random biopsies 
and delay in diagnosis and treatment. Furthermore, results of prospective separate 
functional MR imaging studies for prostate cancer detection are difficult to 
compare, since criteria for cancer detection, methods of analysis, sample sizes, and 
mean PSA levels of patient groups differ or are not always presented.
It is essential to know if combinations of more than one functional MR technique 
could improve results even further. In a logistic regression analysis, ADC value was the 
best performing (area under the receiver operating characteristic curve [Az] = 0.69) 
single parameter for prostate cancer detection when compared with T2-weighted 
imaging findings, Ktrans, and extracellular extravascular space volume fraction V
e
 (73). 
In this study (73), a model based on T2-weighted MR imaging findings, ADCs, and 
Ktrans performed best (Az = 0.706). Although this study had a moderate sample size (n 
= 42) and was retrospective in character, it is one of the few prostate cancer detection 
studies in which prostatectomy specimens were used as the reference standard. 
In a recent evaluation of multiparametric MR imaging at 3 T (76), the addition of 
dynamic contrast-enhanced and/or DW imaging to T2-weighted MR imaging 
significantly improved prostate cancer detection sensitivity from 63% to 79%–81% 
in the peripheral zone, while maintaining a stable specificity. In the transition zone, 
however, multiparametric MR imaging did not improve prostate cancer detection. 
This study was performed in 57 patients, with prostatectomy specimens as ground 
truth. The combination of MR spectroscopic imaging with T2-weighted endorectal 
MR imaging has shown higher sensitivity (72%–89%) and equal specificity (79%–
93%) for prostate cancer detection than was shown for anatomic MR imaging alone 
(sensitivity, 57%–84%; specificity, 50%–94%) (77,78).
Multiparametric MR imaging techniques may also contribute in detection of 
transition zone prostate cancers. The combined use of DW, dynamic contrast-
enhanced, and T2-weighted MR imaging led to increased accuracy in detection of 
transition zone cancer, from 64% to 79%, in a small (n = 23) retrospective study (79).
Multiparametric MR imaging may potentially increase prostate cancer detection 
accuracy compared with the accuracy of T2-weighted MR imaging only. However, 
future research is needed to confirm initial results.
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Figure 9. Added value of combined multiparametric MR imaging for prostate cancer detection 
in a 63-year-old man with PSA level of 27.5 ng/mL, clinical stage T0, and history of seven previous 
negative systematic random biopsy sessions (total of 96 cores). T2-weighted and dynamic contrast-
enhanced MR imaging findings are indeterminate to suspicious for tumor within the transition 
zone, whereas ADC maps may help correct localization of this prostate cancer. (a) Axial T2-weighted 
turbo spin-echo MR image (4260/99; flip angle, 120°) at midprostate shows low-signal-intensity 
region in midventral prostate (white outline), which is suspicious for prostate cancer. Furthermore, 
peripheral zone from dorsal aspect to midline in dorsoventral plane has lower signal intensity than 
the anterior horns (black outline). This area did not show decreased ADC. This may be due to biopsy-
related fibrosis. (b) Top: Same image as a with superimposed Ktrans map (38/1.35; flip angle, 14°) 
shows high Ktrans in midventral transition zone (outline), in addition to the mediodorsal transition 
zone. Bottom: Relative gadolinium concentration (y-axis) versus time (x-axis) curve (Dyna1) shows 
type 3 curve (fast increase and time to peak followed by washout). (c) Axial ADC map (2400/81; 
b = 0, 50, 500, and 800 sec/mm2) at same level as a shows restriction (mean ADC=750×10-6mm2/sec) 
in midventral transition zone (T), indicating intermediate to high tumor aggressiveness. MR-guided 
biopsy revealed a Gleason score 7 (3+4) prostate cancer.
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Localization and Local Staging
Prostate cancer localization is the most important clinical indication for 
multiparametric MR imaging of the prostate. First, accurate definition of prostate 
cancer location helps improve cancer detection in targeting prostate biopsies with 
MR imaging guidance. Second, accurate definition of a prostate cancer location 
also helps improve prostate cancer staging, because better assessment of prostate 
cancer location(s) near the neurovascular bundle is possible in patients in whom 
nerve-sparing surgery is planned. Third, improved evaluation of prostate cancer 
location helps improve and support focused intensity-modulated radiation therapy 
planning of the dominant prostatic lesion and improves guidance of minimally 
invasive focal therapies.
In a large retrospective study in 106 patients in which prostatectomy findings 
were the reference standard (80), MR imaging localization of prostate cancer was 
significantly more accurate than digital rectal examination and systematic random 
biopsy results in the whole prostate except for the apex. Sensitivity and especially 
specificity of endorectal T2-weighted MR imaging prostate cancer localization 
vary, ranging from 54% to 91% and 27% to 91%, respectively (81–84). Variation of 
results in these prospective studies, in which prostatectomy findings served as 
reference standard, might be partially explained by the fact that image analysis 
was based on different numbers of regions of interest, different cut-off points for 
a positive result, and inclusion or exclusion of prostate cancer localization in the 
transition zone. Moreover, results vary as correlation of MR imaging findings with 
prostatectomy findings is difficult owing to different angles and section intervals 
of MR sections and prostatectomy slices and to deformation and shrinkage during 
histopathologic processing of the prostate specimens. Correction for this variability 
has been attempted by using a shrinkage factor (83,85). In a recent prospective 
study (84), correlation of MR imaging and prostatectomy findings was performed 
in an innovative and possibly more accurate way. Aside from dividing the prostate 
into 30 regions, including peripheral and transition zones, the authors also used 
an alternative-neighbor analytic approach to correct for prostate shrinkage and 
deformation. In this approach, tumors visible on MR image and seen in neighboring 
regions of the positive prostatectomy specimen were also considered to be positive 
MR results.
Localization merits of multiparametric MR imaging techniques may be used to draw 
the attention of the radiologist to a suspicious region. This is illustrated in Figures 
5, 9, and 10. Localization accuracy with dynamic contrast-enhanced MR imaging 
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increased to 72%–91%, as compared with 69%–72% for anatomic T2-weighted MR 
imaging only (85–88). The addition of DW imaging (83) to T2-weighted MR imaging 
significantly improved sensitivity to 81% (sensitivity for T2-weighted MR imaging 
alone, 54%), whereas specificity was slightly lower for T2-weighted MR imaging 
combined with DWI (84%) than for T2-weighted MR imaging alone (91%) in this 
prospective prostatectomy-referenced study (83). Also, in other prospective studies 
(89,90), the addition of DW imaging to T2-weighted MR imaging improved prostate 
cancer localization performance, with Az values of 0.66–0.79. However, in a recent 
retrospective 3-T study in 51 patients, with prostatectomy specimens as reference 
standard (91), DW imaging did not add value to T2-weighted MR imaging for 
prostate cancer localization. Az values were 0.76–0.79 for T2-weighted MR imaging 
and 0.78–0.79 for T2-weighted MR imaging combined with DW imaging ADC 
maps. The high percentage of Gleason score 6 (3+3) cancers (36%, of which only 
53%–63% were detected) may explain the poor incremental value of DW imaging 
ADC maps in this study.
MR spectroscopic imaging has shown higher specificity (68%–99%) and lower 
sensitivity (25%–80%) for prostate cancer localization, when compared with 
anatomic T2-weighted MR imaging (specificity, 61%–90%; sensitivity, 68%–87%) 
in prospective studies with prostatectomy specimens as reference standard 
(82,84,85,92). However, a multicenter trial that included 110 patients, with 
prostatectomy findings as reference standard (93), did not show any benefit for 
the addition of 1.5-T MR spectroscopic imaging to T2-weighted MR imaging in 
prostate cancer localization (Az = 0.60 for T2-weighted MR imaging alone vs 0.58 
for combined T2-weighted and MR spectroscopic imaging, P = .09). The omission 
of a multicenter validation and use of a threshold for increased metabolic ratios 
as a criterion for malignancy as well as of a clear definition of tumor focus size 
may have negatively influenced the quality of MR spectroscopic imaging in this 
trial. In a recent multiparametric 3-T MR imaging study with 57 patients (76), DW 
and dynamic contrast-enhanced MR imaging increased the accuracy of prostate 
cancer localization in the peripheral zone but failed to do the same in the transition 
zone. By using prostatectomy specimens as standard of reference and scoring four 
quadrants for both peripheral and transition zones, Az values for the peripheral 
zone increased from 0.81 to 0.91–0.92 by adding DW and/or dynamic contrast-
enhanced MR imaging to T2-weighted MR imaging. In the transition zone, however, 
localization accuracy decreased from Az of 0.84 for T2-weighted MR imaging alone 
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to 0.70–0.75 when dynamic contrast-enhanced imaging was added. With the 
addition of DW imaging to T2-weighted imaging, Az values for cancer localization 
in the transition zone increased slightly from 0.84 to 0.88. By improving localization 
multiparametric MR imaging techniques may also contribute to improved local 
staging accuracy.
For appropriate therapy planning it is important to know if prostate cancer is 
confined to the gland (stages T1 and T2) or if there is extraprostatic extension 
(stages T3 and T4) (94). Current clinical staging, generally based on digital rectal 
examination, PSA and transrectal US findings, results in frequent understaging 
(59%) and some overstaging (5%) (95).
The main application of T2-weighted MR imaging is in local staging of prostate 
cancer. The most widely used criteria for extracapsular spread are (asymmetric) low 
signal intensity in the seminal vesicles, asymmetry of the neurovascular bundle, 
obliteration of the rectoprostatic angle (Fig 11), irregular bulging of the prostatic 
contour (Fig 11), low signal intensity indicative of cancer in the rectoprostatic fat, 
and overt extracapsular cancer. The last three criteria have the highest sensitivity 
(96) while all criteria have high specificity.
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Figure 10. Multiparametric MR imaging for prostate cancer localization in a 71-year-old man 
with stage T1, Gleason score of 7 (3+4) disease in left prostate base who underwent endorectal 
MR staging: pitfalls in dynamic contrast-enhanced MR imaging localization of prostate cancer. 
Dynamic contrast-enhanced MR imaging results in enhancement in multiple areas and is 
therefore indeterminate when performed in addition to T2-weighted MR imaging. DW imaging 
correctly localizes this cancer and shows its aggressiveness. (a) Axial T2-weighted turbo spin-
echo MR image (4260/99; flip angle, 120°) at midprostate shows low-signal-intensity lesion in 
left peripheral zone (outline) next to region of high signal intensity in peripheral zone, with 
minimal signs of extracapsular extension (arrow). (b) Axial MR image with a superimposed 
Ktrans map (38/1.35; flip angle, 14°) at same level as a shows multiple enhancing areas in both 
peripheral and transition zones. Tumor area (T) also shows enhancement. Tumor localization is 
indeterminate. (c) Axial ADC map (2400/81; b = 0, 50, 500, and 800 sec/mm2) at same level as a 
shows restricted diffusion in laterodorsal peripheral zone (T) (mean ADC = 808x10-6 mm2 /sec), 
which indicates intermediate tumor aggressiveness. (d) Axial whole-mount histopathologic 
slice at level corresponding to that of a–c shows a Gleason score 7 (3+4), stage T3A prostate 
cancer in the left laterodorsal peripheral zone (outline), which confirms the T2-weighted and 
DW imaging data.
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Table 2. Diagnostic Statistics for MR Studies of Prostate Cancer Staging Since 2006
Study and Year Field 
Strength 
(T)
No. of 
subjects
PA 
coil 
ER 
coil 
MRI
technique
Sensitivity
%*
Specificity
%*
Accuracy
%*
Lee et al. (107), 
2010
1.5 91 Yes Yes T2-Weighted
DW
PA ECE 30
(8/27)
PA SVI 50 
(2/4)
ERC ECE 
32 (7/22)
ERC SVI 50 
(2/4)
PA ECE90 
(18/20)
PA SVI 98 
(42/43)
ERC ECE 
96 (21/22)
ERC SVI 93 
(37/40)
NR
Augustin et al. 
(100) 2009
3 27 yes no T2-Weighted ECE 67
(4/6)
ECE 100
(21/21)
ECE 85
(23/27)
Porcaro et 
al.(103),2009
1.5 154 NR yes T2-Weighted ECE 78
SVI 88
ECE 96
SVI 98
ECE 91
SVI 97
Torricelli et al. 
(104), 2008
3 42 yes no T2- and T1-
Weighted
ECE 69 †
(11/16)
ECE 92†
(24/26)
ECE 83†
(35/42)
Park et al. (109), 
2007
3 54 yes no T2-Weighted ECE 81
(17/21)
SVI 50
(1/2)
ECE 67
(22/33)
SVI 100
(52/52)
ECE 72
(39/54)
SVI 98
(53/54)
Park et al. (109), 
2007
1.5 54 no yes T2-Weighted ECE 71
(10/14)
SVI 75
(3/4)
ECE 73
(29/40)
SVI 92
(46/50)
ECE 72
(39/54)
SVI 91
(49/54)
Heijmink et al. 
(102), 2007
3 46 yes yes T2-Weighted PA 13‡ 
(2/15)
ERC 80‡
(12/15)
PA 100‡
(31/31)
ERC 100‡
(31/31)
PA 70‡
(32/46)
ERC 93‡
(43/46)
Fütterer et al. 
(98), 2007
1.5 81 yes yes T2-Weighted 64 (23/36) 98 (44/45) 83 (67/82)
Bloch et al. 
(106), 2007
1.5 32 yes yes dynamic 
contrast 
enhanced
ECE 91§
(11/12)
ECE 95§
(21/22)
NR
Chandra et al. 
(101), 2007
1.5 38 yes yes T2-Weighted, 
MR 
spectroscopic 
imaging
ECE 69
SVI 60
ECE 82
SVI 100
ECE 76
SVI 95
Latchamsetty 
et al. (105), 
2007
1.5 80 NR yes T2-Weighted ECE 71|| ECE 78|| ECE 73||
Füttereret al. 
(96), 2006
3 32 yes yes T2-and T1-
Weighted
88 (7/8) 96
(23/24)
94
(30/32)
Note.—Reference standard in all studies was prostatectomy specimen. ECE = extracapsular extension, ER = 
endorectal, NR = not reported, PA = pelvic phased array, SVI = seminal vesicle invasion.*Data in parentheses 
are numbers from which percentages were calculated. † Obtained by experienced radiologist. ‡ Maximal 
values for an examination performed independently by four radiologists. § Maximal percentages for 
assessment of extracapsular extension adjusted to prevalence of disease in the study population at large.|| 
Highest values from two separate groups of 40 patients.
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There has been a longstanding debate on whether or not to use an endorectal 
coil for prostate cancer staging since its use results in a more labor-intensive and 
costly examination. In a meta-analysis, Engelbrecht et al (97) reported on 146 
studies performed at 1.5 T and found that the use of turbo spin-echo sequences, 
an endorectal coil and multiplanar acquisitions all significantly increased staging 
performance. The application of an integrated endorectal-pelvic phased-array coil 
significantly improved staging performance, particularly sensitivity, compared with 
that of a pelvic phased-array coil alone: Az increased from 0.57 to 0.74 at 1.5 T and from 
0.62 to 0.68 at 3 T (P< ,001)(98). Although, in the largest prospective prostate cancer 
staging study performed at 1.5 T of which we are aware (99), where MR imaging with 
a body coil only and with an endorectal coil only were compared, body coil imaging 
performed better (accuracy, 62%) than did endorectal coil imaging (accuracy, 52%). 
In the past decade since this trial, technologic developments such as the use as 
higher field strengths, improved pelvic phased-array coils and multiparametric 
MR imaging techniques have improved staging accuracy considerably. However, 
accuracy results vary between different studies. Table 2 provides an overview of 
recent prostate cancer staging MR imaging studies at both field strengths (100–
107). The results of the MR prostate cancer staging studies, as presented in Table 
2, seem conflicting. One should be careful, as difficulty remains in comparing and 
interpreting results of these studies because different field strengths, comparisons 
of coil types, and endpoints were used for prostate cancer staging.
To our knowledge, only two studies have directly compared 3-T and 1.5-T MR 
staging of prostate cancer (108,109). This comparison was suboptimal, because use 
of a pelvic phased-array coil at 3 T was compared with use of a pelvic phased-array 
coil and/or an endorectal coil at 1.5 T. Conclusions on the effects of higher field 
strength on MR staging of prostate cancer remain difficult to infer because research 
on this topic is still immature.
Multiparametric MR imaging may also improve prostate cancer staging. In a large 
prospective study with 99 patients (110), dynamic contrast-enhanced MR imaging 
combined with T2-weighted MR imaging significantly improved the accuracy of 
prostate cancer staging compared with that of T2-weighted MR imaging alone. Az 
values for less experienced readers were 0.82 for dynamic contrast-enhanced plus 
T2- weighted MR imaging and 0.66 for T2-weighted imaging alone respectively 
(P < .01). In a prospective study with 53 patients (111), addition of three-dimensional 
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MR spectroscopic imaging results to T2-weighted MR imaging results significantly 
improved accuracy for predicting extracapsular extension for both experienced 
and less-experienced readers (Az increase from 0.78 to 0.86 and 0.62 to 0.75, 
respectively, for T2-weighted imaging only vs combined imaging).
Drawbacks of T2-weighted MR imaging for prostate cancer localization and local 
staging include differentiation of inflammatory changes from cancer. Furthermore, 
high inter- and intra-observer variability may lead to under- or overestimation of 
cancer stage (112). Also, postbiopsy hemorrhage can decrease staging accuracy. 
Finally, T2-weighted MR imaging cannot be used to detect microscopic capsular 
invasion. As mentioned earlier, pitfalls of multiparametric MR techniques also affect 
the ability to facilitate prostate cancer localization and local staging (see Figs 5, 10).
Of all clinical indications for multiparametric MR imaging, localization is the most 
important. Accurate prostate cancer localization results in more accurate prostate 
cancer staging and in more accurate MR guidance of prostate biopsy and therapy.
Figure 11. Multiparametric MR imaging in prostate cancer staging in a 70-year-old man with 
PSA level of 12 ng/mL and well-differentiated prostate carcinoma (C). Axial T2-weighted turbo 
spin-echo MR image (4260/99; flip angle, 120°) shows low-signal-intensity region (outline) in 
left peripheral zone. Bulging and obliteration of rectoprostatic angle (open arrows) indicate 
extracapsular extension. There is invasion of the neurovascular bundle (solid arrow). At MR 
imaging, stage T3a prostate cancer was reported. Radical prostatectomy revealed a solitary 
adenocarcinoma with Gleason score 7 (3+4) with extraprostatic extension (stage T3a).
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Determination of Prostate Cancer Aggressiveness
Prostate cancer is graded according to the Gleason score, a combination of the two 
most prevalent Gleason grades (at prostatectomy) or the most prevalent and the 
highest grade (at prostate biopsy), based on architectural characteristics of prostate 
cancer tissue (113,114). Sampling error in biopsy specimens obtained at systematic 
random biopsy occurs in approximately in 64% of procedures (10) and results 
in a changed Gleason score at histopathologic evaluation of the prostatectomy 
specimen.
This results in incorrect evaluation of prostate cancer aggressiveness, which may 
cause under- or overtreatment (115). On T2-weighted MR images, signal intensity 
changes and detection rates for prostate cancer have been associated with its 
aggressiveness. In a retrospective study with 74 patients, in which prostatectomy 
specimens were used as standard of reference (14), low-grade cancers were 
detected at a rate of 43%, while high-grade cancers were detected at a rate of 79%.
In another retrospective study, which also used prostatectomy specimens as reference 
standard (116), higher Gleason scores were associated with lower tumor-to-muscle 
signal intensity ratios on T2-weighted MR images. In a large retrospective study 
with 220 patients (117), T2-weighted MR imaging and MR spectroscopic imaging 
scores based on a three-point scale for clinical prostate cancer aggressiveness were 
significantly correlated to biologic markers such as androgen receptor levels, which 
were associated with prostate cancer progression. In that study, the combination 
of biologic markers with T2-weighted MR imaging and MR spectroscopic imaging 
results yielded an Az of 0.91 for discrimination of clinically unimportant prostate 
cancer, which was defined as cancer confined to the organ and 0.5 cm3 or less in 
volume without poorly differentiated parts at pathologic examination. Moreover, 
at MR spectroscopic imaging, the choline-plus-creatine–to-citrate ratios have been 
shown to be associated with Gleason score (118,119). In a retrospective study of 43 
patients with biopsy-proved prostate cancer, Kobus et al (120) showed that 3-T MR 
spectroscopic imaging is an accurate technique for discriminating patients with 
Gleason grade 2 or 3 cancer from patients with Gleason score 4 or 5 cancer, as 
determined with prostatectomy specimens. By using a standardized-threshold 
approach involving both the choline-plus-creatine–to-citrate ratio and the choline-
to-citrate ratio, an Az of 0.78 was achieved for discrimination of Gleason score 2–3 
from Gleason score 4–5 prostate cancers.
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Results for ADC as a possible marker of cancer aggressiveness are very promising: 
In a retrospective study of 3-T DW imaging (b= 0, 50, 500, and 800 sec/mm2) 
Hambrock et al (45) correlated median ADCs with prostatectomy Gleason grades in 
peripheral zone prostate cancers on a slice-by-slice basis in 51 patients. Cancers with 
Gleason score 2–3 components were discerned from cancers with Gleason score 
4–5 components, with an Az of 0.90. Furthermore, in a study of 1.5-T DW imaging 
(b = 0 and 600 sec/mm2) in 110 patients with 197 tumors, Verma and Rajesh (121) 
found a negative correlation r = -0.39) between mean ADC and Gleason score for 
peripheral zone cancers on prostatectomy specimens. A similar association could 
not be found for cancers in the transition zone. An Az of 0.78 was achieved by 
using both cancer volume and ADC as predictors of tumor aggressiveness (Gleason 
score ≥6). While preliminary studies in the field of prostate cancer aggressiveness 
show promising results (45), different parameters from different multiparametric 
techniques show some overlap among Gleason scores. Because a certain value of 
an MR parameter, such as ADC, cannot be precisely associated with one Gleason 
score component, multiparametric MR imaging cannot yet be applied to the 
determination of prostate cancer aggressiveness in a general clinical environment. 
However, this technique is very helpful for assessing tumor grade and guiding 
biopsy to the most aggressive part of the tumor.
Active Surveillance
With the observation that low-risk cancers do not progress rapidly when treatment 
is deferred (122,123), implementation of active surveillance protocols has become 
more widespread. The aim of this approach is to minimize overtreatment by mean 
of active observation of low-risk cancers and to intervene with curative therapy 
when a presumably low-risk cancer shows signs of progression. Low-risk cancer is 
frequently defined as a cancer with a clinical stage of T2 or lower, a Gleason score 
of 6 or less without a Gleason 4 or 5 component, a PSA level of 10 ng/mL or less, a 
PSA density 0.15 ng/mL/mL or less, and systematic random biopsy criteria of two or 
fewer cores with prostate cancer and 50% volume of cancer or less per core (124).
The cornerstone of active surveillance protocols is the accurate identification of 
low-risk cancers. A frequent cause for inaccurate estimation of prostate cancer 
aggressiveness is sampling error at systematic random biopsy with subsequent 
undergrading of Gleason score. In addition, cancer volume is also often 
underestimated owing to sampling error in systematic random biopsies, because 
cancer volume is estimated by measuring the number and volume percentages 
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of cancer tissue of cancer-positive biopsy cores (10). In patients in whom risk 
stratification was incorrectly determined, repeat biopsies may eventually show 
evidence of high-risk disease, which then triggers a delayed intervention with, 
perhaps, a missed opportunity for definitive curative therapy (125–127).
Multiparametric MR imaging can potentially aid in adequate risk stratification for 
patient selection in active surveillance by improving prostate cancer staging and 
by characterizing cancer aggressiveness (Fig 6). An example of improved staging 
by using MR imaging in active surveillance is in a prospective study by Berglund et 
al (128). In that study, 18 (39%) of 66 patients in whom MR imaging findings were 
suspicious for extracapsular extension were upgraded or upstaged because of 
progression at histologic examination of the repeat biopsy specimen.
During follow-up in active surveillance, detection of cancer progression within the 
curative window is essential. MR imaging can also be valuable in this application. 
Recently, Giles et al (129) showed that ADCs at repeat biopsy were significantly 
lower in patients with a Gleason score increase than in those with a stable score 
(P < .001). In that study, both tumor volume (P = .002) and ADCs calculated 
from DW imaging (300–800 sec/mm2) (P = .02) were significant independent 
predictors of progression of active surveillance patients. Progression was defined 
biochemically (PSA increase >1 ng/mL per year) and/or histopathologically (repeat 
biopsy Gleason grade ≥4 or cancer presence in more than 50% of biopsy cores). 
In another active surveillance study in 86 patients with a mean follow-up of 
29 months (130), DW imaging tumor ADC data were significant predictors of a 
Gleason score 4 component at repeat biopsy (Az = 0.70, P < .001) and of the need 
for initiation of radical treatment during follow-up (Az = 0.83, P < .001). Patients 
were included in this study if they met the following criteria: PSA level of 15 ng/mL 
or lower, Gleason score of 7 or lower with a primary Gleason score of 3 or less, 50% 
or fewer of biopsy cores positive at systematic random biopsy, three monthly PSA 
measurements, repeat systematic random biopsies 12–24 months after inclusion, 
and performance of DWI imaging before inclusion. Similar results were found 
in another retrospective study (131), in which an increase to Gleason score 7 or 
higher at subsequent repeat systematic random biopsy in 114 active surveillance 
patients was associated with T2-weighted MR imaging results although not with 
transrectal US or MR spectroscopic imaging results.
These studies may underestimate results because systematic random biopsy 
specimens, instead of a prostatectomy specimen, were used as the reference 
standard. On the other hand, in a large retrospective study, Cabrera et al (132) 
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found that T2-weighted MR imaging and MR spectroscopic imaging performed 
at baseline were of no additional prognostic value to active surveillance because 
the presence of cancer on MR images could not be associated with biochemical 
outcome in multivariate analysis. Biochemical outcome was defined according to 
serial PSA measurements, which were classified as stable or progressive by using 
slopes of regression lines. These results conflict with those of previous retrospective 
studies (130,131). The field strength of 1.5 T used by Cabrera et al and the use of PSA 
kinetics instead of histologic findings as a measure of prostate cancer progression 
might partly explain these conflicting results. Despite general promising results, 
incorporation of multiparametric MR imaging into active surveillance protocols for 
low-risk prostate cancer is still in an early phase.
Multiparametric MR imaging and MR-guided biopsy may improve initial diagnosis 
and accurate monitoring of prostate cancer stage and aggressiveness in active 
surveillance. Future research addressing the use of multiparametric MR imaging in 
selection and follow-up of patients with low-risk prostate cancer as part of active 
surveillance protocols is needed.
Conclusion
In this review, we have presented and discussed available data on the additional 
value of the different functional MR imaging techniques in various clinical diagnostic 
prostate cancer problems.
To increase MR imaging accuracy for the different clinical prostate cancer 
indications, one or more functional MR imaging techniques should be combined 
with T2-weighted MR imaging in a multiparametric MR examination of the prostate. 
However, within the variety of different acquisition methods, protocols, magnetic 
field strengths and multiparametric techniques that are used, consensus guidelines 
on dedicated MR protocols for specific clinical indications are lacking.
Suggested minimal requirements for a multiparametric MR imaging protocol 
for clinical evaluation of prostate cancer are T1- and T2-weighted MR imaging in 
combination with DW and dynamic contrast-enhanced MR imaging. T1-and T2-
weighted MR imaging should be used for evaluation of anatomy. Dynamic contrast-
enhanced MR imaging can be used for high-sensitivity identification of potential 
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prostate cancer locations. Unfortunately, little standardization in dynamic contrast-
enhanced MR acquisition and analysis exists. DW imaging or MR spectroscopic 
imaging are accurate functional MR techniques, and they may be added to improve 
specificity for different clinical indications. DW imaging is the most practical and 
simple accurate functional imaging technique; however, it is prone to motion and 
susceptibility artifacts. MR spectroscopic imaging is an accurate technique that, like 
DW imaging, can be used for assessing prostate cancer aggressiveness. Expertise 
and longer imaging times are prerequisites for MR spectroscopic imaging, which 
may ultimately decrease its clinical applicability.
Because the reported accuracies of multiparametric MR imaging techniques for 
different indications are inconsistent, definitive conclusions on the accuracies 
of (combined) multiparametric MR imaging techniques for a particular clinical 
prostate cancer problem are difficult to make. In general, the addition of functional 
MR techniques to T2-weighted MR imaging improves accuracy for both localization 
and local staging of prostate cancer in comparison to the accuracy of T2-weighted 
MR imaging alone. Of all clinical indications for multiparametric MR imaging of the 
prostate, localization is the most important. Accurate determination of prostate 
cancer location(s) results in more accurate prostate cancer staging and MR guidance 
of prostate biopsy and therapy.
Currently, multiparametric MR imaging is performed at only a limited number of 
centers worldwide. Development of expertise in functional MR techniques and 
increased availability of equipment are needed, so that multiparametric prostate 
MR imaging can become a more accessible examination. To warrant accurate future 
multiparametric MR imaging prostate cancer diagnostics, computer programs are 
needed to support clinicians by allowing simple post-processing and fast evaluation 
of the data.
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Abstract
Purpose: To retrospectively compare transition zone (TZ) cancer detection and 
localization accuracy of 3-T T2-weighted magnetic resonance (MR) imaging with 
that of multiparametric (MP) MR imaging, with radical prostatectomy specimens as 
the reference standard.
Materials and Methods: The informed consent requirement was waived by the 
institutional review board. Inclusion criteria were radical prostatectomy specimen 
TZ cancer larger than 0.5 cm3 and 3-T endorectal presurgery MP MR imaging (T2-
weighted imaging, diffusion-weighted [DW] imaging apparent diffusion coefficient 
[ADC] maps [b, 1000 sec/mm2], and dynamic contrast material–enhanced [DCE] MR 
imaging).
From 197 patients with radical prostatectomy specimens, 28 patients with TZ 
cancer were included. Thirty-five patients without TZ cancer were randomly 
selected as a control group. Four radiologists randomly scored T2-weighted and 
DW ADC images, T2-weighted and DCE MR images, and T2-weighted, DW ADC, 
and DCE MR images. TZ cancer suspicion was rated on a five-point scale in six TZ 
regions of interest (ROIs). A score of 4–5 was considered a positive finding. A score 
of 4 or higher for any ROI containing TZ cancer was considered a positive detection 
result at the patient level. Generalized estimating equations were used to analyze 
detection and localization accuracy by using ROI-receiver operating characteristics 
(ROC) curve analyses for the latter. Gleason grade (GG) 4–5 and GG 2–3 cancers 
were analyzed separately.
Results: Detection accuracy did not differ between T2-weighted and MP MR imaging 
for all TZ cancers (68% vs 66%, P = .85), GG 4–5 TZ cancers (79% vs 72%–75%, 
P = .13), and GG 2–3 TZ cancers (66% vs 62%–65%, P = .47). MP MR imaging (area 
under the ROC curve, 0.70–0.77) did not improve T2-weighted imaging localization 
accuracy (AUC = 0.72) (P > .05).
Conclusion: Use of 3-T MP MR imaging, consisting of T2-weighted imaging, DW 
imaging ADC maps (b values, 50, 500, and 800 sec/mm2), and DCE MR imaging 
may not improve TZ cancer detection and localization accuracy compared with 
T2-weighted imaging.
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Introduction
American Cancer Society statistics show prostate cancer accounted for more than a 
quarter of the cancer incidence in male subjects in the United States, with mortality 
rates higher than 15%, in 2008 (1). Between 25% and 30% of these cancers were 
transition zone (TZ) cancers (2). No uniform histopathologic definition of TZ cancer 
exists, although a cancer volume of 50%–70% or higher within the TZ is commonly 
used as a histopathologic definition for probable TZ origin (2). TZ prostate cancers 
have a relatively lower Gleason score (3), local stage (4), and biochemical recurrence 
rate (5) in comparison with peripheral zone cancers. However, zonal location of 
high Gleason grade (GG) prostate cancer did not influence biochemical relapse-
free survival (5). Furthermore, in a prostatectomy series, a GG 4 or GG 5 component 
with extracapsular extension and positive resection margins was present in 9% of 
all TZ cancers (6). Therefore, improvement of TZ cancer detection is an important 
goal in prostate cancer diagnostics. Anterior TZ cancers in particular are detected 
less frequently with standard prostate biopsy schemes because they are beyond 
the reach of general random systematic transrectal ultrasonography (US) guided 
biopsies in current prostate cancer diagnostic work-up (7).
At T2-weighted magnetic resonance (MR) imaging, TZ prostate cancers are 
difficult to differentiate from benign prostatic hyperplasia (BPH), as the latter has 
a heterogeneous signal intensity (SI) with lower SI components, which are similar 
to the low SI of prostate cancer. Despite this, T2-weighted imaging has been 
advocated as an accurate technique in the detection of TZ cancer (8,9). Several T2-
weighted imaging features, such as homogeneously low SI (sensitivity, 76%–78%; 
specificity, 78%–87%), ill-defined margins (sensitivity, 76%–78%; specificity, 78%– 
89%), and lenticular shape (sensitivity, 48%–56%; specificity, 85%–98%), may be 
applied to accurately predict TZ cancer (8,9). The use of an endorectal coil in T2-
weighted imaging tumor localization at 1.5 T resulted in an area under the receiver 
operating characteristic curve (AUC) of 0.73–0.84 (8,10,11). Reported results for TZ 
cancer detection and localization accuracy with multiparametric (MP) MR imaging 
vary. Application of endorectal diffusion-weighted (DW) MR imaging and dynamic 
contrast material–enhanced (DCE) MR imaging at 1.5 T did not significantly improve 
TZ cancer detection and localization accuracy compared with T2-weighted imaging 
alone (10,11). However, at 1.5 T, DW imaging has been shown to increase TZ cancer 
detection accuracy when high b values (>1000 sec/mm2) are used (12,13). TZ cancer 
localization accuracy increased from an AUC of 0.69 for T2-weighted imaging alone 
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to an AUC of 0.84 by adding DW imaging with b values of 2000 sec/mm2 (13). With 
DCE MR imaging, quantitative parameters, such as the transfer constant (or Ktrans), 
can be used to differentiate TZ cancer from glandular BPH but not from stromal 
BPH (14).
To our knowledge, 3-T endorectal MP MR imaging including DW and DCE MR 
imaging has not been evaluated in TZ cancer detection and localization. Application 
of higher field strengths may yield better image quality due to a higher signal-to-
noise ratio. Therefore, the purpose of this study was to retrospectively compare TZ 
cancer detection and localization accuracy of 3-T T2-weighted imaging with those 
of MP MR imaging by using radical prostatectomy specimens as the reference 
standard.
Materials and Methods
Patients
The need for informed consent was waived by the local institutional review board. 
Inclusion criteria were TZ cancer, with a cancer volume of more than 0.5 cm3 in 
the radical prostatectomy specimen, and pre-prostatectomy endorectal 3-T MP MR 
imaging, including T2-weighted imaging, DW MR imaging, and DCE MR imaging. 
Patients who had undergone prior radiation therapy or transurethral prostate 
resection were excluded. Twenty-eight patients with TZ cancer met the inclusion 
criteria. These patients were retrospectively selected from 197 consecutive patients 
whose histopathologic specimens were obtained at prostatectomy performed 
within our referral center between January 2007 and August 2011. Subsequently, 
35 patients without TZ cancer but with peripheral zone cancer were randomly 
selected by blindly drawing them from the same group of prostatectomies to 
serve as a control group, as shown in Figure 1. Four of the 39 selected control 
subjects were excluded due to postradiotherapy (n=1), postbrachytherapy (n=1), or 
posttransurethral (n = 2) prostate resection status.
MR imaging acquisition protocol
MR images were obtained with a 3-T MR imager (Trio Tim; Siemens, Erlangen, 
Germany) by using a pelvic phased-array coil and an endorectal coil (Medrad, 
Pittsburgh, Pa) filled with 40 mL of perfluorocarbon (Fomblin; Solvay-Solexis, Milan, 
Italy). MP MR imaging parameters are presented in Table 1. Axial DW imaging 
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followed axial T2-weighted imaging of the prostate and seminal vesicles with the 
same section positions and use of diffusion modules and fat-suppression pulses. 
Apparent diffusion coefficient (ADC) maps were calculated automatically by using b 
values (50, 500, and 800 sec/mm2, without 0 sec/mm2 values). DCE MR imaging was 
performed initially with an axial three-dimensional (3D) proton density–weighted 
gradient-echo sequence and was followed by an axial 3D T1-weighted spoiled 
gradient-echo sequence performed during intravenous administration of 0.1 mmol 
gadopentetate dimeglumine (Dotarem; Guerbet,Paris, France) per kilogram of body 
weight at a rate of 2.5 mL/sec followed by a 20-mL saline flush. Post-processing 
of DCE MR imaging data was performed with in-house–developed software (15). 
Quantitative pharmacokinetic analysis was based on the model by Tofts et al 
(16), with an automatic per-patient calibration for estimation of the arterial input 
function (17).
MR image interpretation
Four radiologists (D.Y., C.M.A.H., T.H., and J.J.F.; 3, 3, 5, and 10 years of experience, 
respectively, with prostate MR imaging) independently and randomly scored 
all cases by using software that was developed in-house (15). Radiologists were 
informed about the diagnosis of cancer in every patient; however, they were blinded 
to the zonal location of present prostate cancer. T2-weighted imaging, T2-weighted 
imaging combined with ADC maps, T2-weighted and DCE MR imaging, and T2-
weighted MR imaging combined with DW MR imaging ADC maps and DCE MR 
imaging were prospectively scored in four separate consecutive sessions with at least 
2 weeks between sessions. T1-weighted MR images were available for evaluation of 
postbiopsy hematoma. The TZ was divided into six regions of interest (ROIs). In the 
coronal plane, the TZ was divided in three parts: the level of the verumontanum, the 
level inferior to the verumontanum, and the level superior to the verumontanum. 
The sagittal plane through the verumontanum was used to divide the TZ into a 
right and left halves. The following five-point scale was used for every ROI and every 
reading session: A score of 1 indicated definite absence of TZ cancer; a score of 
2, probable absence of TZ cancer; a score of 3, possible presence of TZ cancer; a 
score of 4, probable presence of TZ cancer; and a score of 5, definite presence of 
TZ cancer. Radiologists were instructed to score only those cancers with at least 
70% of their volume within the TZ (18). For T2-weighted imaging, the presence 
of homogeneously low SI, irregular boundaries around a low-SI lesion, lenticular 
shape, interruption of the pseudocapsule, and invasion of the anterior fibromuscular 
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stroma or lateroventral TZ were considered suspicious for TZ cancer (score, 4–5) (8,9). 
DW MR imaging ADC maps and DCE MR images were evaluated in conjunction 
with T2-weighted images. For DW imaging, a homogeneously low ADC value in 
comparison with the ADC of the surrounding TZ was suspicious for TZ cancer (score, 
4–5). For DCE MR imaging (19), quantitative pharmacokinetic modelling according 
to the model of Tofts et al (16) was used. Parameter maps of the transfer constant 
and of washout were used as an overlay over T2-weighted images.
In addition, qualitative characteristics of the relative gadolinium concentration-
time curve were used. When this curve showed a plateau or washout after early 
enhancement in combination with focal or asymmetric enhancement of an area 
in the (lateroventral) TZ or of the anterior fibromuscular stroma on the overlaid 
parametric map, the region was suspicious for prostate cancer (score, 4–5).
Table 1. MR imaging parameters.
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T2WI= T2-weighted MR imaging, DWI= diffusion weighted MR imaging, DCE-MRI= dynamic contrast 
enhanced MR imaging, TSE= turbo spin echo, SSEPI= single-shot echo-planar imaging, GE= gradient echo, 
TR= repetition time and TE=echo time, PD= proton density weighted MR imaging.
Histopathologic analysis
Radical prostatectomy specimens served as the reference standard for MP MR 
Imaging results. Specimens were cut into 4-mm-thick axial step-section slices and 
were completely processed. A urogenital pathologist with more than 18 years of 
experience (C.H.) and who was blinded to MP MR imaging results determined 
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location, stage, and GG components for every individual tumor (2005 International 
Society of Urological Pathology criteria [20]). Cancer volume was calculated by 
assuming elliptical tumor shape and multiplying by slice thickness (4 mm) (21). 
Cancer with a volume of at least 70% within the TZ was defined as TZ cancer in the 
radical prostatectomy specimen (18).
Correlation of MR data to the reference standard
Two radiologists (C.M.A.H., T.H.; 3 and 5 years of experience in prostate MP MR 
imaging) correlated MR data and radical prostatectomy specimen data in consensus 
by using landmarks like the verumontanum, urethra, and calcifications. Correlation 
of prostate MP MR imaging data to histopathology data is known to be difficult (22).
Statistical Analyses
Analyses were performed by using PASW Statistics (version 18; SPSS,Hong Kong, 
China) and SAS (version 9; SAS Institute, Cary, NC) software. A two-sided P value 
of less than .05 indicated a significant difference. Patient characteristics were 
compared by using an independent t test for parametric variables, and a Mann-
Whitney U test was used for nonparametric variables. Separate subanalyses were 
performed for GG 4–5 and GG 2–3 TZ cancers. Readers with scores of 4 or higher for 
any TZ-cancer-containing ROI were considered to have detected TZ cancer in that 
particular patient. Localization of TZ cancer was defined as finding a cancer (score 
≥4) in a cancer-containing ROI. Per patient, all four separate reader evaluations were 
used for sensitivity, specificity, and accuracy calculations. Differences between 
diagnostic indexes of the four MP MR imaging readings were evaluated by using 
generalized estimating equations. When an overall score test indicated a significant 
difference, we performed Wald tests for pairwise comparisons. TZ cancer sensitivity 
was corrected for tumor volume.
TZ cancer localization accuracy was analyzed by comparing AUCs of different MP 
MR imaging readings. For every MP MR reading, average scores over the four readers 
were calculated per ROI per subject. Generalized estimating equation analysis was 
applied (binomial distribution, logit link function, and exchangeable correlation 
structure) to account for within-subject correlation between ROIs. Comparison 
of the resulting correlated AUCs and calculation of 95% confidence intervals was 
performed by using the SAS macro roc.sas (http://support.sas.com/kb/25/017.html). 
Interobserver agreement was evaluated by using the intraclass correlation 
coefficient based on our random effects model. Levels of interobserver agreement 
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obtained by using the intraclass correlation coefficient were defined as poor (r, 0.0), 
slight (r =0.0–0.20), fair (r = 0.21–0.40), moderate (r = 0.41–0.60), substantial (r= 0.61–
0.80), and almost perfect (r =0.81–1.00) (23).
Table 2. Patient and prostatectomy characteristics.
Characteristic Patients 
with TZ 
cancer
(n = 28)*
Control 
patients 
without 
TZ cancer
(n=35)
Two-sided P
Value for 
Patients with 
TZ Cancer 
versus Control 
Subjects
Patients 
with
GG 4-5 TZ 
cancer
(n=13)
Patients 
with
GG 2-3 TZ 
cancer
(n=15)*
Two-sided P
Value for Patients 
with GG 4–5 TZ vs 
Patients with GG 
2–3 TZ cancer
Age (years) † 67
(55-73)
63
(45-73)
0.18 67
(55-73)
67
(55-71)
0.60
PSA level
(ng/mL) †
9.3
(1.9-44.0)
6.5
(3.2-14.8)
0.15‡ 17.4
(3.2-44.0)
5.4
(1.9-16.7)
< 0.01‡§
Prostate volume 
(mL) †
37.6
(20.7-103.0)
37.0
(17.0-91.8)
0.75 38.0
(20.7-73.0)
37.0
(23.0-103.0)
0.85
Cancer volume
(cm3) †
4.4
(0.5-22.0)
1.2
(0.5-18.8)
<0.01§ 8.5
(1.5-20.9)
Mean 8.2
1.5
(0.5-22.0)
Mean 4.7
0.03§
MR imaging to 
surgery interval,
in weeks†
8
(1-28)
7
(1-21)
0.54 8
(1-28)
8
(1-15)
0.75
Histopathologic stage
pT2a 0 10 N.A. 0 0 N.A.
pT2c 15 12 N.A. 2 13 N.A.
pT3a 8 12 N.A. 5 3 N.A.
pT3b 3 1 N.A. 3 0 N.A.
pT4 4 0 N.A. 3 1 N.A.
Gleason score 
2+2 0 0 N.A. 0 0 N.A.
2+3 7 0 N.A. 0 7 N.A.
2+4 1 0 N.A. 1 0 N.A.
3+2 4 1 N.A. 0 4 N.A.
3+3 6 12 N.A. 0 6 N.A.
3+4 2 15 N.A. 2 0 N.A.
4+2 1 0 N.A. 1 0 N.A.
4+3 7 7 N.A. 7 0 N.A.
4+5 2 0 N.A. 2 0 N.A.
Note.—P values were calculated with the Mann-Whitney U test. Mean cancer volume in patients with GG 
4–5 TZ cancer and those with GG 2–3 TZ cancer was 8.2 cm3 and 4.7 cm3, respectively.
NA = not applicable.
* Two patients had two 2–3 TZ cancers.
† Data are medians, and data in parentheses are the range.
‡ As prostate-specific antigen level was a parametric variable in both patients with GG 2–3 TZ cancer and 
patients with GG 4–5 TZ cancer, an independent t test was used for this comparison. § Under threshold for 
significance (two-tailed P value < .05).
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Table 3. Diagnostic Accuracy in Detection of All TZ Cancers, of GG 4–5 TZ Cancers, and of GG 
2–3 TZ Cancers for All Readers for Different MP-MR Imaging Protocols
MR Imaging 
protocol
All Patients with TZ Cancer vs 
Control Subjects
without TZ Cancer (n = 63)
Patients with GG 4–5 TZ 
Cancer vs Control Subjects
without TZ Cancer (n = 48)
Patients with GG 2–3 TZ 
Cancer vs Control Subjects
without TZ Cancer(n = 50)
Se
ns
iti
vi
ty
(%
)
Sp
ec
ifi
ci
ty
(%
)
A
cc
ur
ac
y
(%
)
Se
ns
iti
vi
ty
(%
)
Sp
ec
ifi
ci
ty
(%
)
A
cc
ur
ac
y
(%
)
Se
ns
iti
vi
ty
(%
)
Sp
ec
ifi
ci
ty
(%
)
A
cc
ur
ac
y
(%
)
T2-weighted 
imaging
53
(59/112)
[44,62]
80
(112/140)
[73,86]
68
(171/252)
[62,73]
75
(39/52)
[62,85]
80
(112/140)
[73,86]
79
(151/192)
[72,84]
33
(20/60)
[23,46]
80
(112/140)
[73,86]
66
(132/200)
[59,72]
T2-weighted 
imaging 
and
DW imaging 
ADC maps
58
(65/112)
[49,67]
72
(101/140)
[64,79]
66
(166/252)
[58,70]
77
(40/52)
[64,86]
72
(101/140)
[64,79]
73
(141/192)
[67,79]
42
(25/60)
[30,54]
72
(101/140)
[64,79]
63
(126/200)
[56,69]
T2-weighted 
imaging and 
DCE
MR imaging
53
(59/112)
[44,62]
76
(107/140)
[69,83]
66
(166/252)
[60,71]
71
(37/52)
[58,82]
76
(107/140)
[69,83]
75
(144/192)
[68,81]
37
(22/60)
[26,49]
76
(107/140)
[69,83]
65
(129/200)
[58,71]
T2-weighted 
imaging, 
DW imaging 
ADC
maps, and 
DCE MR 
imaging
65
(73/112)
[56,73]
67
(94/140)
[59,74]
66
(167/252)
[60,72]
85
(44/52)
[72,92]
67
(94/140)
[59,74]
72
(138/192)
[65,78]
48
(29/60)
[36,61]
67
(94/140)
[59,74]
62
(123/200)
[55,68]
Generalized 
estimating 
equation
analysis 
overall score 
test*†
0.004 0.002 0.848 0.107 0.002 0.128 0.071 0.002 0.467
Wald test†
T2-weighted 
imaging
vs T2-
weighted 
imaging and 
DW
imaging 
ADC maps
0.116 0.021 0.021 0.021
T2-weighted 
imaging
vs T2-
weighted 
imaging
and DCE MR 
imaging
0.661 0.411 0.411 0.411
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MR Imaging 
protocol
All Patients with TZ Cancer vs 
Control Subjects
without TZ Cancer (n = 63)
Patients with GG 4–5 TZ 
Cancer vs Control Subjects
without TZ Cancer (n = 48)
Patients with GG 2–3 TZ 
Cancer vs Control Subjects
without TZ Cancer(n = 50)
Se
ns
iti
vi
ty
(%
)
Sp
ec
ifi
ci
ty
(%
)
A
cc
ur
ac
y
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)
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)
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ty
(%
)
A
cc
ur
ac
y
(%
)
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ty
(%
)
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ifi
ci
ty
(%
)
A
cc
ur
ac
y
(%
)
T2-weighted 
imaging
vs T2-
weighted 
imaging,
DW imaging 
ADC maps, 
and DCE
MR imaging
0.006 0.005 0.005 0.005
T2-weighted 
imaging and 
DW imaging
ADC maps 
vs T2-
weighted
imaging 
and DCE MR 
imaging
0.092 0.317 0.327 0.327
T2-weighted 
imaging and 
DW imaging
ADC maps 
vs T2-
weighted
imaging, 
DW imaging 
ADC maps,
and DCE MR 
imaging
0.069 0.296 0.296 0.296
T2-weighted 
imaging and 
DCE
MR imaging 
vs T2-
weighted
imaging, 
DW imaging 
ADC maps,
and DCE MR 
imaging
<0.001 0.004 0.004 0.004
Note.—Unless otherwise indicated, data are percentages, data in parentheses are proportions, and data in 
brackets are 95% confidence intervals. Findings are based on four reader evaluations for every patient (all six 
ROIs together), resulting in sensitivity denominators of 112 for 28 patients with TZ cancer, 52 for 13 patients 
with GG 4–5 TZ cancer, and 60 for 15 patients with GG 2–3 TZ cancer. The specificity denominator (i.e., 140) 
was based on 35 control patients (35x4 = 140).
The accuracy denominator was based on the total number of patients with TZ cancer and control subjects 
per group (n = 63 for all cancer patients, denominator = 252; n = 48 for patients with GG 4–5 TZ cancer, 
denominator = 192; n = 50 for patients with GG 2–3 TZ cancer, denominator = 200). Readers with a score 
of 4 or higher for any ROI with TZ cancer were considered to have detected TZ cancer in that particular 
patient (numerator = 1). * For sensitivities, generalized estimating equation analyses were corrected for 
tumor volume. † Data are P values.
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Results
Radical prostatectomy specimens revealed one TZ cancer location in 26 of 28 
patients and two TZ cancer locations in two of 28 patients. Thirteen (46%) of 28 
patients with TZ cancer had a GG 4–5 component, and 15 (54%) of 28 patients 
with TZ cancer had only a GG 2–3 pattern. The mean volume of GG 4–5 TZ tumors 
(8.2 cm3; range, 1.5–20.9 cm3) did not differ significantly from mean volume of GG 
2–3 TZ tumors (4.7 cm3; range, 0.5–22.0 cm3; P = .12). Patient characteristics are 
depicted in Table 2. Examples of patients with endorectal MP MR imaging of GG 
4–5 and GG 2–3 TZ cancers are shown in Figures 2 and 3.
The diagnostic accuracy for detection of all TZ cancers, GG 4–5 TZ cancers, and GG 
2–3 TZ cancers is presented in Table 3. Findings are based on four reader evaluations 
for every patient, defining a reader ROI score of 4 or higher for a patient with TZ 
cancer in that particular ROI as a positive result. Accuracy did not differ significantly 
between T2-weighted imaging and MP MR imaging for (a) all TZ cancers (68% 
vs 66%, P = .85), (b) GG 4–5 TZ cancers (79% vs 72%–75%, P =.13), and (c) GG 2–3 
TZ cancers (66% vs 62%–65%, P = .47). After stratification by dichotomization for 
median cancer volume, differences in detection rates of GG 2–3 TZ cancers versus 
GG 4–5 TZ cancers were not significant (for cancers ≤4 cm3, detection rates were 
16%–32% for GG 2–3 cancers vs 25%–50% for GG 4–5 cancers [P = .37 to P . .99]; for 
cancers >4 cm3, detection rates were 81%–100% for GG 2–3 cancers vs 77%–91% for 
GG 4–5 cancers [P =.18 to P . .99]). These results are presented in Table 4.
Volumes of less frequently detected (≤1 reader) GG 2–3 TZ cancers were lower than 
volumes of more frequently detected (>1 reader) GG 2–3 TZ cancers. Differences 
were significant for T2-weighted imaging alone (1.1 vs 12.4 cm3, P = .04) and for T2-
weighted imaging and DW imaging ADC maps (0.8 vs 12.4 cm3, P = .01). No cancer 
volume differences were present for less versus more frequently detected GG 4–5 
TZ cancers. These results are presented in Table E1 (online). In TZ cancer localization, 
MP MR imaging (AUC range, 0.70–0.77) did not significantly improve T2-weighted 
imaging accuracy (AUC = 0.72, P < .05). T2-weighted imaging and DCE MR imaging 
(AUC, 0.70) performed significantly worse than other MP MR imaging protocols 
(AUC range, 0.76–0.77; P = .0002–.02). Results of ROI ROC analyses are presented 
in Table E2 (online) and Figure 4. Interobserver agreement for TZ cancer detection 
was fair. Intraclass correlation coefficient values for all different multiparametric MR 
imaging protocols ranged from 0.33 to 0.37.
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Table 4. Comparison of Detection Rate of GG 2–3 TZ Cancer with That of GG 4–5 TZ Cancer
Without Stratification for TZ Cancer 
Volume
With Stratification for Largest TZ Cancer Volume in 
Every Patient
MR imaging 
protocol
Patients 
with GG 
2–3
TZ Cancer 
(n = 15) (%)
Patients 
with GG 
4–5
TZ Cancer 
(n = 13) (%)
P Value Patients 
with GG 
2–3
TZ 
Cancer 
≤4 cm3
(n = 11) 
(%)*
Patients 
with GG 
4–5
TZ 
Cancer 
≤4 cm3
(n = 2) 
(%)*
P Value Patients 
with GG 
2–3
TZ 
Cancer 
>4 cm3
(n = 4) 
(%)*
Patients 
with GG 
4–5
TZ 
Cancer 
>4 cm3
(n = 11) 
(%)*
P 
Value
T2-weighted 
imaging
33
(20/60)
[23,46]
75
(39/52)
[62,85]
<0.001 16
(7/44)
[8,30]
25
(2/8)
[6,60]
0.62 81
(13/16)
[56,94]
84
(37/44)
[70,92]
>.99
T2-weighted 
imaging
and DW 
imaging 
ADC
maps
42
(25/60)
[30,54]
77 
(40/52)
[64,86]
<0.001 20
(9/44)
[11,35]
25
(2/8)
[6,60]
>.99 100
(16/16)
[77,100]
86
(38/44)
[73,94]
0.18
T2-weighted 
imaging
and DCE 
imaging
37
(22/60)
[26,49]
71
(37/52)
[58,82]
<0.001 20
(9/44)
[11,35]
38
(3/8)
[13,70]
0.37 81
(13/16)
[56,94]
77
(34/44)
[63,87]
>.99
Note.—Unless otherwise indicated, data are detection rates, data in parentheses are proportions, and 
data in brackets are 95% confidence intervals. Two-sided P values were calculated with the Fisher exact 
test. Stratification of TZ cancer volume was based on dichotomization around the median cancer volume 
(4 cm3). For this analysis, the largest TZ cancer volume was chosen per patient.
* Under threshold for significance (two-tailed P value < .05).
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Figure 1. Flowchart for patient selection. DWI= DW MR imaging, HIFU= high-intensity focused 
ultrasound, PZ= peripheral zone, T2WI= T2-weighted MR imaging, TURP= transurethral resection 
of the prostate.
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(a) (b)
  
(c) (d)
Figure 2. Images in a 70-year-old patient with a prostate-specific antigen level of 6.1 mg/L and 
cT1C cancer (Gleason score 3 + 4 = 7) in the right prostate present in 30% of random biopsies. 
TZ cancer was clearly visible at T2-weighted and MP MR imaging. Radical prostatectomy was 
performed.
(a) Axial endorectal T2-weighted turbo spin-echo (repetition time msec/echo time msec, 
4260/99) image at midprostate level shows low homogeneous SI extending from the anterior 
fibromuscular stroma into the right TZ, with invasion of the peripheral zone (arrows).
(b) Axial ADC map (2500/81; b value = 0, 50, 500, and 800 sec/mm2) at the same level as a. Low 
ADC value (mean, 440 x 10-6 mm2/sec) is present predominantly in right TZ (white arrows). In the 
left peripheral zone, there is a slight decrease in ADC value (black arrow).
 (c) Axial T2-weighted turbo spin-echo image at same level as a, with superimposed transfer 
constant parametric map (38/1.35). Asymmetric enhancement of right ventral TZ and right 
anterior horn of peripheral zone is present (white arrows).Left peripheral zone also shows 
enhancement (black arrow). (d) Axial reconstructed whole-mount-section histopathologic 
sample at the level of a–c shows pT3A (Gleason score 4 + 3 = 7) prostate TZ cancer in right 
ventral medial TZ (black outline), with cancer-negative or clean resection margins (R0). Minimal 
ventral extraprostatic extension (2.5 mm) of this tumor was present (arrow). Next to TZ cancer, 
Gleason 3 + 4 and 3+ 3 tumors were present in right and left peripheral zones, respectively 
(black outlines).
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(a) (b)
  
(c) (d)
Figure 3. Images in a 64-year-old man with a prostate-specific antigen level of 6.0 mg/L and 
clinical stage T2 prostate cancer (Gleason score, 3 + 3) diagnosed in three of six random biopsy 
cores in up to 15 volume-percent of every core on the left side; regions suspicious for TZ cancer 
are depicted less clearly than in Figure 2. (a) Axial endorectal T2-weighted turbo spin-echo image 
(5200/99) at midprostate level shows a low-SI area in right lateral ventral TZ with irregular growth 
pattern and a low-SI area in left TZ, which tends to grow anteriorly (white arrows). Furthermore, 
low-SI area is present in left peripheral zone (black arrow).
(b) Axial ADC map (4000/81; b value = 0, 50, 500, and 800 sec/mm2) at same level as a. Areas 
with low ADC values are present in right (mean ADC, 996 x 10-6 mm2/sec) and left (mean ADC, 
861 x 10-6 mm2/sec) ventral lateral TZ (black arrows). Left peripheral zone (white arrow) also has 
decreased ADC value (mean ADC, 674 x 10-6 mm2/sec). (c) Axial T2-weighted turbo spin-echo 
MR image at same level as a, with superimposed transfer constant parametric map (38/1.35). 
Symmetric diffuse enhancement of TZ, not matching areas suspicious for cancer in a and b, 
is present (black arrows). Left peripheral zone shows asymmetric enhancement (white arrow). 
(d) Axial reconstructed whole-mount-section histopathologic sample at level of a–c shows 
multifocal pT2CN0 (Gleason score, 2 + 3 = 5) prostate TZ cancer in right and left ventral lateral 
TZ (black outline) with cancer-negative resection margins (R0). In left peripheral zone, Gleason 
3 + 3 cancer was present next to a small focus of Gleason 3 + 3 cancer in right peripheral zone 
(black outlines).
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Discussion
Our results indicate that 3-T MP MR imaging consisting of T2-weighted imaging, 
low-b-value (<1000 sec/mm2) DW imaging ADC maps, and DCE MR imaging may 
not improve TZ cancer detection and localization accuracy compared with those 
achieved with 3-T T2-weighted imaging alone.
Our results for MP MR imaging are in agreement with those of Delongchamps 
et al (10), who found no added value of endorectal MP MR imaging compared 
with T2-weighted imaging for TZ cancer detection and localization at 1.5 T. For TZ 
cancer detection, MP MR imaging increased the rather low T2-weighted imaging 
sensitivity; however, it decreased specificity compared with that attained with T2-
weighted imaging. Both DCE MR imaging and DW imaging may have false-positive 
results due to the difficulty of discriminating prostate cancer from BPH. With DCE 
MR imaging, this difficulty is due to BPH hypervascularity (24). With DW imaging, it 
is caused by low ADC values of stromal BPH, which may overlap with those of TZ 
cancer (14). T2-weighted imaging specificity may be higher, as differentiation of TZ 
cancer from BPH is not based on image (quantitative) SI differences only, but merely 
on anatomic characteristics of TZ cancer, such as growth pattern, structure, and 
shape, which are different from those of BPH (8).
The TZ cancer detection accuracy of all TZ cancers for T2-weighted imaging and 
DW imaging ADC maps (66%) in our study was lower than that reported in prior 
studies (8,10–12). A potential reason for better combined T2-weighted imaging and 
DW imaging ADC maps detection accuracy results of some studies (accuracy range, 
62%–81%) was the use of higher b values (≥1000 sec/mm2) (12,13). Our results are in 
agreement with those of studies in which the b value was less than 1000 sec/mm2 
(10,11). Furthermore, the lack of a fixed ADC window level range may further explain 
our lower detection accuracy for T2-weighted imaging and ADC compared with 
the results of Haider et al (11) (accuracy, 81%). For the T2-weighted and DCE MR 
imaging combination (accuracy, 66% for all TZ cancers), our results are comparable 
with those of Yoshizako et al (12) at 1.5 T (sensitivity, 69%; specificity, 68%; accuracy, 
69%). However, our results differ from those of Delongchamps et al (10). They 
reported a sensitivity of 47% and a specificity of 77% for TZ cancer detection; their 
lower sensitivity (56% in our study) may be explained by their lower field strength 
of 1.5 T. Mean cancer volume of GG 2–3 cancers versus GG 4–5 cancers did not 
differ significantly. Our patient population may have been too small to enable us to 
detect a significant difference. Also in TZ cancers of comparable volume, detection 
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rates of GG 2–3 and GG 4–5 cancers did not differ significantly. This may also have 
been caused by our small number of patients. However, differences in T2-weighted 
imaging and MP MR imaging detection rates for GG 2–3 TZ cancers versus GG 4–5 
TZ cancers were influenced by cancer volume. Especially for GG 2–3 TZ cancers, the 
cancers detected by only one reader had significantly smaller or nearly significantly 
smaller volumes than those that were detected by more readers. These results 
agree with the findings of Akin et al (8), who also showed that TZ cancer detection 
was influenced by cancer volume.
For localization of all TZ cancers, GG 2–3 TZ cancers, and GG 4–5 TZ cancers, MP MR 
imaging did not improve accuracy. Moreover, the addition of DCE MR imaging to 
T2-weighted imaging significantly decreased localization accuracy in comparison 
with that of (a) T2-weighted imaging and DW imaging ADC maps and/or (b) T2-
weighted imaging, DW imaging ADC maps, and DCE MR imaging. A possible 
explanation for poor results after addition of DCE MR imaging may be the false-
positive enhancement due to similar enhancement of prostate cancer and BPH (23). 
Our localization accuracy of T2-weighted imaging only (AUC, 0.72) was lower than 
the localization accuracy of most other studies (AUC, 0.79–0.84) (10,11). A possible 
explanation is that in those studies, images were read by only highly experienced 
radiologists. Furthermore, Delongchamps et al (10) used a smaller section thickness 
(1 mm) than we did (3 mm). Our TZ cancer localization accuracy for combined T2-
weighted imaging and DW imaging ADC maps (AUC, 0.76) was comparable to that 
obtained by Haider et al (AUC, 0.78) (11); however, it was lower than that obtained 
by Delongchamps et al (AUC, 0.88) (10). Delongchamps et al (10) used quantitative 
thresholds, which may explain their higher combined T2-weighted imaging and 
DW imaging ADC maps localization performance. Our results for T2-weighted 
and DCE MR imaging (AUC, 0.70) and for T2-weighted imaging, DW imaging ADC 
maps, and DCE MR imaging localization (AUC, 0.77) are comparable with those 
of Delongchamps et al (10) (AUC = 0.70 for T2-weighted imaging and DCE MR 
imaging, AUC = 0.75 for MP MR imaging).
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(a) (b)
(c)
Figure 4. Receiver operating characteristic curves of the different MP MR imaging protocols 
for localization of (a) all TZ cancers, (b) GG 4–5 TZ cancers, and (c) GG 2–3 TZ cancers. MP MR 
imaging did not significantly increase TZ cancer localization accuracy compared with that 
attained with T2-weighted imaging (T2WI). T2-weighted and DCE MR imaging performed 
worse than T2-weighted imaging alone, T2-weighted imaging and DW imaging ADC maps, and 
T2-weighted imaging, DW imaging ADC maps, and DCE MR imaging. For all TZ cancers (a) and 
for GG 2–3 TZ cancers (c), differences were significant for T2-weighted imaging and DW imaging 
ADC maps (AUC = 0.76, P = .02 for all TZ cancers; AUC = 0.71, P = .03 for GG 2–3 TZ cancers) 
and for T2-weighted imaging, DW imaging ADC maps, and DCE MR imaging (AUC = 0.77, 
P, .001 for all TZ cancers; AUC = 0.70, P = .01 for GG 2–3 TZ cancers) versus T2-weighted imaging 
and DCE MR imaging (AUC = 0.70 for all TZ cancers, AUC = 0.62 for GG 2–3 TZ cancers). For GG 
4–5 TZ cancers (b), T2-weighted imaging and DCE MR imaging (AUC = 0.78) only performed 
significantly worse compared with T2-weighted imaging, DW imaging ADC maps, and DCE MR 
imaging (AUC = 0.84, P = .002). Diagonal black line = reference line of 0.50 AUC, Data below the 
threshold for significance (two-tailed P value, .05) (∗) are indicated.
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Our study had limitations. First, because of the small population, our study may 
have had insufficient power to enable us to detect a difference between T2-
weighted imaging and MP MR imaging in the detection and localization of TZ 
cancers. Second, we did not use high-b-value DW imaging and ADC threshold 
values for TZ cancer. Use of quantitative ADC thresholds may have its shortcomings, 
as ADC values are subject to inter- and intrapatient variation (25). At the time of 
image reading, we did not calculate high-b-value trace images. Our performance 
of qualitative image assessment only may have negatively influenced results 
for interobserver agreement and reliability. Third, to use the optimal reference 
standard, we selected only those patients who underwent prostatectomy. This 
may have introduced selection bias into our results, as in many patients with TZ 
cancer surgery is not performed. Fourth, the median TZ cancer lesion volume of 
4.40 mL (range, 0.52–21.99 mL) was larger than that in the study of Akin et al (8) 
(median 0.77 mL; range, 0.0015–16.2 mL) and that of Yoshizako et al (12) (range, 10–
28 mm). Our larger TZ cancer volumes may have positively influenced T2-weighted 
imaging detection and localization accuracies. Fifth, reproducibility and reliability 
of our results were limited, as our interobserver agreement was only fair. A possible 
explanation may be the difference in experience between readers for different MP 
MR imaging techniques in the prostate TZ.
Our results imply that there is ample room for improvement of MP MR imaging 
techniques for accurate TZ evaluation. Studies on MP MR imaging (including high-
b-value DW imaging) with increased spatial resolution are needed to improve 
detection and localization of TZ cancers. Furthermore, false-positive MP MR imaging 
readings may be reduced by training radiologists in recognition of cancer-specific 
patterns rather than in quantitative evaluation of the TZ. In the future, computer-
aided diagnosis may have an important supportive role in pattern recognition in 
the detection and localization of TZ cancers. In conclusion, 3-T MP MR imaging, 
which consists of T2-weighted imaging and low-b-value (<1000 sec/mm2) DW MR 
imaging ADC maps and/or DCE MR imaging, may not improve TZ cancer detection 
and localization accuracy compared with 3-T T2-weighted imaging alone.
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Appendix
Table e1. Differences in Mean Cancer Volume for Less versus More Frequently Detected Gleason 
Grade 2-3 and 45 Transition Zone Cancers
Multiparametric 
MR imaging 
Protocol
Median 
Cancer 
Volume in 
GG 2-3 TZ 
Cancers 
Detected
≤ 1 Reader 
(mL)
Median 
Cancer 
Volume in 
GG 2-3 TZ 
Cancers 
Detected
> 1 Reader
(mL)
P-value * Median Cancer 
Volume in GG 
4-5 TZ Cancers 
Detected
≤ 1 Reader 
(mL)
Mean Cancer 
Volume in GG 
4-5 TZ Cancers 
Detected
> 1 Reader
(mL)
P-value *
T2-weighted MR 
imaging
1.1
(0.5-2.6)
12.4
(7.8-12.4)
0.04 2.51 
(1.6-2.51)
9.2 
(8.0-12.2)
0.31† 
T2-weighed MR 
imaging and DW 
imaging ADC 
maps
0.8
(0.5-2.2)
12.4
(4.5-17.3)
0.01 11.3 
(1.6-11.3)
8.5
(6.4-11.0)
0.84† 
T2-weighted and 
DCE MR imaging
1.2
(0.5-2.4)
10.0
(1.0-14.9)
0.05 11.3 
(1.6-11.3)
8.5
(6.4-11.0)
0.84† 
T2-weighed MR 
imaging, DW 
imaging ADC 
maps and DCE 
MR imaging
0.75
(0.5-2.6)
7.9
(1.1-12.6)
0.06 1.60 (NA)‡ 9.2
(6.9-14.5)
0.11† 
Note.—Data in parentheses are the interquartile range. P <.05 indicates a significant difference. ADC = 
apparent diffusion coefficient, DCE = dynamic contrast material–enhanced, DW = diffusion weighted, GG 
= Gleason grade, TZ = transition zone. * P values were obtained with the Mann-Whitney U test. In patients 
with at least one TZ tumor, the tumor with the largest cancer volume was included.† As the number of 
less frequently (≤1 reader) detected GG 4-5 TZ cancers was small (n = 1-2), results should be interpreted 
carefully. ‡ There was only one patient. NA = not applicable.
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Table e2. Results of Region of Interest Receiver Operating Characteristics Curve Analyses for 
Localization of All TZ Cancers, GG 4-5 TZ Cancers, and GG 2-3 TZ Cancers.
Multiparametric MR 
imaging Protocol
Localization of all TZ 
Cancers
Localization of GG 4-5 TZ 
cancers
Localization of GG 2-3 TZ 
cancers
T2-weighted MR 
imaging
0.72
(0.66-0.78)
0.81
(0.73-0.89)
0.64
(0.55-0.73)
T2-weighed MR and 
DW imaging ADC 
maps
0.76
(0.70-0.82)
0.81 
(0.73-0.90)
0.71
(0.62-0.79)
T2-weighted and DCE 
MR imaging
0.70
(0.64-0.77)
0.78
(0.70-0.87)
0.62
(0.52-0.72)
T2-weighed, DW ADC 
maps and DCE MR 
imaging 
0.77
(0.71-0.83)
0.84
(0.77-0.92)
0.70
(0.61-0.78)
Significant 
differences
Between 
Multiparametric MR 
imaging Protocols
X2(3)=17.37, 
P<.001
X2(3)=10.25,
P=0.02
X2(3)=10.67,
P=0.01
T2-weighted and 
DW ADC maps vs 
T2-weighted and DCE 
MR imaging
P=.02 . ........ P=.03
T2-weighted, DW 
ADC maps and DCE 
MR imaging vs T2-
weighted and DCE 
MR imaging
P<.001 P=.002 P=.01
Note.—Data in parentheses are 95% confidence intervals. Region of interest (ROI) receiver operating 
characteristics (ROC) curve values were compared by using a generalized estimation equation. Pearson 
χ2 tests were used to test for differences in ROI ROC values between MR imaging protocols. All significant 
differences indicate T2-weighted and DCE MR imaging to have a significantly lower area under the ROC 
curve compared with other MP MR imaging sessions.
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Abstract:
Objectives: The objective of this study was to evaluate the apparent diffusion 
coefficient (ADC) of diffusion-weighted magnetic resonance (MR) imaging for the 
differentiation of transition zone cancer from non-cancerous transition zone with 
and without prostatitis and for the differentiation of transition zone cancer Gleason 
grade (GG) using MR-guided biopsy specimens as a reference standard.
Materials and Methods: From consecutive MR-guided prostate biopsies (2008-2012) 
in our referral center, we retrospectively included patients from whom diffusion-
weighted MR imaging ADC values were acquired during MR-guided biopsy and 
whose biopsy cores had a (cancer) core length 10 mm or greater and originated 
from the transition zone. Two radiologists, who were blinded to the ADC data, 
annotated regions of interest on biopsy sampling locations of MR-guided biopsy 
confirmation scans in consensus. Median ADC (mADC) of the regions of interest was 
related to histopathology outcome in MR-guided biopsy core specimens. Mixed 
model analysis was used to evaluate mADC differences between 7 histopathology 
categories predefined as MR-guided biopsy core specimens with primary and 
secondary GG 4Y5 (I), primary GG 4-5 secondary GG 2-3 (II), primary GG 2-3 secondary 
GG 4-5 (III) and primary and secondary GG 2-3 cancer (IV), and noncancerous tissue 
without (V) or with degree 1 (VI) or degree 2 prostatitis (VII). Diagnostic accuracy 
was evaluated using areas under the receiver operating characteristic (AUC) curve.
Results: Fifty-two patients with 87 cancer-containing biopsy cores and 53 patients 
with 101 non-cancerous biopsy cores were included. Significant mean mADC 
differences were present between cancers (mean mADC, 0.77-0.86×10-3 mm2/s) 
and noncancerous transition zone without (1.12×-10-3 mm2/s) and with degree 
1 to 2 prostatitis (1.05-1.12×10-3 mm2/s; P <0.0001-0.05). Exceptions were mixed 
primary and secondary GG cancers versus a degree 2 of prostatitis (P = 0.06-0.09).
No significant differences were found between subcategories of primary and 
secondary GG cancers (P = 0.17-0.91) and between a degree 1 and 2 prostatitis and 
non-cancerous transition zone without prostatitis (P = 0.48-0.94).
The mADC had an AUC of 0.84 to differentiate cancer versus non-cancerous 
transition zone. AUCs of 0.84 and 0.56 were found for mADC to differentiate 
prostatitis from cancer and from non-cancerous transition zone. The mADC had an 
AUC of 0.62 to differentiate a primary GG 4 versus GG 3 cancer.
Conclusions: The mADC values can differentiate transition zone cancer from non-
cancerous transition zone and from a degree 1, and from most cases of a degree 2 
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prostatitis. However, because of substantial overlap, mADC has a moderate accuracy 
to differentiate between different primary and secondary GG subcategories and 
cannot be used to differentiate non-cancerous transition zone from degrees 1 to 
2 of prostatitis. Diffusion-weighted imaging ADC may therefore contribute in the 
detection of transition zone cancers; however, as a single functional MR imaging 
technique, diffusion-weighted imaging has a moderate diagnostic accuracy in 
separating higher from lower GG transition zone cancers and in differentiating 
prostatitis from non-cancerous transition zone.
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Introduction
Prostate cancer is the second most frequently diagnosed cancer in men worldwide 
(1). Based on radical prostatectomy and saturation biopsy specimens, at least 30% 
to 45% of diagnosed cancers are situated in the prostate transition zone (2,3). In 
patients with an elevated prostate-specific antigen (PSA) and cancer-negative 
transrectal ultrasound-guided biopsies, high proportions of transition zone cancer 
(57%-63%) are detected upon magnetic resonance (MR)-guided biopsy (4,5).
The latter finding reflects that many transition zone cancers are missed by transrectal 
ultrasound-guided biopsy, probably because of undersampling of the ventral 
prostate transition zone. Performing MR imaging (6) and MR-guided biopsy in 
patients with an elevated PSA and negative transrectal ultrasound-guided biopsies 
may therefore improve detection of transition zone prostate cancer. However, upon 
MR imaging of the prostate transition zone, differentiation of prostate cancer from 
healthy tissue is difficult because of the overlap of signal intensities and quantitative 
parameters between prostate cancer and stromal benign prostatic hyperplasia (7,8).
Prostate cancer should also be differentiated from prostatitis, which is often 
present also in the transition zone (9). In prostatitis, inflammatory infiltrates may 
increase cellular density and may therefore decrease T2-weighted MR imaging 
signal intensity and diffusion-weighted MR imaging apparent diffusion coefficient 
(ADC) values. For the peripheral zone, prostatitis can be differentiated from healthy 
tissue and from low-Gleason grade (GG) cancer; however, for the transition zone, 
differentiation of prostatitis from a high-GG cancer and from healthy tissue has not 
been described earlier (10).
Once a transition zone cancer is detected on MR imaging, accurate determination 
of its Gleason score is important because transition zone cancers are known to 
have lower Gleason scores and lower biochemical recurrence rates (11). Lower 
diffusion-weighted imaging ADC values have been related to higher prostate 
cancer Gleason scores, predominantly for peripheral zone cancers (12,13). Most 
of these studies have been performed using radical prostatectomy specimens 
as a reference standard. However, exact alignment of MR imaging slices with 
prostatectomy specimen sections remains difficult because of differences in 
angulations of imaging slicing and specimen sectioning and because of prostate 
shrinkage during histopathology processing. Furthermore, observer bias is almost 
unavoidable in attributing a certain region of interest (ROI) on MR imaging to a 
tumor, which is identified in a prostatectomy specimen section (14). Recently, size 
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and positioning of an ROI were shown to influence tumor ADC measurements and 
interobserver variability in rectal cancer (15).
Magnetic resonance-guided biopsy specimens may be a reference-standard 
alternative for radical prostatectomy specimens because the highest GG of an MR-
guided biopsy specimen has a high concordance (88%) with the highest GG of 
the radical prostatectomy specimen(16). This high concordance rate is caused by 
the ability of multiparametric MR imaging and especially of diffusion-weighted 
MR imaging to predict and localize the cancer areas with the highest GG (17). 
When using MR-guided biopsy as a reference standard, T2*-weighted gradient 
echo images, which confirm needle positioning, are available (5). Locations where 
prostate cancer biopsy specimens were sampled can be determined from signal 
voids of the biopsy needle on these MR-guided biopsy confirmation scans. 
Because annotation of biopsy sampling areas on confirmation scans is unrelated 
to the ADC map, it may reduce observer bias in relating ADC values to MR-guided 
biopsy histopathology.
Therefore, our purpose was to evaluate the ADC of diffusion-weighted MR imaging 
for the differentiation of the transition zone cancer from the non-cancerous 
transition zone with and without prostatitis and for the differentiation of transition 
zone cancer GGs using MR-guided biopsy specimens as a reference standard.
Materials and methods
Patients
The need for informed consent for this retrospective study was waived by the 
institutional review board. From all consecutively performed MR-guided biopsies 
between March 2008 and February 2012 in our referral center, we included patients 
using the following inclusion criteria:
• Performed diffusion-weighted imaging and ADC maps as part of the MR-guided 
biopsy procedure.
• Magnetic resonance-guided biopsy cores with prostate cancer in a cancer core 
length of 10 mm or greater and a transition zone location on MR-guided biopsy 
confirmation scans. A cancer core length of 10 mm or greater is 60% of a standard 
needle notch length of 17 mm and was chosen to limit variation because of 
mADC measurements in noncancerous tissue. By choosing this limit, at least 60% 
of the annotated ROI was related to prostate cancer.
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• Magnetic resonance-guided biopsy cores without prostate cancer with a core 
length of 10 mm or greater and a transition zone location of the needle sample 
on MR-guided biopsy confirmation scans.
The exclusion criteria were an existing diagnosis of prostate cancer before the 
MR-guided biopsy (n = 50) or unavailable biopsy histopathology specimens from 
external hospitals (n = 5). Also, needle positions for which MR-guided biopsy core 
identification was impossible were excluded. The latter was caused by simultaneous 
unspecified sampling of more cores referred for histopathology analysis as 1 
sample unit (n = 22) or caused by a lack of MR-guided biopsy confirmation scans 
with needle artifacts (n = 1) or caused by impossible accurate registration of the 
ADC map to the confirmation scans (n = 1). Patient selection is depicted in a flow 
diagram in Figure 1.
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Figure 1. Study flow-diagram. ADC indicates apparent diffusion coefficient in diffusion 
weighted MR imaging; DWI, diffusion-weighted MR imaging; MRGB, MR guided prostate biopsy; 
n, number of patients; PSA, prostate specific antigen.
MR imaging and MR guided biopsy acquisition
Two 3-T whole-body systems (MAGNETOM Trio and MAGNETOM Skyra; Siemens 
Medical Solutions, Erlangen, Germany) were used to perform MR imaging and MR-
guided biopsy. An MR compatible manual biopsy device, an endorectal needle 
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guider, and an 18-gauge biopsy gun (all from Invivo, Gainesville, FL) were used to 
perform the MR-guided biopsy. To detect prostate cancer, MR-guided biopsies were 
performed on the basis of the results of a previously performed multiparametric MR 
imaging examination, consisting of T2-weighted, diffusion-weighted, and dynamic 
contrast-enhanced MR imaging (5). The multiparametric MR imaging and MR-
guided biopsy sequence parameters are depicted in Table 1. Two radiologists with 
10 and 19 years of experience in prostate MR imaging (J.J.F. and J.O.B.) evaluated the 
initial MR images on a clinical software workstation while having access to patient 
data (18). Cancer suspicious regions were defined as described earlier (19).
The patients received antibiotic prophylaxis of 2 daily doses of 500-mg ciprofloxacin 
orally for 3 days and the biopsy was performed on the second day. Biopsies were 
performed by 1 radiologist with 3 years (C.M.A.H.), 1 radiologist with 2 years (J.G.R.B.), 
and 1 radiologist (E.K.V.) with 1 year of experience in MR-guided biopsy (19). Initially, 
T2-weighted MR imaging and diffusion-weighted imaging were performed for the 
re-identification of previously defined cancer suspicious regions. Consequently, 
sagittal and axial balanced gradient echo sequences were acquired during the 
repositioning of an endorectally inserted needle guide towards a cancer-suspicious 
region. When the needle guide was accurately targeted at a cancer- suspicious 
region, biopsies were taken by insertion of the 18-gauge needle biopsy gun (In 
vivo, Schwerin, Germany) through the needle guide. Directly after the MR-guided 
biopsy with the needle situated in the prostate, gradient echo sequences were 
repeated to confirm the position of the (sampling part of the) needle in a cancer-
suspicious region. Acquisition times for the transverse and sagittal confirmation 
scans for MAGNETOM Trio and Skyra were 8.9 and 9.0 seconds for the axial scans 
and 7.5 and 7.6 seconds for the sagittal scans, respectively.
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Histopathology
Biopsy core specimens were directly fixated in formalin. The cores were fixated 
and analyzed separately. All cores were histopathologically re-evaluated by 1 
experienced urogenital pathologist with 20 years of experience (C.A.H.), who 
was blinded to the MR imaging results. Gleason grade was evaluated using the 
2005 International Society of Urological Pathology-modified Gleason grading 
criteria (20). Prostatitis was defined as the presence of inflammatory infiltrates in 
the prostate (21). A degree 1 (mild), 2 (moderate), and 3 (severe) prostatitis were 
respectively defined as follows: an MR-guided prostate biopsy specimen core tissue 
area involvement of 1 lower than 10% by inflammatory cell infiltrates consisting of 
individual cells, separated by distinct intervening spaces (<100 cells/mm2), 2 10% to 
50% consisting of confluent sheets of inflammatory cells with no tissue destruction 
or lymphoid nodule or follicle formation (100-500 cells/mm2), 3 greater than 50% 
consisting of confluent sheets of inflammatory cells with tissue destruction or 
nodule/follicle formation (>500 cells/mm2) (21). Differentiation was made between 
chronic, chronic active, and granulomatous prostatitis (21).
Annotation of MR guided biopsy confirmation scans
Magnetic resonance-guided biopsy confirmation scans were analyzed with an in-
house-developed software (18). Two radiologists (one with 3 years [C.M.A.H.] and one 
with 1 year [E.K.V.] of experience in prostate MR imaging) annotated ROIs in consensus 
while they were blinded for histopathology results. In case of prostate displacement 
during the MR-guided biopsy procedure, the ADC maps were manually registered 
with the post-biopsy confirmation scans to correct for this displacement. Slices that 
most optimally represented the middle of the needle artifact were identified on both 
the sagittal and the transversal post-biopsy T2-weighted balanced gradient echo 
images. Subsequently, the presumed in vivo needle track of 22 mm was measured 
from the visible needle tip inside the signal void, taking into account a signal void of the 
needle artifact (2-3 mm) in front of the needle trajectory. The last 17 mm of this 22 mm 
represented the needle notch, where the tissue core was obtained. This last 17 mm 
area was annotated on the transverse T2-weighted balanced-gradient echo image. 
The notch length of 17 mm was annotated with overlapping ROIs (4.0×4.0×4.0 mm) 
matching the visible needle within the artifact signal void. An example of our 
annotation method is depicted in Figure 2. The radiologists annotated all cores 
over the entire core length (17 mm) in all patients. In patients in whom the core 
sample involved extraprostatic tissue, only the core parts situated in the prostate 
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were annotated. All ROIs of 1 notch length represented 1 core and were analyzed as a 
unit. For every annotated core, the mean, the SD, and the median ADC (mADC) were 
calculated by the software using the ADC values from all annotated ROIs in the core.
Statistics
The analyses were performed using Predictive Analytics SoftWare (PASW) Statistics 
version 18 (SPSS, Inc, Quarry Bay, Hong Kong). The threshold for significance was 
defined as P <0.05. Differences in patient characteristics were evaluated using 
independent t tests for parametric continuous variables and the Mann-Whitney 
test for non-parametric continuous variables.
The ROI ADC was related to the histopathology outcome in MR-guided biopsy 
specimens, which served as a reference standard. Linear multilevel mixed model 
analysis was used to evaluate mADC differences for 7 histopathology categories, 
defined as MR-guided biopsy core specimens with a primary and secondary GG 
4-5 (I), primary GG 4-5 secondary GG 2-3 (II), a primary GG 2-3 secondary GG 4-5 (III) 
and primary and secondary GG 2-3 cancer (IV) cancer, and noncancerous transition 
zone tissue without (V) or with degree 1 prostatitis (VI) or degree 2 prostatitis (VII). 
To correct for possible correlations between different cores coming from 1 patient, 
patients were used as a random factor in this model. Because non-cancerous parts 
in cancer-containing cores may have caused mADC variation, we compared mADC 
for cancer core lengths of respectively 10 to 12, 13 to 15, and greater than 15 mm.
Receiver operating characteristic (ROC) analyses were performed to evaluate 
diagnostic accuracy for mADC to differentiate between predefined histopathological 
categories.
Results
We included 87 MR-guided biopsy cores containing transition zone cancer in 
52 patients and 101 non-cancerous transition zone cores in another 53 patients. 
Patient characteristics are depicted in Table 2. For every patient, MR-guided biopsy 
cores were taken from 1 cancer-suspicious region. A patient example is depicted in 
Figure 3. Of the 87 cancer-containing cores, 27 cores had a primary and secondary 
GG 4-5, 12 cores had a primary GG 4-5 and a secondary GG 2-3, 24 cores had a 
primary GG 2-3 and a secondary GG 4-5, and another 24 cores had both primary 
and secondary GG 2-3. Of the 101 non-cancerous transition zone cores, 46 cores 
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existed out of healthy transition zone tissue without prostatitis, 50 cores contained 
a degree 1 prostatitis (of which 88% [44/50] were of a chronic type and 12% [6/50] 
were of a chronic active type), and 5 cores involved prostatitis up to a degree 
of 2 (2 of the chronic and 3 of the chronic active type). Because the subtotals of 
cores with a chronic (active) type of prostatitis were very small, no further analyses 
were performed to differentiate between the chronic and chronic active types of 
prostatitis. For patients with transition zone cancer, MR-guided biopsy core lengths 
ranged from 12.0 to 16.0 mm (interquartile range) and were invaded by cancer 
(cancer core length) in a length of (interquartile range) 11.0 to 14.0 mm. Core length 
of the non-cancerous MR-guided biopsy specimens ranged from 10.3 to 15.0 mm.
Upon linear mixed model analysis, significant mADC differences were present between 
transition zone cancers (mean mADC, 0.77-0.86×10-3 mm2/s) and non-cancerous 
transition zone without (1.12 ×10-3 mm2/s) and with degrees 1 to 2 prostatitis (1.05-
1.12×10-3 mm2/s; P<0.0001-0.05). The exceptions were transition zone cancers with a 
primary GG 4-5 and a secondary GG 2-3 or a primary GG 2-3 and a secondary GG 4-5 
versus a degree 2 of prostatitis (P = 0.06-0.09). No significant differences were found 
between subcategories of transition zone cancer primary and secondary GG (P = 0.17-
0.91) and between healthy transition zone without prostatitis versus both degree 1 and 
2 prostatitis (P = 0.48-0.94). In Figure 4, boxplots of mADC values for MR guided biopsy 
specimen histopathological categories are presented. Comparing the cores with a 
Gleason score 3+3 (n = 14) versus a Gleason score 4+4 (n = 6) only, the mean ADC 
values were 0.85×10-3 mm2/s (95% confidence interval[CI], 0.70-0.99×10-3 mm2/s) and 
0.79×10-3 mm2/s (CI, 0.57-1.01×10-3 mm2/s), respectively (P = 0.66). Because only 1 core 
had a single GG 5 pattern, this core was left out of the analysis. For cancer-containing 
cores, a scatterplot depicting mADC values for different Gleason scores is shown in 
Figure 5. Taking into account the MR-guided biopsy cancer core length, no significant 
mADC differences were present for cancer core lengths of, respectively, 10-≤12, >12-
≤15 and greater than 15 mm for patients with primary GG 3 (P = 0.22-0.87), 4 (P = 0.05-
0.84), and 5 cancers (P = 0.70-0.91). Receiver operating characteristic analysis for mADC 
to differentiate transition zone cancer cores (n = 87) from non-cancerous transition 
zone cores (n = 46) resulted in an AUC of 0.84 (95% CI, 0.77-0.91). For the differentiation 
between the cancerous (n = 87) and non-cancerous cores with prostatitis (n = 55), the 
AUC also was 0.84 (0.77-0.90). The AUC for differentiating the non-cancerous cores 
with any degree of prostatitis (n = 55) versus the non-cancerous cores without (n = 46) 
prostatitis was 0.56 (0.44-0.67). The mADC had an AUC of 0.62 (0.49-0.74) for the 
differentiation of primary GG 4-5 (n = 39) from GG 2-3 (n = 48) cancers..
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Table 2. Patient characteristics
Characteristic
Median (IQR)
Patients with cores 
containing TZ cancer 
(n=52)
Patients with cores 
containing non-
cancerous TZ (n=53)
p-value†
Age (yrs) 67 (63-71) 66 (61-68) n.a.
PSA
(ng/mL)
19.6 (11.4-26.6) 14.0 (9.5-20.6) 0.02*
Prostate volume
(mL)
43.0 (35.0-62.0) 57.3 (55.1-107.6) <0.001
PSA density
(ng/mL/mL)
0.42 (0.28-0.70) 0.19 (0.09-0.32) <0.001*
Previous TRUS biopsy sessions 3 (2-4) 2 (1-3) n.a.
Included MRGB cores per patient 2 (1-2) 2 (2-3) n.a.
MRGB cancer core length (mm) 12.0 (11.0-14.0) n.a. n.a.
MRGB total core length (mm) 15.0 (12.0-16.0) 13.0 (10.3-15.0) 0.008
Gleason score‡
2+4 1 n.a. n.a.
3+2 10 n.a. n.a.
3+3 14 n.a. n.a.
3+4 18 n.a. n.a.
3+5 5 n.a. n.a.
4+3 9 n.a. n.a.
4+4 6 n.a. n.a.
4+5 13 n.a. n.a.
5+3 3 n.a. n.a.
5+4 7 n.a. n.a.
5+5 1 n.a. n.a.
Gleason score is given on a core basis because some patients had different Gleason scores in different 
magnetic resonance-guided prostate biopsy cores. Continuous parametric variables were compared with 
independent t tests. A significance level of P < 0.05 was used.
*The Mann-Whitney test was used to evaluate the differences between continuous non-parametric 
variables. †P values between the patients with magnetic resonance-guided prostate biopsy specimens 
containing transition zone cancer versus the patients with magnetic resonance-guided prostate biopsy 
specimens containing non-cancerous transition zone. ‡Numbers of MR guided biopsy core specimens. IQR 
indicates interquartile range; MRGB, magnetic resonance-guided prostate biopsy; n.a., not applicable; PSA, 
prostate-specific antigen; TRUS, transrectal ultrasound.
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(c)
Figure 2. Illustration of the annotation of an MR guided biopsy core on a T2-weighted balanced 
gradient echo confirmation scan. Note the appearance of the inserted needle as a large signal 
void, strongly exaggerating the true size of the needle (diameter 1.27 mm). (a) Measurement 
of the needle pathway of 22 mm in the needle artifact on a transversal T2-weighted balanced 
gradient echo confirmation scan (TR 4.48 ms, TE 2.24 ms). (b) Annotation of the core length (the 
last 17 mm of the 22 mm as depicted in (a)) with regions of interest on a transversal T2-weighted 
balanced gradient echo confirmation scan (TR 4.48 ms, TE 2.24 ms). This anatomical scan was 
used to reconfirm correct positioning of the whole needle sampling part within the prostate 
transition zone. (c) Completed annotation of an MR guided biopsy core. Regions of interest are 
appended in one unit for analysis. The location of the annotated core (IV) can be seen in the 
baseline diffusion weighted image (TR 3300 ms, TE 60 ms) (I), baseline T2-weighted image (TR 
3620 ms, TE 103 ms) (II) and the corresponding sagittal T2-weighted balanced gradient echo 
confirmation scan (TR 4.48 ms, TE 2.24 ms) (III).
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Figure 3. Projection of annotated cores on the MR-guided biopsy ADC maps. A 63-year-old man 
with a PSA of 20 ng/mL and 1 previous negative transrectal ultrasound biopsy session. During 
the MR-guided biopsy, a GG 3+5 prostate cancer was detected in 100 volume percent of the 
depicted core. A, The annotated MR-guided biopsy core on a transversal T2-weighted balanced 
gradient echo confirmation scan (TR, 4.48 milliseconds; TE, 2.24 milliseconds). B, Gradient echo 
image (A) fused with the diffusion-weighted imaging ADC map in color. The diffusion-weighted 
imaging ADC values within the annotated MR-guided biopsy core (black demarcations) are 
visible. In the middle of the core, the ADC was 0.4×10-3 mm2/s, whereas, at both core ends, the 
ADC was 0.7-0.9×10-3 mm2/s. The color scale of the ADC map on image B and C was as follows: 
red-pink, 0.135×10-3 mm2/s or less; dark blue, 0.852×10-3 mm2/s or less; light blue, 1.330 ×10-3 
mm2/s or less; and green-yellow 1.750×10-3 mm2/s or less. C, The same annotated MR-guided 
biopsy core (black demarcations) over a sagittal projection of the diffusion-weighted imaging 
ADC map. D, Hematoxylin and eosin-stained tissue section of the prostate biopsy core with 
indications of GG at scanning magnification of ×10. This core is corresponding to the core in A 
to C. I to III, Higher magnifications of the different areas indicated by the boxes (×20). The lower 
ADC value in the middle of the core agrees with a primary GG 5 situated in between lower GGs.
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Discussion
Our results show that mADC values can differentiate the transition zone cancer from 
the non-cancerous transition zone (AUC 0.84) and from any degree of prostatitis 
(AUC 0.84). However, because of substantial overlap, mADC has a poor accuracy 
to distinguish primary GG 4-5 from GG 2-3 transition zone cancers (AUC 0.62) and 
cannot be used to differentiate between noncancerous transition zone with and 
without prostatitis (AUC 0.56).
Our significant mADC differences for transition zone cancer versus non-cancerous 
transition zone confirm findings in other studies (8,13,22,23). The ADC for transition 
zone cancer in these studies varied between 0.61-1.13×10-3 mm2/s versus the ADC 
values for noncancerous transition zone of 1.08-1.73×10-3 mm2/s. In so far as the 
ADC values can be compared for diffusion-weighted MR imaging sequences with 
different b-values, our mean mADC values for both cancer (0.77-0.86-10-3 mm2/s) 
and for non-cancerous transition zone tissue (1.12×10-3 mm2/s) were in the lower 
range of these reported values. As we targeted cancer-suspicious regions using 
MR-guided biopsy specimens as a reference standard, our ADC values may have 
been in the lower ranges of the former radical prostatectomy-referenced studies. 
To our knowledge, one other study also used MR-guided biopsy specimens as 
a reference standard for diffusion-weighted imaging ADC (10). Our significant 
mADC differences between degrees and 1 and 2 of prostatitis and most transition 
zone cancers confirmed the results of the latter study, in which a significant ADC 
difference between prostatitis and low-GG transition zone cancer was found 
(P <0.001) (10).
Inflammatory infiltrates in prostatitis lead to an increased cellular density and may 
therefore decrease ADC (21). In a healthy transition zone, a large ADC variation 
may be present because of higher variability of the different tissue components 
with different cellular densities. Stromal benign prostatic hyperplasia has a more 
compact and more homogeneous cell density and is known to have lower ADC 
values (1.27×10-3 mm2/s) compared with glandular benign prostatic hyperplasia 
(1.73×10-3 mm2/s) (8). Therefore, a relative local ADC decrease due to focal chronic 
prostatitis may not be discerned in the transition zone. The higher the degree of 
the prostatitis is, the lower the mADC is, as is depicted in Figure 4. Despite only 
including 5 cores with a degree 2 of prostatitis, we showed that, because of a lower 
ADC in a higher degree of prostatitis, a significant mADC difference between the 
magnetic resonance-guided prostate biopsy (MRGB) specimen cores with degree 
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2 prostatitis (mADC, 1.12× 10-3 mm2/s) versus the primary GG 4-5 and secondary GG 
2-3 transition zone cancers and vice versa (histopathological categories II and III) did 
not exist (P = 0.06-0.09). This significant mADC difference did exist for cores with a 
degree 1 prostatitis (mADC, 1.05×10-3 mm2/s), which had a higher ADC compared 
with any transition zone cancer (P <0.0001). Our mean mADCs for primary GG 2-3 
and 4-5 cancer-containing cores (mean [SD], 0.84-0.85×10-3 mm2/s and 0.77-0.86 
×10-3 mm2/s, respectively) differ from the ADC values reported for primary GG 2-3 
versus 4-5 cancers upon radical prostatectomy by Kobus et al (13) (respectively, 
minimum 25th percentiles of 0.51-0.95×10-3 mm2/s and 0.61×10-3 mm2/s) and by 
Kitajima et al (22) (respectively, mean ADC of 1.12-1.21×10-3 mm2/s and 0.64-1.01 
×10-3 mm2/s). Kobus et al (13) reported minimum 25th percentiles, which are lower 
compared with our mean 50th percentiles, whereas Kitajima et al (22) reported 
mean ADC values, which may be higher compared with our median values. Next 
to differences in image to histopathology correlation between studies, these 
ADC differences may have been caused by the application of b-values of 0 and 
1000 s/mm2 by Kitajima et al (22) versus the applied b-values of 50, 500, and 
800 s/mm2 in our study (22).
Our AUC value of 0.84 for discriminating transition zone cancer from non-cancerous 
transition zone tissue agrees with the results reported by Kitajima et al (22) (0.87-
0.89) and by Oto et al (8) (0.78-0.99). To our knowledge, our study is the first to 
report AUC values for mADC differentiation of prostatitis from the transition zone 
cancer (0.84) and from the noncancerous transition zone (0.56).
Our moderate AUC value for differentiation of a primary GG 4-5 versus a GG 2-3 in 
MR-guided biopsy cores acquired in the transition zone (0.62) is comparable with 
AUC values of 0.61 to 0.62 found by Verma et al (12) for differentiation of a radical 
prostatectomy specimen Gleason score higher than 6 versus 6 or lower in the 
transition zone using both mean ADC and tumor volume. Our moderate accuracy 
in differentiating primary GG 4 from GG 3 cancer cores was caused by mADC overlap 
between the GGs, which, itself, may have been the result of mADC variations. mADC 
variations may have been caused by the inclusion of a secondary GG core tissue 
and by inter-patient and intra-patient mADC variations (24). Variation of the amount 
of noncancerous tissue in the cancer-containing cores did not cause significant 
mADC differences when we analyzed mADC for the primary GG 3 and 4 transition 
zone cancer cores with a cancer core length of 10-≤12, >12-≤15, and >15 mm 
(P = 0.22-0.87).
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This study has limitations. First, our results are subject to selection bias. Because we 
used a cancer core length of 10 mm and greater, we excluded smaller cancers from 
our retrospective analysis.
However, because MR-guided biopsy is performed in a larger patient group 
compared with patients undergoing surgery, still, less patient selection bias is 
present compared with radical prostatectomy specimens. Second, as mentioned, 
including secondary GG tissue that was different from the primary GG may have 
reduced accuracy of our differentiation of primary GG 4 from primary GG 3 cancers. 
Although present in a smaller volume compared with the primary GG, the presence 
of adifferent secondary GG causes variation and overlap in ADCs for primary GG. 
As mentioned earlier, our results clearly showed a larger ADC difference and less 
overlap for a secondary GG, which was identical to the primary GG compared with a 
secondary GG, which was different from the primary GG. Furthermore, inaccuracies 
in our measurements may have been caused by possible needle, prostate, or patient 
movement in the short time gap between the actual biopsy and the acquisition of 
confirmation scans (25). Despite our manual registration of confirmation scans to 
the diffusion-weighted imaging ADC maps, some variation in measurements due 
to patient movement throughout the whole MR-guided biopsy procedure may 
still have occurred. Third, we took into account a larger apparent size of the needle 
tip artifact on the MR images compared with the actual needle size. However, 
we did not adjust this measure for the angle of needle insertion with the static 
field (B0) of the MR scanner, which may influence the apparent needle size (26). 
Fourth, because our reference standard MR-guided biopsy was based on targeting 
MR imaging cancer-suspicious regions, selection bias may have occurred. Cancer-
suspicious regions may have a relatively higher cell density, resulting in lower ADC 
values compared with the whole transition zone.
Diffusion Weighted Magnetic Resonance Imaging in the Prostate Transition Zone:
Histopathological Validation using Magnetic Resonance-Guided Biopsy Specimens
111
4
Figure 4. Box plot of median ADC values in annotated ROIs on MRGB needle artifacts versus 
MRGB core specimen histopathology categories. Values in between 1.5 to 3 box lengths above 
the upper box margin are presented as outliers with a circle. GG indicates Gleason grade; mADC, 
median apparent diffusion coefficient values; MRGB, MR guided biopsy; TZ, prostate transition 
zone.
Figure 5. Scatterplot of median ADC values in annotated ROIs on MRGB needle artifacts versus 
MRGB core specimen Gleason scores. ADC indicates apparent diffusion coefficent; MRGB, MR 
guided biopsy; ROI, region of interest.
To clinically apply our detected mADC differences for different histopathology 
entities in the transition zone, variation of ADC values should be reduced. In a 
recent study, correction for interpatient variation of healthy peripheral zone ADC 
significantly improved (P = 0.04; AUC, 0.91-0.96) differentiation of GG 4 and/or 5 
versus GG 2 and/or 3 cancers (27). This principle may also be applied for cancers 
located in the transition zone.
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In conclusion, mADC values can differentiate the transition zone cancer from the 
non-cancerous transition zone and from degree 1 and, sometimes, from degree 
2 prostatitis. However, because of mADC overlap between the histopathology 
categories, mADC had a poor accuracy to distinguish between different 
subcategories of transition zone cancer primary and secondary GG and cannot be 
used for differentiation between non-cancerous transition zone with and without 
prostatitis. Diffusion-weighted MR imaging ADC may therefore contribute in 
the detection of transition zone cancers, but as a single functional MR imaging 
technique, diffusion-weighted MR imaging has a moderate diagnostic accuracy in 
separating higher versus lower GG components in transition zone cancers and in 
differentiating prostatitis from non-cancerous transition zone.
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Abstract:
Background: Patients with elevated prostate-specific antigen (PSA) and one or 
more previous negative transrectal ultrasound (TRUS) biopsy sessions are subject 
to diagnostic uncertainty due to TRUS-biopsy undersampling. Magnetic resonance 
(MR)–guided biopsy (MRGB) has shown high prostate cancer (PCa)–detection rates 
in studies with limited patient numbers.
Objective: Determine the detection rate of (clinically significant) PCa for MRGB of 
cancer suspicious regions (CSRs) on 3-T multiparametric MR imaging (MP-MRI) in 
patients with elevated PSA and one or more negative TRUS-biopsy session(s).
Design, setting, and participants: Of 844 patients who underwent 3-T MP-MRI in our 
referral centre between March 2008 and February 2011, 438 consecutive patients 
with a PSA >4.0 ng/ml and one negative TRUS-biopsy session or more were 
included. MRGB was performed in 265 patients. Exclusion criteria were existent PCa, 
endorectal coil use, and MP-MRI for indications other than cancer detection.
Intervention: Patients underwent MRGB of MP-MRI CSRs.
Measurements: (clinically significant) MRGB cancer-detection rates were determined.
Clinically significant cancer was defined based on PSA, Gleason score, stage, and 
tumour volume. Follow-up PSA and histopathology were collected. Sensitivity 
analysis was performed for patients with MP-MRI CSRs without MRGB.
Results and limitations: In a total of 117 patients, cancer was detected with MRGB 
(n = 108) or after negative MRGB (n = 9). PCa was detected in 108 of 438 patients 
(25%) and in 41% (108 of 265) of MRGB patients. The majority of detected cancers 
(87%) were clinically significant. Clinically significant cancers were detected in seven 
of nine (78%) negative MRGB patients in whom PCa was detected during follow-up. 
Sensitivity analysis resulted in increased cancer detection (47–56%). Complications 
occurred in 2.0% of patients (5 of 265).
Conclusions: In patients with elevated PSA and one or more negative TRUS-biopsy 
session(s), MRGB of MP-MRI CSRs had a PCa-detection rate of 41%. The majority of 
detected cancers were clinically significant (87%).
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Introduction:
Prostate cancer (PCa) is a major health care problem with 899000 new cases and 
258000 deaths per year in Europe (1). In patients with elevated prostate-specific 
antigen (PSA) and/or abnormal digital rectal examination (DRE), random systematic 
transrectal ultrasound (TRUS) biopsy is the most commonly used technique to 
further evaluate PCa diagnosis. However, like PSA, which is an unspecific marker 
(specificity: 36%), and DRE, which is a rather insensitive examination (sensitivity: 
37%) for PCa detection, TRUS biopsy also has its shortcomings (2,3). Due to 
sampling error, >20% of cancers are not detected in the first TRUS biopsy session 
(4). With repeat TRUS biopsies, PCa detection rates decreased from 22% to 4% in 
four subsequent TRUS-biopsy sessions (4). As a result of the mentioned issues, a 
large number of patients with a persistently elevated or increasing PSA and one or 
more negative TRUS-biopsy sessions are subject to diagnostic uncertainty.
Magnetic resonance (MR)–guided prostate biopsy (MRGB) of a detected cancer-
suspicious region (CSR) on MR imaging (MRI) is a feasible diagnostic technique: 
PCa detection rates with this method range from 37% to 59% (5–10). Moreover, the 
implementation of MRGB has resulted in detection of predominantly (93%) clinically 
significant PCa (8). Functional MRI techniques increased PCa-localization accuracy 
(area under the curve (AUC): 0.84–0.91) when added to anatomic T2-weighted MRI 
(T2WI; AUC: 0.69–0.81) in a multiparametric MRI (MP-MRI) exam (11,12). Using its 
localization strength, MP-MRI of the prostate has increased opportunities for image-
guided techniques like MRGB. However, most MRGB studies were performed with 
a low number of patients at a lower field strength of 1.5 T. Therefore, we aimed 
to determine the detection rate of (clinically significant) PCa for MRGB of CSRs 
detected on 3-T MP-MRI in patients with an elevated PSA and at least one previous 
negative TRUS-biopsy session in a large population.
Material and Methods
Patients
The need for informed consent for this retrospective study was waived by our 
institutional review board. Between March 2008 and February 2011, 844 consecutive 
patients underwent MP-MRI in our referral centre. Of these, 438 patients with PSA 
>4 ng/ml and at least one previous negative TRUS-biopsy session and who had 
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undergone MP-MRI and/or MRGB were included. Exclusion criteria were existent 
PCa, use of an endorectal coil, and MP-MRI for other indications than cancer 
detection. Patient selection is shown in a flow diagram in Figure 1.
Magnetic resonance imaging
MP-MRI and MRGB were performed on two comparable 3-T MR scanners 
(MAGNETOM Trio and MAGNETOM Skyra; Siemens Medical Solutions, Erlangen, 
Germany) using a combined spinal and pelvic-phased array coil. MRI parameters 
are presented in Table 1.
Magnetic resonance imaging interpretation 
Two radiologists with 9 yr and 18 yr of experience in prostate MRI, respectively, 
evaluated the MP-MRI examinations using in-house-developed software (13). CSRs 
were defined on T2WI in combination with diffusion-weighted MRI (DWI) and 
dynamic contrast-enhanced MRI as described earlier (14). In addition to apparent 
diffusion coefficient (ADC) maps, DWI-calculated b1400 images were used to 
determine CSRs. A lesion was defined as a CSR on DWI in cases of focal restriction 
on the ADC map combined with an iso- to hyper-signal intensity on the calculated 
b1400 image. Clinical data of all patients were available at MRI reading.
Magnetic resonance-guided prostate biopsy
MRGB was performed in a separate session and every CSR was targeted. Two 
radiologists with 2 yr and two radiologists with 1 yr of MRGB experience performed 
transrectal prostate MRGB as described earlier (14). Axial T2WI and DWI were 
acquired as baseline images for targeting.
Histopathology
Biopsy specimens were immediately fixed in formalin and subsequently underwent 
routine histopathologic evaluation by a urogenital histopathologist who had 18 yr 
of experience.
Prostate cancer: clinical significance
When prostatectomy was not performed, clinical significance of MRGB-detected 
PCa was defined by: (1) a PSA >10 ng/ml and a PSA density >0.15 ng/ml per ml; (2) 
clinical stage ≥T2b; (3) a Gleason grade (GG) 4 or 5 within the biopsy specimen; or 
(4) a total cancer-core length (TCCL) ≥10 mm, where TCCL is the total cancer length 
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in all MRGB cores from one CSR (15–18). This definition was based on i.a. Epstein and 
D’Amico criteria (15,18). In case of performed prostatectomy, PCa was considered 
clinically significant when PCa volume was ≥0.5 ml or a stage ≥pT3 or a GG 4 or 5 
(19,20) was present.
Follow-up
Post-MRGB PSA measurements and histopathology results were collected until 
July 22, 2011, for all MRGB patients.
Statistical analysis
Parametric continuous variables were reported as mean plus or minus the 
standard deviation; nonparametric continuous variables were reported as median 
and the interquartile range (IQR). The Pearson chi-square test was used to test for 
differences in proportions. In a multivariable logistic regression analysis, PSA, PSA 
density, and prostate volume were assessed as predictors for MRGB PCa detection. 
We used sensitivity analyses in which we assumed that, in all patients with visible 
MRI lesions, PCa would have been detected if MRGB would have been performed. 
A significance level of <0.05 was used for all analyses.
CHAPTeR 5
122
Figure 1. Study flow diagram. MP-MRI = multiparametric magnetic resonance imaging; TRUS 
= transrectal ultrasound; PSA = prostate-specific antigen; MRGB = magnetic resonance guided 
prostate biopsy.
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Table 1. Multiparametric (MP) magnetic resonance imaging (MRI) parameters
Protocol Sequence TR,
ms
TE,
ms
Flip 
angle, 
degrees
Slice
thickness
mm
Field
of view
mm ´ 
mm
Matrix 
size
Voxel size, 
mm×
mm×mm
b-values,
s/mm2
Temporal 
resolution,
s
MP-MRI of the prostate (MAGNETOM Trio)
T2WI axial
(TSE) and
coronal
4480 103 120 3.0 180×180 320×320 0.6×0.6×3.0 NA NA
sagittal 4950 110 120 3.0 180×180 320×320 0.6×0.6×3.0 NA NA
DWI SSEPI
axial
2500 64 NA 4.0 256×256 128×128 2.0×2.0×4.0 0/50/500/
800
NA
DCE-MRI GE
Axial 3D
800 1.47 8 4.0 230×230 180×180 1.8×1.8×4.0 NA NA
DCE-MRI Spoiled GE
Axial 3D
32 1.47 10 4.0 230×230 128×128 1.8×1.8×4.0 NA 2.5
MP-MRI of the prostate (MAGNETOM Skyra)
T2WI TSE
axial
5180 101 160 3.0 192×192 320×320 0.6×0.6×3 NA NA
coronal 4320 101 160 3.0 192×192 320×320 0.6×0.6×3 NA NA
sagittal 4000 101 160 3.0 180×180 320×320 0.56×0.56×3 NA NA
DWI SSEPI
axial
3000 64 NA 4.0 256×256 128×128 2×2×4 0/50/100/
1200
NA
DCE-MRI GE
axial
800 1.53 14 3.0 192×192 128×128 1.5×1.5×3 NA NA
DCE-MRI GE
axial
36 1.41 14 3.0 192×192 128×128 1.5×1.5×3 NA 3.5
MRGB (MAGNETOM Trio)
T2WI TSE
axial
3620 103 120 4.0 256×256 320×320 0.8×0.8×4.0 NA NA
DWI EPI
axial
3300 60 NA 3.6 260×211 160×120 2.2×1.6×3.6 0/100/400/
800
NA
Balanced 
SSFP
GE
Axial and
Sagittal
4.48 2.24 70 3.0 280×280 256×256 1.1×1.1×3.0 NA NA
MRGB (MAGNETOM Skyra)
T2WI TSE
Axial
3560 104 120 120 256×256 320×320 0.8×0.8×4 NA NA
DWI EPI
Axial
3000 64 NA 4.0 256×212 128×128 2.0×2.0×4.0 50/100/
1600
NA
Balanced 
SSFP
GE
Axial and
Sagittal
4.56 2.28 70 3.0 280×280 256×256 1.1×1.1×3.0 n.a. n.a.
T2WI = T2-weighted magnetic resonance imaging; DWI = diffusion weighted magnetic resonance imaging; 
DCE-MRI = dynamic contrast-enhanced magnetic resonance imaging; SSFP = steady-state free procession; 
TR = repetition time; TE = echo time; TSE = turbo spin echo; SSEPI = steady-state echo planar imaging; GE 
= gradient echo; EPI = echo-planar imaging; NA = not applicable.
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Results
Inclusion criteria were met in 438 of 844 consecutive men. MRGB was performed in 
265 of these 438 men (Fig. 1). MRGB was not performed due to lack of visible lesions 
(n = 80); advice for follow-up MP-MRI in lesions suspicious for prostatitis, benign 
prostatic hyperplasia, or low-grade cancer (n = 64); or despite MRGB advice (n = 29). 
Patient characteristics are presented in Table 2. The last TRUS biopsy had a median 
of nine cores (IQR: 9–10, available in 123 of 265 MRGB patients) with transition zone 
(TZ) sampling in protocols of eight or more cores. The median MRGB duration was 
44 min (IQR: 35–51 min).
In a total of 117 patients, PCa was detected with MRGB (n = 108) or during follow-
up after negative MRGB (n = 9). PCa-detection rates were 25% (108 of 438; 95% 
confidence interval (CI), 21–29%) in included patients and 41% (108 of 265; CI, 35–
47%) in patients who underwent both MP-MRI and MRGB. The majority of detected 
cancers were clinically significant: a total of 87% (94 of 108) met the clinical criteria 
and 93% (26 of 28) met radical prostatectomy-specimen criteria.
A total of 368 CSRs were indicated in the 265 MRGB patients. With a median of 
two cores per CSR, PCa was detected in 33% of CSRs (123 of 368; CI, 29–38%). 
The majority of CSRs (63% (78 of 123); CI, 55–71%) were detected in the TZ. 
Thirty-three percent (40 of 123; CI, 25–41%) of detected CSRs were located in the 
peripheral zone (PZ). The remaining 4% (5 of 123; CI, 2–9%) were situated on the 
TZ-PZ border or in the seminal vesicles. Other predominant CSR diagnoses are 
shown in Table 3.
Significantly more PCa was detected in patients with a prostate volume ≤50 ml 
(60%) versus >50 ml (36%; p < 0.0001) and in patients with PSA density >0.15 ng/ml 
per ml (52%) versus ≤0.15 ng/ml per ml (24%; p < 0.0001). With multivariable 
logistic regression. PSA was not a predictor of MRGB PCa detection. After 
correction for PSA, only prostate volume ≤50 ml (p = 0.008) and PSA density 
>0.15 ng/ml per ml (p < 0.0001) were predictors of MRGB PCa detection in a final 
multivariable logistic regression model. These results are presented in Table 4.
In sensitivity analysis, PCa-detection rates would have increased to 47% (137 of 
294; CI, 41–52%) if MRGB would have been performed and PCa would have been 
detected in patients with a MP-MRI CSR who were advised to undergo MRGB 
(n = 29). Detection rates would have increased even further to 56% (201 of 358; 
CI, 51–56%) if MRGB would have been performed and PCa would also have been 
detected in patients with an MP-MRI suspicious for prostatitis, benign prostatic 
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hyperplasia, or low-grade cancer, and in whom repeat MP-MRI was advised 
(n = 64). A patient example of MP-MRI and MRGB is shown in Figure 2.
Table 2. Patient Characteristics
Characteristic All patients
(n=438)
Patients with 
detected 
prostate cancer 
on MRGB
(n=108)
Patients 
without 
detected 
prostate cancer 
on MRGB
(n=156)
p-value*
for patients 
with vs. without 
detected 
prostate cancer
Age, yr, median (IQR) 66 (61-69) 65 (62-70) 64 (61-69) 0.29
PSA level, ng/mL, median (IQR) 11.4 (8.6-18.3) 18.0 (10.0-27.9) 12.0 (9.1-17.1) <0.001#†
Prostate volume, ml, median (IQR) 67 (50-93) 53 (36-68) 70 (51-89) <0.001#†
Previous negative TRUS biopsy 
sessions, median (IQR)
2 (2-3) 3 (2-3) 2 (2-3) n.a.
Interval last TRUS – MRGB, mo, 
median (IQR)
12 (5-20) 13 (6-21) 11 (5-20) 0.16
Interval MRI–MRGB, mo, median 
(IQR)
2 (1-2) 1 (1-2) 2 (1-2) 0.002*
Biopsied CSR, median (IQR) 1 (1-2) 1 (1-2) 2 (1-2) n.a.
MRGB cores for one CSR, median 
(IQR)
2 (2-3) 2 (2-3) 2 (2-3) n.a.
MRI= Magnetic Resonance Imaging, IQR = interquartile range; PSA = prostate-specific antigen; TRUS = 
transrectal ultrasound; MRGB = magnetic resonance–guided biopsy; CSR = cancer-suspicious region; NA 
= not applicable. * P values were calculated using an independent t test and a Mann-Whitney U test for 
nonparametric variables. # Mann-Whitney U test. † p < 0.05 was considered statistically significant.
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(a)
  
(b) (c)
Figure 2. A 76-yr-old patient with a prostate-specific antigen level of 32 ng/ml and density of 
0.46 ng/ml per ml, clinical stage T1C, and one previous negative transrectal ultrasound–guided 
biopsy session underwent multiparametric magnetic resonance imaging (MRI) for a clinical 
indication of prostate cancer detection. (A) A ventral transition-zone cancer is visible (demarcated 
regions). A focal lenticular-shaped homogeneous low-signal intensity (blue demarcation) in 
the ventral prostate is visible on (iii) sagittal and (v) axial T2-weighted MRI (T2WI). A focal (ii) 
low apparent diffusion-coefficient value (blue demarcation) and (iv) high signal intensity (blue 
demarcation) on the calculated b1600 image are visible in the same area on diffusion-weighted 
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MRI. (i)The Ktrans overlay on T2WI can be appreciated. Dynamic contrast-enhanced MRI shows 
symmetric increased enhancement (black demarcation) matching the other functional images 
and T2WI. Benign prostate hyperplasia nodules are also enhanced (white arrows). (B) Sagittal 
and (C) transverse balanced gradient echo images were made to confirm the needle positions. 
Needle artefacts (white lines) and needle guiders (blue lines with white-dotted top) are visible. 
In this magnetic resonance–guided biopsy specimen, a Gleason score 4 + 5 prostate cancer was 
found in the ventral transition zone.
Table 3. Magnetic resonance–guided biopsy histopathology results for cancer- suspicious 
regions on multiparametric magnetic resonance imaging
Histology in MRGB cores of CSRs Percentage of CSRs*,
% (no./total)
Prostate cancer 33 (123/368)
Prostatitis 30 (109/368)
Healthy intra-prostatic tissue 23 (85/368)
Atrophia 8 (31/368)
Material not representative for prostate tissue 5 (18/368)
HGPIN 4 (16/368)
Reactive atypia 2 (9/368)
AAH 2 (8/368)
Fibrosis 0.003 (1/368)
Total number of CSRs 100 (368/368)
CSRs = cancer-suspicious regions; MRGB = magnetic resonance–guided biopsy; HGPIN = high-grade 
intraprostatic neoplasia; AAH = atypical adenomatous hyperplasia. * Because some CSRs had more than 
one diagnosis, the sum of percentages is higher than 100%.
In sensitivity analysis, PCa-detection rates would have increased to 47% (137 of 
294; CI, 41–52%) if MRGB would have been performed and PCa would have been 
detected in patients with a MP-MRI CSR who were advised to undergo MRGB 
(n = 29). Detection rates would have increased even further to 56% (201 of 358; 
CI, 51–56%) if MRGB would have been performed and PCa would also have been 
detected in patients with an MP-MRI suspicious for prostatitis, benign prostatic 
hyperplasia, or low-grade cancer, and in whom repeat MP-MRI was advised (n = 64). 
A patient example of MP-MRI and MRGB is shown in Figure 2.
Follow-up 
Reported MRGB complications were sepsis with hospitalization in one patient and 
a vasovagal reaction in four other patients.
Only in 51 of 156 negative-MRGB patients was a follow-up of 5 mo, including 
two PSA measurements or histopathology, available. In 6% (9 of 156; CI, 3–6%) of 
negative-MRGB patients, PCa was detected during this mean follow-up of 5 mo. 
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Detected cancers were clinically significant in 78% (seven of nine patients) based on 
clinical criteria and in 100% (four of four) based on radical prostatectomy-specimen 
criteria. Follow-up results of patients who underwent MP-MRI for suspicion of PCa 
are presented in Figure 3.
Table 4. Univariable and multivariable analysis of dichotomized prostate-specific antigen, 
prostate volume, and PSA density related to magnetic resonance–guided biopsy (MRGB) 
prostate cancer detection in patients with initial positive MRGB and initial negative MRGB 
results*
Percentage 
of patients 
with prostate 
cancer, %
(no./total)
95% CI Patients with 
prostate 
cancer upon 
MRGB,
% (no./total)
[95 CI]#
Univariable 
analysis
X2 test
Multivariable 
logistic 
regression 
analysis,
Initial model
OR [95% CI] 
(p value)
Multivariable 
logistic 
regression 
analysis,
Final model
OR [95% CI] 
(p value)
MRGB+
MRGB-
100 (108/108)
6 (9/156)
96-100
3-11
44 (116/263),
[38-50]
NA NA NA
PSA ≤ 10 ng/mL
MRGB+
MRGB-
100 (28/28)
4 (2/57)
86-100
0-13
36 (30/84),
[26-46]
0.06
1.13 (PSA >10/ 
≤10 ng/mL)
[0.53-2.40]
(0.75)
NA
PSA > 10 ng/mL
MRGB+
MRGB-
100 (80/80)
6 (6/99)
95-100
3-13
48 (86/179),
[41-55]
Prostate volume 
≤50 cc
MRGB+
MRGB-
100 (47/47)
13 (5/40)
96-100
5-27
60 (52/86),
[50-70]
<0.0001†
2.28
(prostate volume
≤ 50/ > 50 cc)
 [1.23-4.21]
(0.009†)
2.21
(prostate 
volume 
≤ 50/ > 50 cc)
[1.23-3.97]
(0.008†)
Prostate volume 
>50 cc
MRGB+
MRGB-
100 (61/61)
3 (3/116)
93-100
1-8
36 (64/177)
[29-43]
PSA density 
≤0.15 ng/mL/
mL
MRGB+
MRGB-
100 (15/15)
4 (2/57)
76-100
0-13
24 (17/71),
[15-35]
<0.0001†
3.50
PSA density
> 0.15 / ≤ 0.15 
ng/mL /mL
 [1.52-8.05]
(0.003†)
3.76
(PSA density 
> 0.15 / ≤ 
0.15 
ng/mL /mL)
[1.84-7.68]
(p<0.0001†)
PSA density 
>0.15 ng/mL/
mL
MRGB+
MRGB-
100 (93/93)
6 (6/99)
95-100
3-13
52 (99/192),
[45-59]
CI = confidence interval; PSA = prostate-specific antigen; MRGB+ = patients with prostate cancer on initial 
MRGB; MRGB_ = patients without prostate cancer on initial MRGB; CI = confidence interval; DR = detection 
rate; OR = odds ratio; x2 = Pearson chi-squared test, NA = not applicable.
 * The final multivariable logistic regression model consisted of two independent variables (PSA density 
and prostate volume [as dichotomized categorical covariates]) and one dependent variable (prostate 
cancer detection on MRGB). † Statistically significant difference at a threshold of p < 0.05.
# One patient with initial negative MRGB had prostate cancer detected upon TRUS biopsy. This patient is 
not added to the totals in the fourth column.
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Figure 3. Follow-up histopathology results in patients with multiparametric magnetic 
resonance imaging (MP-MRI): (A) excluded patients with MP-MRI, (B) patients without magnetic 
resonance–guided biopsy (MRGB), (C) patients with MP-MRI and MRGB. GG = Gleason grade; 
TRUS = transrectal ultrasound; PCa = prostate cancer; RP = radical prostatectomy specimen; PSA 
= prostate-specific antigen.
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Discussion
In patients with one or no negative TRUS-biopsy sessions, MRGB of 3-T MP-
MRI–detected CSRs resulted in a PCa detection rate of 41%. In our study, MRGB 
detected more cancers than repeated TRUS biopsy (≤18%) (21,22). Furthermore, 
our number of detected clinically significant cancers (87%) is high compared to an 
estimated 56% of clinically significant cancers for repeat TRUS biopsy in screening 
(23). We detected more clinically significant cancers because our referred patient 
population probably contained cancers of higher Gleason score than a screening 
population. Another reason for detecting many clinically significant cancers may 
be higher MRI detection rates for higher Gleason score cancers (24). Furthermore, 
MRGB has higher GG concordance with prostatectomy specimens compared to 
systematic TRUS biopsy and, therefore, less undergrading may have occurred (25).
Our detection rate of 41% is in agreement with some MRGB publications (37–39%) 
(6,10). However, our detection rate is lower compared to other MRGB studies (52–
59%) (5,8,9). This may be explained by the fact that in our study, as opposed to 
these last studies, not all patients underwent MRGB. Finally, for clinically significant 
cancers, our detection rate (87%) approaches that of Hambrock et al. (93%). The 
detection rate of clinically significant cancers of Roethke et al. was lower than ours 
(81%) (5). This may be explained by the fact they did not add MP-MRI to T2WI in the 
first 52 of their 100 patients.
Our relatively high detection rates of PCa in the TZ (63%) agree with results of 
Hambrock et al. (57% in TZ) (8). However, in other reports, TZ cancer-detection rates 
(47% and 35%, respectively) were lower than PZ cancer-detection rates (respectively, 
53% and 64%) (5,6). Heterogeneity of patient populations due to differences in the 
number of previous TRUS-biopsy sessions, the TRUS-biopsy protocol, and in the 
number of cores in TRUS biopsies makes it difficult to compare results of reported 
predominant PCa locations.
Clinical alternatives to MRGB are limited to saturation biopsy protocols (including 
transperineal template biopsies). Saturation biopsies have the disadvantages of 
possibly requiring anaesthesia and a high number of cores. Detection rates of 
protocols including 20–38 cores ranged from 14% to 41% without significantly 
increasing the likelihood of detecting clinically significant cancers (26). In MRGB, 
only a limited number of cores (median two cores per CSR) are needed to detect 
a high percentage (86%) of clinically significant cancers. Furthermore, in MRGB, no 
general anaesthesia is required. Clinical use of MRGB is currently restricted by its 
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limited availability and its rather long procedure times (median: 44 min). However, 
application of MR-ultrasound fusion techniques (using registration), needle-guide 
tracking sequences, and implementation of robotics may improve these drawbacks 
in the near future (27–29). When these issues are solved, MP-MRI and MRGB could be 
applied on a larger scale for PCa detection in patients with an elevated PSA and one 
or more negative TRUS-biopsy sessions. However, PCa-detection rates for random 
systematic TRUS biopsy versus targeted MRGB should be prospectively compared 
in patients stratified for previously performed similar TRUS-guided biopsy protocols.
Our study has several limitations. First, our follow-up is limited to two or fewer PSA 
measurements within 1 yr without histopathology examinations in most patients. 
Inferring conclusions from false-negative MRGB results remains difficult based on 
this limited follow-up. However, regardless of follow-up duration, differentiation of 
a patient with small-volume cancer missed by MRGB from a patient without PCa 
remains problematic without availability of radical prostatectomy specimens directly 
after MRGB. Second, as our work was performed in a referral centre, inter-patient 
variation in the number and the protocols of previous negative TRUS-biopsy sessions 
is present. Furthermore, intra-patient variation exists due to time differences between 
protocols of different TRUS-biopsy sessions in a single patient. Furthermore, in some 
patients, bias may have been caused by the relatively low number of TRUS-biopsy 
cores for the sampled prostate-cancer volume. Third, MRGB was performed by four 
radiologists who did not perform consensus image reading. Possible differences 
in image interpretation between reading radiologists and MRGB radiologists may 
have biased our results. Finally, a TCCL ≥10 mm, recently defined to predict a radical 
prostatectomy specimen tumour volume ≥0.5 ml using TRUS (5-mm grid) template 
biopsy simulations (17), was used as a criterion for targeted precisely to a lesion and is 
not taken every 5 mm according to a grid, our TCCL criterion may have overestimated 
MRGB results for clinically significant cancers. However, as no results on MRGB TCCL 
for prediction of tumour volume exist currently, we incorporated this ultrasound 
criterion for estimation of tumour volume based on MRGB specimens.
Conclusions
In conclusion, in patients with an elevated PSA level and one or more previous 
negative TRUS-guided prostate biopsy session(s), MRGB of 3-T MP-MRI-detected 
CSRs has a detection rate of 41% for predominantly clinically significant PCa (87%).
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Abstract
Background: Accurate pre-treatment assessment of prostate cancer (PCa) 
aggressiveness is important in decision making. Gleason grade is a critical predictor 
of the aggressiveness of PCa. Transrectal ultrasound–guided biopsies (TRUSBxs) 
show substantial undergrading of Gleason grades found after radical prostatectomy 
(RP). Diffusion-weighted magnetic resonance imaging (MRI) has been shown to be 
a biomarker of tumour aggressiveness.
Objective: To improve pre-treatment assessment of PCa aggressiveness, this study 
prospectively evaluated MRI-guided prostate biopsies (MR-GBs) of abnormalities 
determined on diffusion-weighted imaging (DWI) apparent diffusion coefficient 
(ADC) maps. The results were compared with a 10-core TRUSBx cohort. RP findings 
served as the gold standard.
Design, setting, and participants: A 10-core TRUSBx (n = 64) or MR-GB (n = 34) was 
used for PCa diagnosis before RP in 98 patients.
Measurements: Using multiparametric 3-T MRI: T2-weighted, dynamic contrast 
enhanced imaging, and DWI were performed to identify tumour-suspicious regions 
in patients with a negative TRUSBx. The regions with the highest restriction on ADC 
maps within the suspicions regions were used to direct MR-GB. A 10-core TRUSBx 
was used in a matched cohort. Following RP, the highest Gleason grades (HGGs) in 
biopsies and RP specimens were identified. Biopsy and RP Gleason grade results 
were evaluated using chi-square analysis.
Results and limitations: No significant differences on RP were observed for 
proportions of patients having a HGG of 3 (35% vs 28%; p = 0.50), 4 (32% vs 41%; 
p =0.51), and 5 (32% vs 31%; p = 0.61) for the MR-GB and TRUSBx cohort, respectively. 
MR-GB showed an exact performance with RP for overall HGG: 88% (30 of 34); for 
TRUS-GB it was 55% (35 of 64; p = 0.001). In the MR-GB cohort, an exact performance 
with HGG 3 was 100% (12 of 12); for HGG 4, 91% (10 of 11); and for HGG 5, 73% 
(8 of 11). The corresponding performance rates for TRUSBx were 94% (17 of 18; 
p = 0.41), 46% (12 of 26; p = 0.02), and 30% (6 of 20; p = 0.01), respectively.
Conclusions: This study shows prospectively that DWI-directed MR-GBs significantly 
improve pre-treatment risk stratification by obtaining biopsies that are representative 
of true Gleason grade.
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Introduction
The Gleason grading system is the key method to describe the pathologic 
characteristics of prostate cancer (PCa). Of all the clinically determinable parameters, 
the Gleason score (GS) has proven to be the most important in measuring 
aggressiveness, disease outcome, and the risk of mortality from PCa (1).
Transrectal ultrasound–guided biopsy (TRUSBx) is currently the most accepted 
method for establishing a definite diagnosis of PCa in patients with a clinical suspicion 
based on prostate-specific antigen (PSA) values or digital rectal examination (DRE). 
The most frequently used schemes include sampling 10–12 cores with emphasis 
on the lateral peripheral zone and transition zone (2,3). The tumour biopsy cores are 
scored according to the Gleason grading scheme to determine aggressiveness. PCa 
can be multifocal and heterogeneous in composition, often presenting with well-, 
moderately, and poorly differentiated components in the same tumour. TRUSBx 
determined GS has been shown (4–6) to be substantially discordant (undergrading 
in 34–38%) with the GS determined in radical prostatectomy (RP) specimens. 
Because risk stratification affects individualised treatment decisions and prognosis, 
the accurate pre-treatment prediction of GS remains essential.
Multiparametric MR imaging (MP-MRI), including T2-weighted imaging, diffusion-
weighted imaging (DWI), and dynamic contrast-enhanced MR imaging (DCE-
MRI),have all been shown (especially in combination) to localise PCa accurately 
(7,8). Improved localisation of suspicious regions on MP-MRI have also been biopsy 
targeted under MR guidance and shown to increase tumour detection rates 
substantially (9,10). DWI has been shown to provide information about tumour 
aggressiveness (11,12).
The aim of this study was to determine prospectively whether DWI-guided prostate 
biopsies could improve the pre-treatment assessment of PCa aggressiveness. These 
results were compared with a standard clinical cohort of patients who underwent 
10-core TRUSBxs. In both cohorts the performance of Gleason grades in biopsy and 
RP (the gold standard) was determined.
CHAPTeR 6
138
Materials and methods
Patients
Between August 2006 and April 2009, 123 consecutive patients underwent RP at 
the Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, and 
were retrospectively included after a PCa diagnosis was made with 10-core TRUSBx 
or MR-GB. Patients with prior hormonal/radiotherapy were excluded.
Transrectal ultrasound–guided biopsy sampling
Extended systematic 10-core TRUSBxs (6 lateral and 4 transition zone) were 
obtained using a Pro Focus B-K ultrasound device (B-K Medical, Herlen, Denmark) 
and 18G needles with a 17-mm sampling length. Indications for biopsies were 
based on clinical parameters: elevated PSA ≥4 ng/ml and/or abnormal DRE. TRUSBx 
represented the first biopsy session in these patients.
Magnetic resonance imaging
MP-MRI at 3-T (Trio Tim, Siemens, Erlangen, Germany) that included T2-weighted, 
DWI, and DCE-MRI was performed in patients with at least one prior negative 
10-core TRUSBx but persistent clinical suspicion for PCa defined by elevating or 
persistently elevated PSA >4 ng/ml. Table 1 lists the MRI parameters. Apparent 
diffusion coefficient (ADC) maps were calculated from the DWI by the scanner. 
Two radiologists determined up to three tumour-suspicious regions (TSRs) per 
patient in consensus using the combined information of the features suspicious 
for malignancy on the different MP-MRI modalities. PSA values were available to 
radiologists. Each of the imaging modalities was scored on a tumour probability 
scale of 1–5 with a maximum cumulative score of 15. Per modality, the scale 
is defined as follows: 1, definitely no tumour; 2, probably no tumour; 3, possibly 
tumour; 4, probably tumour; and 5, definitely tumour. A score ≥8 of 15 was an 
indication for biopsy of a TSR.
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Table 1. Magnetic resonance imaging sequence parameters
Sequence 
type
Slice 
thickness 
mm
No. of 
slices
In-plane 
resolution 
mm
TR 
ms
TE 
ms
Averages GRAPPA b-values
mm/s2
T2-w axial TSE 4 15-19 0.6×0.6 3540 104 2 - -
T2-w coronal TSE 4 15-19 0.6×0.6 3350 105 2 - -
T2-w sagittal TSE 4 15-19 0.6×0.6 3810 105 2 - -
DWI SE-EPI 4 15-19 2.0×2.0 2800 81 10 2 0, 50, 
500, 800
T1-w DCE GRE
(FLASH 3D)
4 14 1.8×1.8 37 1.47 1 - -
TR = repetition time; TE = echo time; GRAPPA = parallel imaging factor; T2-w = T2-weighted; TSE = turbo 
spin echo; DWI = diffusion-weighted imaging; SE-EPI = spin echo-echo planar imaging; T1-w = T1-weighted; 
DCE = dynamic contrast enhanced imaging; GRE = gradient echo imaging; FLASH = fast low-angle shot 
imaging.
Magnetic resonance imaging–guided biopsy
An average of 4 wk (range: 2–6 wk) following tumour detection by MP-MRI, an 
MR-GB (using MR-compatible 18G needles with a sampling length of 17 mm) of 
the previously determined TSRs was performed using a commercially available 
transrectal MR biopsy device (Invivo, Schwerin, Germany). The translation of initial 
MR imaging findings to the subsequent MR-GB was previously described in detail 
(13). The lowest signal areas on the ADC maps within the TSR were used to target 
biopsies.
Histopathologic analysis of biopsy specimens
Biopsy tissue cores were fixed in 10% neutral-buffered formalin stained with 
haematoxylin-eosin, and a 5-mm tissue section was prepared before evaluation by 
one urogenital pathologist (CAHK) with 17 yr of experience in prostate pathology. 
All clinical features were available to the histopathologist. For cores containing 
cancer, a GS was determined using the 2005 International Society of Urogenital 
Pathology (ISUP) criteria. The primary, secondary, and tertiary Gleason grades were 
determined, and the highest Gleason grade (HGG) was identified.
Reconstructed whole-mount step-section preparation
Following RP, specimens were processed and cut into 4-mm-thick slices, 
perpendicular to the dorsal-rectal surface and parallel to the transverse T2-weighted 
imaging plane. All slices were completely evaluated on 5-mm sections stained with 
haematoxylin-eosin. The presence and extent of PCa was outlined by the same 
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pathologist (who also evaluated all biopsies). Each tumour was graded according 
to the 2005 ISUP modified Gleason grading system (14). As with the assessment of 
biopsies, the primary to tertiary Gleason grades and the HGG identified within the 
prostate was noted.
Statistical analysis
Cross-tabulation analysis of the biopsy and RP findings was done. For both MR-GB 
and TRUSBx cohorts, performance rates (percentage) with RP were determined for 
the HGG. Then, for RP HGG 5, undergrading was further defined as ‘‘substantial’’ if 
the corresponding biopsy was HGG 3. Finally, performance rates between biopsy 
and RP HGG groups were determined separately for patients with PSA ≤10 ng/ml 
and those with PSA >10 ng/ml. Chi-square analyses with Fisher exact tests were 
performed to evaluate the significance of differences between MR-GB and TRUSBx 
performance rates. The t test was performed to determine the differences in mean 
PSA, prostate volume, and dominant tumour volume. Significance was considered 
when p < 0.05. Statistical analyses were performed with SPSS software v.16.0.01 
(IBM Corp, Somers, NY, USA) (Figs. 1–3).
Results
Ninety-eight patients fulfilled the inclusion criteria. In 34 of 98 patients a tumour 
diagnosis was made using MR-GB (median: 3 cores, range: 1–5; median number of 
biopsies/TSR: 2, range: 1–3), and in 64 of 98 patients a diagnosis was made using 10-
core TRUSBx. The median duration of the procedure for MR-GB was 29 min (range: 
15–75 min). The median duration between MR-GB and RP was 6 wk (range: 3–11 wk) 
and between TRUSBx and RP was 5 wk (range: 2–9 wk). Table 2 summarises the 
patients’ demographic and clinical parameters.
No significant differences between MR-GB and TRUSBx cohorts were observed for 
percentage stage pT3 (35% vs 38%; p = 0.83), mean dominant aggressive tumour 
volume (4.85 cm3 vs 4.52 cm3; p = 0.69), or mean prostate volume (41 cm3 vs 36 cm3; 
p = 0.61). No significant differences were observed for the overall proportions of 
patients on RP having HGG 3 (35% vs 28%; p = 0.50), 4 (32% vs 41%; p = 0.51), and 5 
(32% vs 31%; p = 1.00) for the MR-GB and TRUSBx cohort, respectively. The RP presence 
of HGG 4 was associated with extracapsular extension in 39–46% and the presence of 
HGG 5, in 64–70%. Table 3 and 4 present a summary of biopsy and RP findings.
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Categorisation of HGG on biopsy and RP revealed an overall performance for MR-
GB of 88% (30 of 34) versus 55% (35 of 64) for TRUSBx. In the MR-GB cohort, an exact 
performance with RP HGG 3 was 100% (12 of 12); for HGG 4, 91% (10 of 11); and for 
HGG 5, 73% (8 of 11). The corresponding performance rates for TRUSBx were 94% 
(17 of 18; p = 0.41), 46% (12 of 26; p = 0.01), and 30% (6 of 20; p = 0.02), respectively 
(Fig. 1). For biopsies determined as low grade (HGG 3), the positive predictive value 
(PPV) for MR-GB to represent true low grade was 92% (12 of 13); for TRUSBx the PPV 
was 45% (17 of 38; p = 0.001). Overall, undergrading of tumours with RP HGG 4/5 
was 46% (25 of 46) for TRUSBx and 5% (1 of 22) for MR-GB. No overgrading was 
observed for MR-GB, although this was evident in one TRUSBx patient (false HGG 4 
instead of 3). Undergrading for RP HGG 5 was 27% (3 of 11) in MR-GB compared with 
70% (14 of 20) for TRUSBx. TRUSBx showed substantial undergrading (RP HGG 5) in 
57% (8 of 14), whereas no substantial undergrading occurred with MR-GB.
Table 2. Patient and pathology characteristics
MR-GB 10-core biopsy Significance, p-value
No. of patients 34 64 NA
Age, yr (range) 66 (51-74) 66 (41-74) 0.22
No. of biopsies (range) 3 (1-5) 10 NA
Stage (%)
  pT2
  pT3
22/34 (65)
12/34 (35)
40/64 (62)
24/64 (38)
0.83
Prostate volume
  Median, cm3 (range) 41 (12-79) 36 (17-126) 0.61
PSA
  Median, ng/ml (range) 12 (3-40) 8 (2-47) 0.02*
DA tumour volume
  Median, cm3 (range) 4.85 (0.1-33) 4.52 (0.1-33.5) 0.69
Prevalence of tumours in RP
  HGG category, %
  HGG 3
  •Stage pT3
  HGG 4
  •Stage pT3
  HGG 5
  •Stage pT3
35 (12/34)
0 (0/12)
32 (11/34)
45 (5/11)
32 (11/34)
64 (7/11)
28 (18/64)
0 (0/18)
41 (26/64)
38 (10/26)
31 (20/64)
80 (16/20)
0.50
NA
0.51
0.73
1.00
0.41
MR-GB = magnetic resonance imaging guided prostate biopsies; NA = not applicable; PSA = prostate-
specific antigen; DA = dominant aggressive; RP = radical prostatectomy; HGG = highest Gleason grades.
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PSA values for the MR-GB cohort (median PSA: 12 ng/ml) and TRUSBx cohort 
(median PSA: 8 ng/ml) showed a significant difference (p = 0.02). Subgroup analysis 
was performed for patients with PSA >10 ng/ml versus PSA ≤10 ng/ml. For patients 
with PSA ≤10 ng/ml, 0% (0 of 12) undergrading was seen for MR-GB, whereas 
for TRUSBx, undergrading occurred in 41% (18 of 44; p = 0.01). For patients with 
PSA > 10 ng/ml, MR-GB revealed an 18% (4 of 22) undergrading and TRUSBx a 55% 
(11 of 20; p = 0.01) undergrading. Table 3 summarises the performance rates. Figs. 2 
and 3 show imaging findings in a TRUSBx and MR-GB patient.
Discussion
In this prospective study, 3-T DWI targeted MR-GB sampling improved the pre-
treatment assessment of PCa aggressiveness. The Gleason grades as determined 
with MR-GB showed a high performance rate (88%) with prostatectomy. This is in 
sharp contrast to 10-core TRUSBx, which showed a 55% performance rate.
In this study the most abnormal ADC regions following MP-MRI localisation of 
tumour were used to target biopsies. To our knowledge, this is the first prospective 
report on the use of DWI to obtain PCa biopsies that are more representative for true 
RP Gleason grade. These results confirm prior retrospective studies on the ability of 
DWI to visualise tumour aggressiveness and serve as a platform for improved pre-
treatment prediction of true Gleason grades (15,16).
Table 3. Cross-tabulations for cohorts based on highest Gleason grade grouping
Prostatectomy
HGG 3 HGG 4 HGG 5
TRUSBx HGG 3 17 14 8 44%   (17/39)
HGG 4 1 12 6 63%   (12/19)
HGG 5 0 0 6 100% (6/6)
94% (17/18) 46% (12/26) 73% (8/11) 55%   (35/64)
MR-GB HGG 3 12 1 0 92%   (12/13)
HGG 4 0 10 3 77%   (10/13)
HGG 5 0 0 8 100% (8/8)
100% (12/12) 91% (10/11) 73% (8/11) 88%   (30/34)
HGG = highest Gleason grade; TRUSBx = transrectal ultrasound-guided biopsy; MR-GB = magnetic 
resonance imaging guided biopsy.
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biopsy (MR-GB).
Table 4. Performance analysis between biopsy and radical prostatectomy cohorts
Performance rates 
MR-GB, %
Performance 
rates 10-core 
TRUSBx, %
Significance 
(p-value)
Overall Bx concord. with RP HGG 88 (30/34) 55 (35/64) 0.001*
Bx concord. With RP HGG 3 100 (12/12) 94 (17/18) 0.41
Bx concord. With RP HGG 4 91 (10/11) 46 (12/26) 0.01*
Bx concord. With RP HGG 5 73 (8/11) 30 (6/20) 0.02*
Bx concord. With RP HGG 4/5 95 (21/22) 54 (25/46) 0.001*
PPV for Bx and RP HGG 3 92 (12/13) 45 (17/38) 0.003*
PSA
≤10 ng/ml (percentage of patients) 35 (12/34) 69 (44/64) 0.01*
Overall HGG performance 100 (12/12) 59 (26/44) 0.01*
>10 ng/ml (percentage of patients) 65 (22/34) 31 (20/64) 0.01*
Overall HGG performance 82 (18/22) 45 (9/20) 0.01*
MR-GB = magnetic resonance imaging guided biopsy; TRUSBx = transrectal ultrasound-guided biopsy; 
RP = radical prostatectomy; Bx = biopsy; concord. = concordance; PPV = positive predictive value; PSA = 
prostate-specific antigen. * Denotes significance.
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The importance of correct pre-treatment assessment of PCa aggressiveness is 
widely accepted. A shift from radical therapy to individualised tailored therapy has 
been advocated (17). A cornerstone of this individual-based risk stratification is the 
correct pre-treatment identification of true Gleason grades. Patients without grade 
4/5 components are potential candidates for less invasive treatment, such as active 
surveillance or local therapy (18). Patients harbouring high-grade components 
definitely need further evaluation for possible extracapsular extension and 
skeletal or nodal metastasis. High-grade PCa managed with non-curative intent 
substantially reduces life expectancy (19). A European Organisation for Research 
and Treatment of Cancer trial showed that high-risk patients definitely benefit 
from adjuvant hormone therapy. Correctly stratifying patients into low or high risk, 
therefore, is of utmost importance (20).
Numerous studies have addressed the correlation between GS in biopsy and 
corresponding RP. These show that increasing the number of biopsies increases the 
performance. In earlier studies using sextant biopsies, undergrading was reported 
in 44–60% (21,22), whereas recent studies with extended biopsy schemes reported 
lower values of 32–38% (4,5,21,23). When comparing overall performance rates 
between studies, the most important factor that needs diligent consideration is 
the prevalence of low-grade tumours. Using extended 12 cores, San Francisco et al. 
(24) showed an exact GS performance rate of 76%.
However, the prevalence of low-grade tumours in their RP was 72%. This artificially 
increases the overall performance rates. When only evaluating their high-grade 
tumours (HGG 4/5), a 32% undergrading was still evident. A large cohort from 
John Hopkins (25) revealed an overall GS agreement of 76%. The prevalence of 
low-grade tumours in RP was high at 67%. When only the high-grade tumours on 
RP were chosen, an undergrading of 42% was noted. Our TRUSBx revealed a 46% 
undergrading of tumours identified as HGG 4/5 on RP. This is in agreement with 
these two studies. Yet, for MR-GB, only a 5% undergrading of high-grade tumours 
was seen. Our TRUSBx revealed substantial undergrading in 57% of RP HGG 5 
tumours (i.e., showing a biopsy HGG of 3). In all cases of HGG 5 undergrading, MR 
biopsies revealed a HGG of 4, thus showing a more acceptable underestimate. The 
prevalence of HGG 3, 4, and 5 groups in our two cohorts did not show statistically 
significant differences. We therefore believe our results with MR-GB show a 
substantial improvement of performance rates compared with current practice 
and literature. In addition, with MR-GB, only a median of 3 cores per patient were 
taken, instead of 10 with TRUSBx.
Prospective Assessment of Prostate Cancer Aggressiveness Using 3-T Diffusion-Weighted Magnetic Resonance
Imaging–Guided Biopsies Versus a Systematic 10-Core Transrectal Ultrasound Prostate Biopsy Cohort.
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Clinically important factors may be associated with prostate biopsy undergrading. 
Isariyawongse et al. (26) showed that both age and PSA values are important in 
this respect. Biopsies in patients with PSA values 10–20 ng/ml and PSA >20 ng/ml 
had odds ratios of 2.11 and 3.64, respectively, compared with PSA <10 ng/ml for 
representing undergrading of true GS in prostatectomy. Our overall baseline PSA 
values for the two cohorts did indeed show a significant difference, however, to 
the detriment of MR-GB where higher PSA values were found. Usually a PSA cut-off 
value of 10 ng/ml is used as an integral part of decision making regarding further 
diagnostic tests and treatment (i.e., opting for active surveillance) (27).We therefore 
performed a subgroup analysis for patients with PSA ≤10 ng/ml and those with 
PSA >10 ng/ml. For both subgroups, MR-GBs were superior in performance rates. 
The PSA value evidently did not influence the performance rates of biopsies with 
RP findings in our study. Stackhouse et al. (28) evaluated additional factors that 
may predict undergrading. Of relevance to our study would also be their identified 
factors: patient age and prostate weight (and thus prostate volume). Increasing age 
has been shown to have increasing odds ratios for undergrading. In our cohort, 
both groups had the same median ages of 66 yr (p = 0.22). No significant differences 
in prostate volumes (p = 0.61) or dominant tumour volume (p = 0.69) were seen in 
our cohorts.
In addition, we evaluated two further factors that in our opinion may also represent 
biases in cohorts and possibly having an influence on the degree of undergrading: 
dominant aggressive tumour volume and tumour stage at RP. In a paper by Resnick 
et al. (29) with a large cohort of 2411 patients, biopsy and prostatectomy features 
of patients at first, second, and third TRUSBx sessions were evaluated. With each 
increase in the number of biopsy sessions, the undergrading of GS ≥7 increased 
from 18% at the first biopsy session, to 55% at the second, to 58% at the third, 
despite the increasing overall prevalence of GS 6 tumours with every subsequent 
session. These findings would suggest an increased likelihood of undergrading for 
our repeat biopsies. On the contrary, however, despite representing a re-biopsy 
session, our MR-GB still outperformed a first-session 10-core TRUSBx. We therefore 
believe that despite these minor differences between our cohorts, no important 
clinical or pathologic factor could be determined that might bias our MR-GB cohort 
to a more favourable group regarding the likelihood of undergrading.
DWI is rapidly gaining importance as a valuable non-invasive biomarker for 
determining tumour response to therapy in a large variety of tumours (30). In 
addition, DWI is also increasingly being used to determine tumour aggressiveness 
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noninvasively. Its role for the assessment of aggressiveness and cellularity in breast 
tumours (31), soft tissue sarcomas (32), renal tumours (33), and hepatocellular 
tumours (34) has been reported. For PCa, recent data have shown that ADC values 
derived from DWI have a high discriminatory performance in separating low-grade 
versus combined intermediate- and high-grade cancers (15).
A number of limitations exist. A randomised trial between MR-GB versus TRUSBx or 
performing both TRUS- and Mr-guided biopsies in the same patient would represent 
the ideal scenario. Our approach, however, was to determine the performance 
in a routine clinical setup as performed in our hospital. A second limitation was 
the relatively low number of patients. Nonetheless, differences were statistically 
significant, even with this small number of patients. Although a multiparametric 
approach has been proven to be the most useful for the evaluation of PCa on 
MR imaging, it still requires a high level of expertise, and observer variability may 
be an issue (35). Our results represent findings of an expert centre that uses in-
house developed analytical software and whose clinicians have numerous years 
of experience, so they might be an overoptimistic prediction of performance 
attainable in smaller non-expert institutions. A final limitation is the potential 
differences of the two cohorts as discussed previously.
Conclusions
Biopsies targeted towards the most abnormal regions on 3-T DWI MR imaging 
represent a substantially improved method for the assessment of true tumour 
aggressiveness and can therefore represent an indispensable tool in the diagnosis 
and management of patients with PCa. This will probably also hold true for other 
malignancies. Thus its use is strongly advocated.
Prospective Assessment of Prostate Cancer Aggressiveness Using 3-T Diffusion-Weighted Magnetic Resonance
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Abstract
Purpose: To evaluate 3T multiparametric magnetic resonance (MR) imaging (MP-
MRI) and MR guided biopsy (MRGB) for early risk re-stratification of patients on 
active surveillance in the Prostate cancer Research International: Active Surveillance 
(PRIAS) trial.
Materials and Methods: Within 4 hospitals participating in PRIAS, a side-study was 
initiated in 66 of 82 consecutively and prospectively included patients (2009-2012). 
Informed consent was obtained and institutional review boards approved our 
study.
Pelvic MR imaging, prostate MP-MRI and MRGB were performed at 3 and at 12 
months after prostate cancer diagnosis. Cancer suspicious regions (CSR)s were 
defined on MP-MRI using PI-RADS scores.
Risk re-stratification criteria for active surveillance discontinuance were 1) based 
on MR imaging: histopathologically proven MR imaging suspicion of node/bone 
metastases and/or 2) based on MRGB specimen histopathology: Gleason grade 
(GG) 4 and/or 5 and/or a stage ≥ pT3 (cancer invading peri-prostatic fat or seminal 
vesicles) and/or cancer multifocality (≥ 3 foci).
Results: Based on MP-MRI and MRGB an additional 24% (15/64) and 10% (3/30) of 
patients were risk re-stratified at 3 and 12 months of follow-up. An overall CSR PI-
RADS ≤2 had a negative predictive value (NPV) of 84% (38/45) and 100% (45/45) 
for detection of cancer and GG 4-5 cancer upon MRGB. A CSR PI-RADS ≥4 had a 
sensitivity of 92% (11/12) for detection of GG 4-5 cancer upon MRGB.
Conclusion: Application of MP-MRI and MRGB in active surveillance may contribute 
in early identification of patients with GG 4-5 prostate cancers, while improving the 
selection of active surveillance suitable patients.
Value of 3T multiparametric MR Imaging and MR guided biopsy for early risk re-stratification in active
surveillance of low-risk prostate cancer: a prospective multicentre cohort study.
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Introduction
Prevalence of low-risk prostate cancer (PCa) has increased due to the application 
of prostate-specific antigen (PSA) testing (1). Low-risk PCa patients are prone to 
overtreatment and its complications, which can undermine a patient’s quality 
of life (1, 2). To avoid overtreatment, active surveillance is an accepted treatment 
alternative for low-risk PCa patients (3).
Active surveillance is mostly performed within trials, such as the Prostate cancer 
Research International: Active Surveillance (PRIAS) trial (4). Selected patients with 
presumed low-risk PCa are followed by regular PSA measurements, digital rectal 
examinations and annual repeat systematic transrectal ultrasound-guided biopsy 
(TRUS-Bx). PSA kinetics, Gleason grade (GG) upgrading (GG 4 or 5) and volume 
progression are generally used as criteria for disease progression (5). However, 
rather due to TRUS-Bx undersampling upon inclusion than due to true cancer 
progression, 20-30% of active surveillance patients actually harbor intermediate- 
to high-risk cancers at inclusion (5, 6,7). Early identification of these patients, who 
were incorrectly deemed suitable for active surveillance, may be essential to 
maintain the opportunity for appropriate curative treatment within their window 
of curability. The detection of a GG 4-5 component or of a larger cancer volume 
or of multifocality of a GG ≤3 cancer (5), results in re-stratification of these PCa 
patients into a higher risk category. Risk re-stratification implies that a patient 
cannot continue active surveillance and needs radical treatment.
Magnetic resonance (MR) guided biopsy (MRGB) has shown to improve identification 
of patients with GG 4-5 cancers due to a better highest GG concordance (88%) 
with prostatectomy specimens compared to TRUS-Bx (55%, p=0.001). This higher 
GG concordance of MRGB specimens with radical prostatectomy specimens is 
possible due to better detection and targeting of the most aggressive area of a 
cancer suspicious region (CSR) on MR imaging (8). Only a few studies have related 
MR imaging results to active surveillance outcome (9-13).
To our knowledge, MRGB has not previously been evaluated at active surveillance 
inclusion. Our hypothesis is that combined multiparametric MR imaging (MP-MRI) 
and MRGB will improve current TRUS-Bx-based selection of patients for active 
surveillance by early detection of patients harboring intermediate- to high-risk 
cancers. Therefore, our purpose is to evaluate the value of 3T MP-MRI and MRGB 
for early risk re-stratification of patients on active surveillance in the Prostate cancer 
Research International: Active Surveillance (PRIAS) trial.
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Figure 1. Study Flow-diagram showing patient selection. CSR= cancer suspicious region, MRI= 
magnetic resonance imaging, MP-MRI= multiparametric MR imaging, MRGB= MR guided 
prostate biopsy, MR= magnetic resonance, PRIAS= Prostate Cancer Research International 
Active Surveillance study, MR-PRIAS= MR-PRIAS= MR imaging sub-study of the Prostate Cancer 
Research International Active Surveillance study, CSR= cancer suspicious region on magnetic 
resonance imaging, TRUS-Bx= systematic transrectal ultrasound biopsy.
Value of 3T multiparametric MR Imaging and MR guided biopsy for early risk re-stratification in active
surveillance of low-risk prostate cancer: a prospective multicentre cohort study.
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Materials and methods
Within 4 reference centers participating in the PRIAS trial (NTR1718 http://www.
trialregister.nl), a prospective side-study (MR-PRIAS: NTR2006) was initiated in 
consecutively and prospectively included patients from August 2009 to March 2012. 
Patient selection is presented in Figure 1. Patient informed consent was obtained 
for the study as well as for the side-study and institutional review boards of the 
participating hospitals approved our study. Inclusion and exclusion criteria are 
depicted in Appendix 1. In our side-study, patients on active surveillance underwent 
MP-MRI in the second and MRGB in the third month of follow-up after initial cancer 
diagnosis upon systematic TRUS-Bx (time-point zero). Initial systematic TRUS-Bx 
existed out of 9-10 cores sampling both the transition and the peripheral zone.
Part of our patient population has been reported earlier (14). The earlier paper 
described the value of apparent diffusion coefficient values of MRGB DWI scans for 
PCa differentiation in prostate cancer patients on active surveillance. The current 
study reports on overall outcome of incorporating MP-MRI and MRGB in active 
surveillance and the consequences for patient management.
MR imaging
Pelvic MR imaging for lymph node and bone staging (30 min) was followed 
by MP-MRI of the prostate, consisting of T2-weighted MR imaging, diffusion-
weighted imaging (DWI) and dynamic contrast-enhanced imaging (DCE-MRI) 
(40 min protocol). Imaging was performed on a 3T MR system (Trio Tim, Siemens, 
Erlangen, Germany) using a pelvic phased-array and an endorectal coil (Medrad, 
Pittsburgh, USA) filled with 40 mL of perfluorcarbon (Fomblin, Solvay-Solexis, Milan, 
Italy). DCE-MRI was performed by initial acquisition of proton-density weighted 
images, followed by spoiled T1-weighted gradient echoes during fast (2,5 mL/s) 
intravenous injection of 0,1 mmol of gadopentetate dimeglumine (Dotarem, 
Guerbet, Paris, France) per kilogram of bodyweight. MR imaging parameters are 
presented in Table 1.
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Appendix 1. Inclusion and Exclusion criteria used in the PRIAS study with an additional exclusion 
criterion used in the MR-PRIAS sub-study.
Inclusion criteria
Histopathologically proven adenocarcinoma of the prostate
Men should be fit for curative treatment
PSA level at diagnosis ≤10.0 ng/mL
PSA density <0.2 ng/mL/mL
Clinical stage T1C or T2
Gleason score ≤ 3+3
1 or 2 biopsy cores invaded with cancer
Participants must be willing to attend the follow-up visits
Exclusion criteria
Men who cannot or do not want to be operated or irradiated
A former therapy for prostate cancer
Additional exclusion criterion MR-PRIAS sub-study
Contra-indications to MRI or to gadolinium based contrast agents
PSA = prostate specific antigen, MR-PRIAS = MR imaging sub-study of the PRIAS study, PRIAS = Prostate 
Cancer Research International: Active Surveillance, MRI= Magnetic Resonance Imaging.
Table 1. MP-MRI and MRGB parameters.
Protocol Sequence TR
(ms)
TE
(ms)
Flip
angle
(degrees)
Slice 
thickness
(mm)
Field
of view
(mm ´ 
mm)
Matrix
size
Voxel size
(mm×
mm×mm)
b-values
(s/mm2)
Temporal 
resolution
(s)
Multiparametric MR imaging lymph nodes and bone structures
3D T2WI TSE
coronal
1390 100 100 1.0 320×320 320×320 1.0×1.0×1.0 n.a. n.a.
T1WI TSE
coronal
500 11 120 3.0 384×384 320×256 1.5×1.5×3.0 n.a. n.a.
WBDWI EPI 6500 71 n.a. 3.0 385×385 154×154 2.5×2.5×3.0 600 n.a.
WBDWI EPI 6200 66 n.a. 3.0 385×385 154×154 2.5×2.5×3.0 50 n.a.
Endorectal multiparametric MR imaging local prostate
T2WI axial (TSE) 4280 99 120 3.0 180×178 448´448 0.4×0.4×3.0 n.a. n.a.
coronal 3590 98 120 3.0 192´96 384×384 0.5×0.5×3.0 n.a. n.a.
sagittal 4290 98 120 3.0 192×134 384×384 0.5×0.5×3.0 n.a. n.a.
DWI SSEPI
Axial
2600 90 n.a. 3.0 204×204 136×136 1.5×1.5×3.0 0/50/500/
800
n.a.
DCE-MRI GE
Axial 3D
800 1.51 14 3.0 192×192 128×128 1.5×1.5×3.0 n.a. n.a.
DCE-MRI Spoiled GE
Axial 3D
36 1.4 10 3.0 192×19 128×128 1.5×1.5×3.0 n.a. 3.4
MR guided biopsy
T2WI TSE
Axial
3620 103 120 4.0 256×256 320×320 0.8×0.8´4.0 n.a. n.a.
DWI EPI
Axial
3300 60 n.a. 3.6 260×211 160×120 2.2×1.6×3.6 0/100/400/
800
n.a.
Balanced 
SSFP
GE
Axial and
Sagittal
4.48 2.24 70 3.0 280×280 256×256 1.1×1.1×3.0 n.a. n.a.
3D= three-dimensional, T2WI= T2-weighted MR imaging, DWI=diffusion-weighted MR imaging, DCE-
MRI= dynamic contrast-enhanced MR imaging, TSE= turbo-spin echo, GE= gradient echo, SSEPI= single-
shot echo-planar imaging, SSFP= steady state free precession, TR= repetition time, TE= echo time, MR= 
magnetic resonance.
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MR imaging interpretation
An experienced radiologist (x.x) with 18 years of experience in prostate MR imaging 
evaluated the MP-MRI examinations on in-house developed software, while 
disposing of clinical patient data (15). On the software, T2-weighted MR imaging, 
DWI and DCE-MRI were interpreted simultaneously (16). The PI-RADS system was 
used to define CSRs (16). Every CSR was scored on a 1-5 point scale for T2-weighted 
MR imaging, DWI and DCE-MRI separately. Subsequently an overall 5 point score, 
based on the whole MP-MRI exam, was given for every CSR (17). The five-point 
scale was defined as 1) highly unlikely 2) unlikely 3) equivocal 4) likely 5) highly likely 
presence of clinically significant PCa. PCa staging was performed in compliance 
with established criteria (18). When MP-MRI lacked CSRs, active surveillance was 
continued without performing MRGB.
MR guided prostate biopsy
Only when MP-MRI showed one or more CSRs, another experienced radiologist 
(x.x.) with 3 years of experience performed MRGB of every predefined CSR on a 3T 
scanner in a separate examination session (MAGNETOM Skyra, Siemens, Erlangen, 
Germany) (16). MRGB was performed for every CSR, regardless of CSR PI-RADS scores.
Risk re-stratification
Risk re-stratification, i.e. stratification into a higher PCa risk category, was based on 1) 
histopathologically proven MR imaging suspicion of node/bone metastases of PCa 
(4) and/or 2) MRGB histopathology specimens (of CSRs) containing a) a GG 4 and/or 
5 component (4) and/or b) stage ≥ pT3 cancer (cancer invading peri-prostatic fat or 
seminal vesicles) (19) and/or c) multifocality of ≥ 3 foci Gleason score ≤3+3 cancer 
(including the foci in the initial TRUS-Bx). The latter criterion of cancer multifocality 
was applied to evaluate the number of additionally detected cancer foci by MRGB 
and to compare it to the PRIAS risk re-stratification criterion of >2 cores with PCa 
in TRUS-Bx (4). An MRGB focus located contra-lateral to the initial TRUS-Bx cancer 
location or a focus in the apex versus the base and vice versa was considered a 
separate cancer focus. Risk re-stratified patients were no longer eligible for active 
surveillance and were referred to undergo radical treatment.
In order to evaluate cancer volume using MRGB and TRUS-Bx specimens, we 
retrospectively measured maximal cancer core length (MCCL): the longest biopsy 
core specimen cancer core length taken from one CSR. A MCCL ≥ 6 mm is related 
to a cancer volume ≥ 0.5 mL in RP specimens using schematic mapping biopsy (20).
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Follow-up
After 11-12 months of follow-up, repeat MP-MRI of the local prostate, with identical 
imaging parameters to the initial MR imaging exam, was performed. Based on 
repeat MP-MRI, an additional repeat MRGB, similar in procedure to the initial MRGB, 
was performed in a second separate imaging session. After repeat MRGB, a repeat 
TRUS-Bx session was performed later on the same day by a nurse practitioner of 
our Urology Department, who was blinded for MR imaging results.
Repeat TRUS-Bx existed out of 10 cores from the peripheral zone and transition 
zone. TRUS-Bx risk re-stratification criteria consisted of PCa presence in >2 cores or 
a Gleason score ≥7 (7). Risk re-stratification criteria for repeat MP-MRI and repeat 
MRGB were according to initial criteria.
Histopathology
All biopsy samples were processed by fixation and staining and were evaluated by 
one genitourinary pathologist (x.x) with 19 years of experience, who was blinded 
to prior histopathology results. Gleason grading was performed according to the 
modified consensus of the International Society of Urological Pathology in 2005 (21).
Statistical analysis
Patient risk re-stratification rates were determined for initial and repeat MRGB and 
for repeat TRUS-Bx. Kolmogorov-Smirnov and Shapiro-Wilk tests were used to test 
variables for normality. Parametric continuous variables were reported as mean +/- 95% 
confidence interval, whereas and non-parametric continuous variables were reported 
as median and the inter-quartile range (IQR). Parametric variables were analyzed using 
independent t-tests and non-parametric variables were evaluated using Mann-Whitney 
U tests. Two-sided Pearson Chi-square tests were used to compare proportions. 
Receiver operating characteristic analyses were applied to compare different MP-MRI 
techniques. Analyses were performed using PASW Statistics version 18 (SPSS Inc. Hong 
Kong). The threshold for significance was set at p <0.05.
Results
Initial risk re-stratification
Sixty-six patients were included in our side-study and underwent MP-MRI (Figure 1). 
Two patients requested to be excluded from the protocol before MRGB. Patient 
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characteristics of the remaining 64 active surveillance patients are shown in Table 2. 
One patient was excluded due to MR imaging suspicion of a bone metastasis in 
his third lumbar vertebra, which upon biopsy appeared to be a metastasis from 
malignancy of unknown origin.
MRGB was performed in 62 out of the 63 remaining patients. In one patient MRGB 
was not performed, as MP-MRI did not show a CSR and this patient remained on 
active surveillance. In the other 62 patients, a median of 2 (IQR 1-2) CSRs were 
present and a median of 4 MRGB cores (IQR 3-5) were taken. A patient example is 
illustrated in Figure 2.
Twenty four percent (15/63) of the 63 patients were risk re-stratified and thus 
underwent radical treatment. MRGB and MCCL results are presented in Table 3. Sixty 
percent (9/15) of risk re-stratified patients had an MCCL ≥ 6.0 mm. The remaining 48 
patients continued active surveillance. Sixty-three percent (30/48) of these patients 
had a cancer-negative MRGB specimen. In 70% (21/30) of these patients with a 
cancer-negative MRGB, prostatitis was present in the histopathology specimen.
Risk re-stratification at 12 months follow-up
In 37 out of 48 remaining patients (77%) a follow-up of 12 months was available at 
July 31st 2012. Of these 37 patients 7 patients did not undergo repeat examinations 
due to other reasons as summarized in Figure 1.
Follow-up MRGB and MCCL results for the remaining 30 patients are presented in 
Table 4. Forty-seven percent of these follow-up patients (14/30) were risk re-stratified 
based on MRGB (10% (3/30) MRGB only) and/or TRUS-Bx. Forty-three percent (6/14) 
of risk re-stratified patients had an MCCL ≥6.0 mm. These fourteen risk re-stratified 
patients remained undetected on initial combined MP-MRI and MRGB. In 4 of these 
patients the CSR was detected on initial MP-MRI. The initial MRGB, however, did not 
sample prostate tissue (n=2) or did not detect small cancers (MCCL 1.5-2 mm) (n=2). 
In the other 10 out of 14 patients small lesions (<0.5 cc) were missed on MP-MRI 
(MCCL 0.3-4.5 mm).
For 14 out of 30 patients with an initial cancer-negative MRGB, repeat examinations 
were available. The negative predictive value (NPV) of a cancer-negative MRGB for 
risk re-stratification at repeat examinations was 79% ((11/14) with a 95% confidence 
interval of 52%-93%).
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Table 2. Patient Characteristics of 64 MP-MRI patients.
Characteristic All included patients #
(n=64)
Patients remaining 
on active surveillance 
(n=48) ^
Patients with risk re-
stratification (n=15) ¶
p- value
Age (years),
Median (IQR)
65.7 (62.1-70.1) 66.9 (62.0-70.5) 65.2 (61.8-68.2) n.a.
PSA (ng/mL)
Mean (CI)
6.5 (5.99-6.93) 6.5 (5.87-7.03) 6.6 (5.8-7.4) 0.90
PSA density
(ng/mL/mL)
Mean (CI)
0.1 (0.12-0.14) 0.1 (0.11-0.14) 0.2 (0.14-0.19) 0.004*
Prostate volume 
(mL) Median (IQR)
45.8 (38.0-66.1) 48.2 (40.0-69.4) 38.0 (30.0-55.0) 0.027*
Number previous
negative TRUS-Bx
sessions Median 
(Range)
0 (0-7) 0 (0-7) 0 (0-0) n.a.
Total number of
TRUS-Bx cores at
diagnosis, Median 
(IQR)
10 (9-10) 10 (9-10) 9 (9-10) n.a.
TRUS-Bx to MRI 
interval in months 
Median (IQR)
2.1 (1.6-2.7) 2.3 (1.6-2.8) 1.8 (1.5-2.3) n.a.
 TRUS-Bx to MR-Bx 
 Interval months,
 median (IQR)
2.7 (2.0-3.3) 2.7 (2.1-3.4) 2.4 (2.0-2.7) n.a.
Characteristic All included patients #
(Percentage, (fraction), 
[95% confidence 
interval)
Patients remaining 
on active surveillance 
(n=48) ^
(Percentage, (fraction), 
[95% confidence 
interval)
Patients with risk re-
stratification
(n=16)
(Percentage, (fraction), 
[95% confidence interval)
p-value
Chi-
square 
test
Clinical stage,
T1c
T2a
T2b
T2c
76.6  (49/64), [64.8-85.4]
18.8 (12/64), [10.9-30.1]
3.1   (2/64),   [0.2-11.3]
1.6   (1/64),   [0.0-9.1]
77.1 (37/48), [63.3-86.9]
18.8 (9/48), [10.0-32.2]
2.1 (1/48), [0.0-11.9]
2.1 (1/48), [0.0-11.9]
73.3 (11/15), [47.6-89.5]
20.0 (3/15), [6.3-46.0]
6.7 (1/15), [0-31.8]
0.0 (0/15), [0-23.9]
1,00
1.00
0.42
1.00
Positive TRUS-Bx
cores at diagnosis,
1
2
67.2 (43/64), [55.0-77.5]
32.8 (21/64), [22.5-45.0]
68.8 (33/48), [54.6-80.1]
31.3 (15/48), [19.9-45.4]
60.0 (9/15), [35.7-80.3]
40.0 (6/15), [19.8-64.3]
0.76
0.78
Gleason score at
diagnosis,
3+3=6
lower
93.8 (60/64), [84.6-98.0]
6.3   (4/64),   [2.0-15.4]
91.7 (44/48), [79.9-97.2]
8.3 (4/48), [2.8-20.1]
100.0 (15/15), [76.1-100.0]
0.0 (0/15), [0-23.9]
0.56
0.57
Prostate volume was the only non-parametric continuous variable. P-values were calculated using an 
independent t-test for parametric, a Mann-Whitney u test for non-parametric variables and a Chi-square 
test for proportions. A p-level <0.05* was considered to represent a significant difference. # All patients 
did not include patients excluded on patient request. However this column does include the patient, who 
was excluded due to a bone metastasis of cancer of unknown origin. ^= n=47 MR-Bx patients + 1 patient 
without MR-Bx due to lack of CSRs on MP-MRI. ¶ = this column of patients with risk re-stratification does 
not include the patient who was risk re-stratified based on a bone metastasis of unknown cancer origin. 
SD= standard deviation, IQR= inter-quartile range, TRUS-Bx= random systematic transrectal ultrasound 
biopsy, AS= active surveillance, PSA= prostate specific antigen, MRI = magnetic resonance imaging, CI= 
95% confidence interval, MR-Bx= MR guided prostate biopsy.
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Table 3. Reasons for initial patient risk re-stratification and deferred treatment at 3 of follow-up.
MRGB results:
MR-PRIAS unsuitable patients with risk 
re-stratification
Number
(%)
MRGB maximal cancer core length in mm
(mean, (95% confidence interval))
MRGB GG 4 or 5 and stage ≥pT3 2 (13) 8.8(7.2-10.4.)
≥6 mm: n=2
MRGB GG 4 or 5 5 (31) 9.7 (7.7-11.7)
≥6 mm: n=4
MRGB Multifocality 2 (13) 4.0 (0.0-7.9)
≥6 mm: n=1
MRGB
2 foci GS 3+3#
4 (25) 4.3 (0.9-7.7)
≥6mm: n=1
MP-MRI suspicion ≥T3,
Local MRGB: GS 3+3 without extracapsular 
extension#
2 (13) 8.5 (6.5-10.5)
≥6 mm: n=1
Total (% MR-Bx) 15 (24)  6.9 (4.3-9.5)
≥6mm: n=9
# not conform predefined risk re-stratification criteria, MRGB= MR guided prostate biopsy, MR-PRIAS= MR 
imaging sub-study of the Prostate Cancer Research International Active Surveillance study, GG= Gleason 
grade, GS= Gleason score, MP-MRI= multiparametric MR imaging, MCCL= maximal cancer core length. 
Calculation of MRGB maximal cancer core length is based on the highest MRGB maximal cancer core length 
for every patient. A stage T3 was defined as cancer invading the (peri-prostatic) fat in the MR guided biopsy 
specimen core.
MR imaging
MP-MRI evaluation on both 3 and 12 months resulted in a total of 168 CSRs. As 
this study started at the beginning of the PI-RADS implementation, PI-RADS scores 
were available for 155 CSRs. Seventy-eight percent (121/155) of CSRs were located 
in the peripheral zone, 15% (23/155) were located in the transition zone or at the 
border of the peripheral and transition zone or seminal vesicles (7% (11/155)). MRGB 
specimens showed cancer in 48/155 (31%) CSRs. Cancer-negative MRGB specimens 
mainly contained prostatitis in 41% (44/107) and healthy prostate tissue in 38% 
(41/107). Az values for PCa and GG 4-5 PCa detection using overall PI-RADS scores 
were 0.73 (0.65-0.82) and 0.81 (0.70-0.92) respectively.
In cancer-negative CSRs DCE-MRI was more frequently false-positive (with a score 
of 1-3 points higher than the T2-weighted MR imaging score in 43% (46/107)) as 
compared to DWI (in 32% (33/107), p=0.07).
An overall CSR PI-RADS ≤2 had a NPV of 84% (38/45) for detection of cancer and a 
NPV of 100% (45/45) for detection of a GG 4-5 cancer upon MRGB. A CSR PI-RADS 
≥4 had a sensitivity of 75% (36/48) and f 92% (11/12) for detection of cancer and of 
GG 4-5 cancer upon subsequent MRGB respectively. Sixty-four percent (69/107) of 
cancer-negative CSRs had an overall PI-RADS ≥3.
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Table 4. Reasons for patient risk re-stratification and deferred treatment at repeat examinations 
at 12 months of follow-up.
Repeat MRGB results:
MR-PRIAS unsuitable patients 
with risk re-stratification at 12 
months of follow-up
Number
(% subtotal risk re-stratification 
patients)
MR-Bx maximal cancer core 
length in mm
(mean, (95% confidence interval))
Both MRGB and TRUS-Bx
GG 4 and/or 5
4 (31) 5.3 (3.8-6.8)
≥6 mm: n=2
MRGB GG 4 and/or 5 and TRUS-Bx 
GS ≤3+3 cancer in >2 cores
1 (8) 4.4 (n.a.)
Only TRUS-Bx GG 4 and/or 5 1 (8) 2.7 (n.a.)
TRUS-Bx GS ≤3+3 cancer in >2 
cores and MRGB multifocality
2 (14) 6.5 (5.5-7.5)
≥ 6mm: n=2
Only MRGB multifocality,
2 foci, n=1#
3 (21) 4.2 (1.3-7.0)
≥6mm: n=1
Only TRUS-Bx GS ≤3+3 cancer in 
>2 cores
3 (23) 5.7 (2.8-8.6)
≥6mm: n=1
Total
(%  MR-Bx)
14 (47) 5.0 (3.0-6.0)
≥6 mm: n=6\
# not conform predefined risk re-stratification criteria. Calculation of MRGB maximal cancer core length is 
based on the highest MRGB maximal cancer core length for every patient.
MRGB= MR guided prostate biopsy, TRUS-Bx= systematic transrectal ultrasound biopsy, MR-PRIAS= MR 
imaging sub-study of the Prostate Cancer Research International Active Surveillance study, GG= Gleason 
grade, GS= Gleason score, MP-MRI= multiparametric MR imaging.
Discussion
Our initial results show that the application of multiparametric MR imaging and 
MR guided biopsy in an active surveillance protocol may contribute in early 
identification of patients with GG 4-5 cancers, while also improving the selection of 
active surveillance suitable patients.
Our initial risk re-stratification rate using MP-MRI and MRGB at 3 months (24%) is 
comparable to risk re-stratification rates (17-27%) in studies on repeat TRUS-Bx within 
3 months after initial diagnosis (10, 22). At 12 months of follow-up, combined MP-
MRI and MRGB added little to repeat systematic TRUS-Bx, as MRGB only additionally 
risk re-stratified 3 patients (21% (3/14)) due to PCa multifocality. Most patients, 
which were risk re-stratified by MRGB also were risk re-stratified by TRUS-Bx. Due to 
TRUS-Bx systematic sampling of GG 2 and/or 3 cancers (23) or of small(er) volume 
GG 4 and/or 5 cancers, which may have been missed on initial and/or repeat MR 
imaging, repeat TRUS-Bx may have risk re-stratified a similar amount of patients 
compared with MRGB.
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Fourteen patients with risk re-stratification at repeat examinations were missed 
on initial combined MP-MRI and MRGB. Missing cancers on initial MP-MR imaging 
may be caused by low tumor GG and/or a small volume GG 4-5 components (23). 
In general, detected cancers at 12 months of follow-up had a lower mean cancer 
volume (5.0 mm MCCL) compared with cancers detected at 3 months of follow-up 
(6.9 mm MCCL).
MP-MRI had a sensitivity of 92% for detection of GG 4-5 cancer in case of higher 
PI-RADS scores (≥4) and a NPV of 100% for detection of GG 4-5 PCa in case of 
lower PI-RADS scores (≤2)). Furthermore, an initial cancer-negative MRGB specimen 
had a NPV of 79% for risk re-stratification at 12 months follow-up. These results 
are comparable to those of Vargas et al., who reported an NPV of 96-100% and 
a sensitivity of 87-96% for biopsy upgrading in case of an MR imaging score ≤2 
and ≥5 for cancer presence (13). While both scoring systems predicted presence of 
cancer from highly unlikely to highly likely on a 5-point scale, the system used by 
Vargas et al was based on lower signal intensity on T2-weighted MR imaging and/
or restricted diffusion on ADC maps, while the PI-RADS system also took shape and 
invasion of surrounding structures into account.
Our results for prostate cancer detection accuracy using MP-MRI and MRGB in 
patients on active surveillance are difficult to compare to literature. Other studies 
on MRI implementation in active surveillance did not use MP-MRI and/or MRGB 
(9,11-13,24,25). Our accuracies of 73% and 81% for detection of PCa and GG 4-5 PCa 
were quite reasonable considering the expected prevalence of predominantly 
lower GG (2-3) cancers in this selected active surveillance patient population. 
Lower GG cancers are known to have lower detection rates compared to higher 
GG cancers (23).
Upon simultaneous MP-MRI reading, DCE-MRI had more false-positive results 
compared to DWI. DCE-MRI may have false-positive results in case of benign 
conditions like prostatitis and/or benign prostatic hyperplasia (26).
As our study is the first to evaluate MRGB in active surveillance, we applied low 
threshold criteria for CSR determination on MP-MRI followed by biopsy of all CSRs, 
also including equivocal (low PI-RADS 1-3) regions. This resulted in a high number 
of patients (48% (30/63)) with cancer-negative CSRs upon MRGB. With increasing 
MR imaging experience in active surveillance patients, false-positive results may 
be reduced. However, within the current explorative phase of MRI implementation 
in active surveillance, an important clinical implication of our study is that in active 
surveillance patients acquisition of histopathology of a MP-MRI CSR is required due 
CHAPTeR 7
166
to the large amount of false-positive CSRs. Lack of histopathologic confirmation 
of a CSR may explain the poor results for MP-MRI as a predictive tool for active 
surveillance outcome in other studies (9, 12, 24, 25).
Limitations of this study are firstly its small patient population and secondly its 
limited follow-up. Thirdly, as mentioned earlier, our risk re-stratification criteria may 
have been too strict as patients with multifocal Gleason score 3+3 cancer in both 
MRGB and TRUS-Bx also were risk re-stratified. Therefore, our risk re-stratification 
rates may be inaccurate. Fourthly, as MP-MRI results were read by an experienced 
radiologist, the general applicability of our results may be limited.
Incorporation of MR-MRI and MRGB in patients on active surveillance may be 
useful as it results in early additional risk re-stratification and radical treatment of 
patients with intermediate to high-risk cancers, who were undersampled by initial 
TRUS-Bx. Standardized MP-MRI interpretation using PI-RADS reveals that MP-MRI 
is a promising technique for differentiation between active surveillance suitable 
patients and patients with GG 4-5 cancers, the latter needing radical treatment. 
However, smaller (< 4.4 mm MCCL) cancers may be missed by MP-MRI and MRGB.
Follow-up of our preliminary results of initial cancer-negative MRGB specimens 
showed a NPV of 79% of an initial cancer-negative MRGB specimen for risk re-
stratification after 12 months. This finding shows that a cancer-negative initial MRGB 
may be a promising prognostic parameter for active surveillance patient selection.
In conclusion, application of MP-MRI and MRGB biopsy in active surveillance 
may contribute in early identification of patients with GG 4-5 cancers, while also 
selecting active surveillance suitable patients.
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Figure 2. Sixty-one year-old male on active surveillance with a PSA level of 7.1 ng/mL, a PSA 
density of 0.19 ng/mL/mL and a clinical stage T1C. This patient was diagnosed with Gleason 
score 6 (3+3) prostate cancer in 5 volume-percent in 1 out of 12 cores in the peripheral zone 
right base. Multiparametric MR imaging and MR guided biopsy, existing out of 4 cores only, 
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were performed within 3 months after diagnosis. (a) Axial T2-weighted turbo spin echo image 
(TR 4280 ms, TE 99 ms): a low signal intensity (white arrows) is present in the ventral transition 
zone at the level of the mid-prostate. The inhomogeneous nodular pattern of the transition 
zone has been replaced by a drop-shaped homogeneous low-signal intensity. This cancer 
suspicious region has asymmetry to the right side. (b) Axial apparent diffusion coefficient (ADC) 
map of diffusion weighted imaging (single-shot echo planar imaging, TR 2600 ms, TE 90 ms, 
b-values 0/50/500 and 800 s/mm2) at the level of the mid-prostate. A low ADC value of ADC 
0.50×10-3 mm2/s, suspicious for prostate cancer, was present in the right side of the ventral 
transition zone (dotted line). (c) Axial overlay of Ktrans parameter in dynamic contrast enhanced 
MR imaging (three-dimensional spoiled gradient echo TR 36 ms, TE 1.4 ms, temporal resolution 
3.4 s), as calculated by the Tofts model, on the axial T2-weighted turbo spin echo image (TR 
4280 ms, TE 99 ms). Red areas of increased contrast enhancement are present in large areas of 
the prostate. Increased enhancement may be present in case of benign prostate hyperplasia, 
prostatitis and prostate cancer. Also in the right ventral prostate (dotted line) increased 
enhancement is present. Enhancement in this region was suspicious for prostate cancer, due 
to wash-out: a decline at the end of the relative gadolinium contrast-to-time curve (d). (e) Axial 
angulated balanced gradient echo image (TR 4.48 ms, TE 2.24 ms) of the needle position in the 
lesion presented in a-c directly after biopsy. The lesion (green dotted line) can be appreciated 
in the prostate (blue dotted line). The needle artifact (white line) is present in the lesion. The 
needle guide (white arrows) is also depicted. The MR guided biopsy specimen (total only 4 
cores) contained a Gleason score 4+3=7 prostate cancer in 80 volume-percent. This patient’s 
management was subsequently redirected towards definitive therapy, which existed of EBRT.
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Abstract:
Purpose: We aimed to determine whether diffusion-weighted magnetic resonance 
imaging, by means of the apparent diffusion coefficient (ADC), is able to guide 
magnetic resonance guided biopsy in patients fit for active surveillance (AS) and 
identify patients harboring high-grade Gleason components not suitable for AS.
Materials and Methods: Our study was approved by the institutional review board 
of all participating hospitals, and all patients signed informed consent at inclusion. 
Fifty-four consecutive patients with low-risk prostate cancer (PCa) underwent 
multiparametric magnetic resonance imaging (MP-MRI) at inclusion for AS. 
Cancer-suspicious regions (CSRs) upon 3-T MP-MRI were identified in all patients, 
and magnetic resonance guided biopsy was performed in all CSRs to obtain 
histopathological verification. For all CSRs, a median ADC (mADC) was calculated. 
Wilcoxon signed ranks and Mann-Whitney tests was performed to detect 
differences between the groups. We used the area under the receiver operating 
characteristic curve to evaluate the accuracy of mADC to predict the presence of 
PCa in a CSR. Level of statistical significance was set at P < 0.05.
Results: Mean mADC in the CSRs with PCa was 1.04×10-3 mm2/s (SD, 0.29), whereas the 
CSRs with no PCa displayed a mean mADC of 1.26×10-3 mm2/s (SD, 0.25; P < 0.001). 
Cancer-suspicious regions with a high-grade Gleason component displayed a 
mean mADC of 0.84×10-3 mm2/s (SD, 0.35) vs a mean mADC for the low-grade 
CSRs of 1.09×10-3 mm2/s (SD, 0.25; P < 0.05). A diagnostic accuracy of mADC for 
predicting the presence of PCa in a CSR with an area under the receiver operating 
characteristic curve of 0.73 was established (95% confidence interval, 0.61-0.84).
Conclusion: Median ADC is able to predict the presence and grade of PCa in CSRs 
identified by MP-MRI.
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Introduction
With the increasing incidence of low-risk prostate cancer (PCa) due to prostate-
specific antigen (PSA) testing (1), active surveillance (AS) for PCa has become an 
appealing strategy in an increasing number of patients (2). Although there is an 
ongoing debate on the use and implications of PSA screening on a population-
based scale, AS as a strategy for low-risk PCa may turn out to be an important 
measure to prevent overtreatment of patients with PSA-detected low-risk PCa. 
Because more experience is accumulating with AS, a consistent intervention rate 
of 14% to 37% has been reported within the first years after diagnosis following 
unfavorable PSA kinetics and/or Gleason score/cancer volume progression at 
repeated transrectal ultrasound (TRUS) guided biopsy (3-7), even when the wide 
diversity in inclusion criteria and definition of progression renders comparison 
between series difficult. This substantial intervention rate could be explained by 
true PCa progression or incorrect risk stratification at the time of initiation of AS. 
At this moment, the initiation of AS has been based predominantly upon PSA 
and TRUS-guided biopsy histopathological characteristics. Our hypothesis is that 
multiparametric magnetic resonance (MR) imaging (MP-MRI) and MR-guided 
biopsy (MRGB) at the initiation of AS might provide better risk stratification of PCa 
resulting in lower intervention rates during follow-up. Limited reports on the use 
of diffusion-weighted MR imaging (DWI) as a monitoring tool within AS protocols 
for PCa have been published, showing that the DWI-derived apparent diffusion 
coefficient (ADC) is a highly significant predictor of adverse random repeat biopsy 
findings in an AS cohort (8). We describe a series of AS participants in which DWI/
ADC was performed at inclusion with immediate histopathological verification 
by targeted biopsies by MRGB of the abnormal regions suspicious for PCa. To the 
best of our knowledge, this is the first report on the use of DWI at inclusion in an 
AS protocol, with histopathological verification obtained by targeted biopsies of 
cancer-suspicious regions (CSR).
Materials and Methods
We prospectively identified patients eligible for AS according to the PSA and 
biopsy criteria as used within the Prostate Cancer Research International Active 
Surveillance (PRIAS) study (Dutch Trial Register NTR1718): asymptomatic cT1c/cT2 
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PCa, PSA level of 10.0 ng/mL or lesser, PSA density of less than 0.2 ng/mL/mL, TRUS-
guided biopsy Gleason score of 3 + 3 = 6 or lesser, and 2 positive TRUS-guided 
biopsy cores or lesser. Initial TRUS-guided biopsies were obtained according to 
local protocols with 9 to 13 cores taken. All consecutive patients included in PRIAS 
in 4 participating referral centers without contraindications for magnetic resonance 
imaging (MRI) were asked to sign informed consent for inclusion in a separate arm 
of PRIAS incorporating MP-MRI and MRGB (MRPRIAS, Dutch Trial Register NTR2006), 
which was approved by the local institutional review board.
Multiparametric MRI and MRGB
All patients underwent MP-MRI including anatomical T2-weighted and DWI 
sequences within 12 weeks from the inclusion in our protocol. Two radiologists 
(J.J.F., J.O.B.), with 9 and 18 years of experience in prostate MRI, evaluated the MP-
MRI studies while being informed on the clinical data of the patients during the 
reading. Multiparametric magnetic resonance imaging was obtained on a 3-T MR 
system (Trio Tim; Siemens, Erlangen, Germany) using a pelvic phased-array coil and 
an endorectal coil (Medrad, Pittsburgh, PA) filled with 40 mL of perfluorocarbon. 
Dynamic contrast-enhanced MR imaging was performed using fast intravenous 
injection (2.5 mL/s) of 0.1 mmol of gadopentetate dimeglumine per kilogram of 
body weight. The used MP-MRI parameters are shown in Table 1. Every CSR was 
defined on anatomical T2-weighted MRI using DWI and dynamic contrast-enhanced 
MRI as described earlier (9). In short, all obtained MP-MRI imaging modalities were 
separately analyzed for CSRs according to the established criteria, (10) and in case 
of an equivocal suspicion of PCa on any of the imaging modalities, the region was 
defined as a CSR delivering a high sensitivity reading. Importantly, DWI-derived 
b800 images (s/mm2) were used to delineate CSRs. A lesion was defined as a CSR 
on DWI in case of focal restriction on the conventional ADC map in combination 
with an isointense to hyperintense signal intensity on the b800 image. From every 
CSR, at least 1 real-time MRGB was obtained on a 3-T scanner (MAGNETOM Skyra; 
Siemens, Erlangen, Germany) in a separate session by a single radiologist (C.M.H.) 
with 3 years of experience in prostate MRGB according to local protocol; MP-MRI 
data obtained at the MRGB procedure was not used for determination of additional 
CSRs. All patients received antibiotic prophylaxis with ciprofloxacin (500 mg) twice a 
day for 3 days, which started on the day before the biopsy. Two radiologists (C.M.H., 
T.H.), with 3 and 6 years of experience in MRGB, determined CSR sampling accuracy 
in a blinded consensus reading of MRGB confirmation scans.
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Determination of ADC Characteristics
In a consensus reading by 2 observers (D.M.S., C.M.H.) who were blinded to patient 
and biopsy characteristics, regions of interest (ROIs), measuring 5 × 5 × 1 mm, were 
annotated on the MRGB procedure ADC maps according to needle position, (Fig. 1). 
In case of multiple MRGB cores of a single CSR, the 1 biopsy with the presence of 
PCa and/or the highest combined Gleason score upon histologic examination was 
used for the ROI analysis. In case of a cancer-negative MRGB, the 1 biopsy with the 
most adequate position in the CSR was used for further ROI analysis. A contralateral 
normal ROI was also annotated when appropriate; in case of a bilateral CSR, no 
contralateral normal ROI was annotated. For every ROI, the median ADC (mADC) 
was calculated and used for further analysis.
Pathology Review
All TRUS-guided biopsy results were centrally reviewed by a single pathologist with 
18 years of experience in uropathology (C.A.H.) using the International Society of 
Urological Pathology modified Gleason score classification (11). Identically, all biopsy 
cores obtained by MRGB were evaluated by the same pathologist in a separate 
session.
Statistics
Mann-Whitney U testing was performed to detect differences in PSA, PSA density, or 
number of positive TRUS-guided biopsy cores for patients with Gleason upgrading 
vs those without Gleason upgrading upon MRGB. The acquired ADC characteristics 
were used for analysis of all ROIs. For detecting the differences between CSRs and 
contralateral normal ROIs, the Wilcoxon signed ranks test was used. For detecting 
the differences between CSRs harboring low grade PCa vs those harboring high-
grade (Gleason 4 and/or 5 component) PCa, Mann-Whitney testing was performed. 
ROC analysis was used for determination of the area under the ROC curve for 
differentiation between CSRs containing PCa upon MRGB vs those failing to 
histologically diagnose PCa. Statistical analysis was performed using SPSS version 
19.0 (Statistical Package for Social Sciences, Chicago, IL). Level of significance was 
set at P < 0.05.
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Table 1. Multiparametric MRI and MRGB characteristics.
Pr
ot
oc
ol
Se
qu
en
ce
TR
, m
s
TE
, m
s
Fl
ip
 a
ng
le
, d
eg
re
es
Sl
ic
e 
th
ic
kn
es
s, 
m
m
Fi
el
d
of
 v
ie
w
,
m
m
 ´ 
m
m
M
at
rix
 s
iz
e
Vo
xe
l s
iz
e,
 
m
m
×
m
m
×
m
m
b-
va
lu
es
,
s/
m
m
2
Te
m
po
ra
l r
es
ol
ut
io
n,
s
Endorectal MP-MRI of the prostate
T2WI axial
(TSE)
4280 99 120 3.0 180×178 448´448 0.4×0.4×3.0 n.a. n.a.
coronal 3590 98 120 3.0 192´96 384×384 0.5×0.5×3.0 n.a. n.a.
sagittal 4290 98 120 3.0 192×134 384×384 0.5×0.5×3.0 n.a. n.a.
DWI SSEPI
Axial
2600 90 n.a. 3.0 204×204 136×136 1.5×1.5×3.0 0/50/500/
800
n.a.
DCE-MRI GE
Axial 3D
800 1.51 14 3.0 192×192 128×128 1.5×1.5×3.0 n.a. n.a.
DCE-MRI Spoiled GE
Axial 3D
36 1.4 10 3.0 192×19 128×128 1.5×1.5×3.0 n.a. 3.4
MRGB
T2WI TSE
Axial
3620 103 120 4.0 256×256 320×320 0.8×0.8´4.0 n.a. n.a.
DWI EPI
Axial
3300 60 n.a. 3.6 260×211 160×120 2.2×1.6×3.6 0/100/400/
800
n.a.
Balanced
SSFP
GE
Axial and
Sagittal
4.48 2.24 70 3.0 280×280 256×256 1.1×1.1×3.0 n.a. n.a.
DCE indicates dynamic contrast-enhanced; EPI, echo-planar imaging; GE: gradient echo; NA, not applicable; 
SSEPI, single-shot echo-planar imaging; SSFP, steady-state free precession; TE, time-to -echo; TR, time-to-
repetition; TSE, turbo-spin echo; T2WI, T2-weighted imaging; and 3D, 3-dimensional.
Table 2. Patient characteristics
All subjects (n=54) MRGB Gleason ≤3+3=6
or no PCa (n=48)
MRGB Gleason >3+3=6 
(n=6)
Mean PSA 6.2 (1.2-10.1) 6.3 (1.2-10.1) 6.2 (4.9-7.3)
Mean PSA-density 0.13 (0.02-0.28) 0.13 (0.02-0.28) 0.16 (0.09-0.19)
Mean number of positive 
TRUS-guided biopsy cores
1.4 (1-2) 1.3 (1-2) .5 (1-2)
Mean number of CSRs 
identified at MP-MRI
2.1 (0-4) 2.1 (0-4) 1.7 (1-2)
Mean number of PCa-
positive CSRs on MRGB
0.6 (0-2) 0.5 (0-1) 1.2 (1-2)
Mean number of MRGB 
cores taken
3.9 (0-6) 3.8 (0-6) 4.0 (3-5)
All values are expressed as mean (range).
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Figure 1. Case presentation. Images taken from a 62-year old patient with an initial PSA of 7.2 ng/
mL and a PSA-density of 0.11 ng/mL/mL. Digital rectal examination revealed no abnormalities 
(cT1c), with a Gleason 3+3=6 PCa in 2 out of 9 random TRUS-guided biopsies. Multiparametric 
MRI revealed a single CSR of which MRGB was performed confirming a Gleason 3+3=6 PCa at 
histopathology. Multiparametric MRI, including T2-weighted (A), dynamic contrast enhanced 
(B) and diffusion-weighted (C) MR images of the presented patient showing a discrete hypo-
intense lesion in the left peripheral zone upon T2-weighted imaging, corresponding to an area 
of hyperperfusion on dynamic contrast-enhanced imaging and hypo-intensity on the ADC-
map, defined as CSR. Conventional ADC map at MRGB (D) showing a hypo-intense lesion in 
the left peripheral zone corresponding to CSR on the pre-MRGB multiparametric MRI (dotted 
outline). MRGB of CSR as identified on multiparametric MRI (E). Apparent diffusion coefficient 
calculation of this specific CSR established a median ADC of 0.88 x 10-3 mm2/s, with a mADC of 
1.70 x 10-3 mm2/s for the contralateral ROI Pathological examination of the obtained MRGB cores 
confirmed a Gleason 3+3=6 PCa.
Results
We included 54 consecutive patients from November 2009 to September 2011 
according to the criteria for AS as stated in the Methods section. Median age in 
our cohort was 65.0 (interquartile range, 62.0-69.0), with a mean PSA of 6.2 ng/mL 
(SD, 1.85) and a mean PSA density of 0.13 ng/mL/mL (SD, 0.05). The number 
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of positive TRUS-guided biopsy cores was 1 in 35 participants, whereas 19 
participants showed PCa in 2 cores. We were able to identify at least 1 CSR in 53 
participants, with a median of 2 CSRs (range, 0-4) per patient, accounting for a 
total of 111 CSRs eligible for analysis. Of these, 7 CSRs were consequently excluded 
from the analysis because they were subject to inadequate tissue sampling by 
MRGB, as verified by the absence of prostate tissue on the final histopathologic 
examination or severe motion artifact rendering the obtained imaging not useful 
for analysis. From the remaining 104 CSRs, at least 1 MRGB was performed, with 
a median number of 2 cores taken from every CSR (range, 1-4) and a median 
number of 4 cores taken per patient (range, 0-6). In 5 CSRs, we were not able to 
identify a contralateral normal ROI.
Magnetic resonance-guided biopsy confirmed PCa in 29 of the 53 patients (54.7%) 
and 32 of 104 CSRs (30.8%), thus leaving 24 of the 53 patients (45.3%) with no 
histological evidence of disease upon MRGB after MP-MRI despite a histological 
diagnosis of PCa upon random TRUS-guided biopsies. Six patients had 1 CSR with a 
high-grade Gleason component (Gleason grade 4 and/or 5) upon MRGB, of which 
5 were upgraded to a Gleason 3 + 4 = 7 PCa and 1 had a Gleason 3 + 5 = 8 PCa. 
No statistically significant differences in PSA, PSA density, or number of positive 
TRUS-guided biopsy cores were recorded for the patients with Gleason upgrading 
vs those without Gleason upgrading upon MRGB (Table 2).
The mean mADC for all CSRs was 1.19×10-3 mm2/s (SD, 0.28) compared with a 
mean mADC of 1.43×10-3 mm2/s (SD, 0.29; P <0.001) for the contralateral normal 
ROIs. The mean mADC in a CSR positively sampled for PCa by MRGB was 1.04×10-3 
mm2/s (SD, 0.29), whereas the CSRs with no PCa upon MRGB displayed a mean 
mADC of 1.26×10-3 mm2/s (SD, 0.25; P < 0.001). A diagnostic accuracy of mADC for 
predicting the presence of PCa in a CSR sampled by MRGB with an area under 
the ROC curve of 0.73 was established (95% confidence interval, 0.61-0.84) (Fig. 2). 
Cancer-suspicious regions with a high-grade Gleason component upon MRGB 
displayed a mean mADC of 0.84×10-3 mm2/s (SD, 0.35) vs a mean mADC for the 
low-grade CSRs of 1.09×10-3 mm2/s (SD, 0.25; P < 0.05; Fig. 3).
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Figure 2. ROC-curve of mADC for discrimination between CSRs harbouring no PCa versus any 
PCa upon MRGB.
Figure 3. Box-plots of mADC for CSRs harbouring no, low-grade or high grade PCa.
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Discussion
In our presented series, we found mADC, as acquired from DWI, to significantly 
predict the presence of PCa when sampled by targeted MRGB in the lesions 
qualified as CSR upon MP-MRI. We therefore think that obtaining DWI within an MP-
MRI setting might be able to efficiently guide targeted biopsies in participants who 
are supposed to be fit for AS. In our cohort, MRGB was able to establish high-grade 
(Gleason 4 and/or 5 component) PCa not sampled by TRUS-guided biopsy in 6 of 
the 54 patients (11.1%), with CSRs harboring high-grade PCa displaying a significantly 
lower mADC compared with the low-grade CSRs. Because the progression rate in 
AS is likely to be dependent on the inclusion criteria used, we can only refer to 
the published short-term results of the PRIAS project, with 22% Gleason and/or 
volume upgrade at repeat biopsy (5). Interestingly, 10% of the patients in this series 
were subject to Gleason upgrade, which is more or less comparable with the 11.1% 
percentage we found in our current series. However, direct comparison between 
the 2 series is difficult because the progression rates within PRIAS are established 
at 1 year of follow-up and this might comprise a mix of true grade and/or volume 
progression as well as initial undergrading and/or understaging, whereas we 
performed restaging at inclusion, leaving true progression unlikely to occur in our 
presented cohort.
Stringent inclusion criteria for AS will lead to low secondary intervention rates, 
however, at the cost of greatly limiting the number of candidates for such 
protocols. On the other hand, liberal inclusion criteria for AS will reduce the 
number of patients considered not eligible for AS while harboring true low-risk PCa 
but consequently lead to substantial higher intervention rates during follow-up. 
In our opinion, the delicacy of this balance is largely determined by inadequate 
staging and grading tools used to identify candidates for AS. Therefore, controversy 
persists on adequate inclusion criteria used for such protocols (6,12). The use of 
Gleason grade as an inclusion parameter for AS is definitely hampered by the well-
known phenomenon of Gleason undergrading by TRUS-guided biopsies (13,14). 
This potentially leads to high ‘‘progression’’ rates during AS representing initial 
undergrading and/or understaging of PCa by TRUS-guided biopsies, which has 
been shown in up to 27.8% of candidates for AS undergoing radical prostatectomy 
(15-17). An interesting approach by Eggener et al (18) incorporated an immediate 
restaging biopsy round before inclusion in an AS protocol, showing a consequently 
low intervention rate of 9% at 2 years of follow-up in their cohort. Unfortunately, 
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they did not report separately on the results of this immediate restaging biopsy and 
it remains unknown how many patients were not included based upon upstaging 
at this second biopsy round. The importance of this issue is also underlined by 2 
recent series showing a 16% to 18% rate of Gleason upgrading after immediate 
repeat biopsy in an AS population (19,20).
Approaching the problem of Gleason undergrading by another set of TRUS-guided 
biopsies before inclusion in an AS protocol obviously has limitations of its own. 
Multiparametric magnetic resonance imaging of the prostate in combination with 
MRGB might be very well able to fill in this lacuna. T2-weighted MRI as a single 
entity has not been able to differentiate reliably between the low grade and 
high-grade PCas (21), whereas T2-weighted MRI combined with DWI in a radical 
prostatectomy correlated series has been shown to have good sensitivity and 
specificity for detecting clinical significant PCa, defined as a Gleason score of 6 or 
greater and a tumor diameter greater than 4 mm (22). The discriminatory value of 
ADC for the low-risk group vs the intermediate-risk/high-risk groups based upon 
PSA and TRUS-guided biopsy histopathology has been described (23). Apparent 
diffusion coefficient values have been established to correlate well with Gleason 
score in TRUS-guided biopsies (24,25) and, more importantly, radical prostatectomy 
specimens (26-28).
In addition, ADC has been shown to be able to predict Gleason score undergrading 
in patients with a Gleason grade 3 + 3 = 6 or less upon TRUS-guided biopsy (29) 
and did outperform TRUS-guided biopsy Gleason grade as a predictor of low-risk 
Gleason grade vs intermediate/high-risk Gleason grade upon radical prostatectomy 
(30), suggesting that DWI might be able to identify patients who are not correctly 
graded by TRUS-guided biopsy.
In an AS cohort, the proportion of very low-volume/low-grade PCa is likely to be 
high, which might lead to a high false-negative ratio of MP-MRI for predicting the 
presence of PCa upon MRGB. This was confirmed by the inability of MP-MRI and 
MRGB to detect PCa in 45.3% of patients in our series, thus failing to diagnose PCa 
in a substantial number of AS patients. Potentially, TRUS-biopsy artifacts upon MP-
MRI might have been contributing to the high rate of false-positive CSRs; however, 
in our experience, an interval of more than 4 weeks from TRUS-guided biopsies 
does not hamper PCa detection and should be able to limit biopsy artifacts. So 
far, the lack of follow-up in our described cohort does not elucidate whether the 
patients in whom the presence of PCa was not histologically confirmed after MP-
MRI and MRGB do harbor truly low-risk disease. If this holds true after a prolonged 
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follow-up, in our opinion, MP-MRI with MRGB remains the test of choice to confirm 
the low-risk character of PCa in participants eligible for AS and might even be used 
as a technique to identify patients who need to be subjected to further histological 
diagnosis in case of an elevated PSA. Published data on the performance of DWI 
in AS use progression at repeat biopsy and risk of definitive treatment during 
follow-up as outcome parameters and do not elaborate on the issue of incorrect 
risk stratification at inclusion in AS protocols. Using these outcomes within an AS 
cohort with a PSA less than 15 and a Gleason score of 7 or less, 1 group found ADC 
to be a significant predictor of both adverse repeat biopsy findings and progression 
to definitive curative treatment (8,31). However, the criteria used for AS in these 
series make inclusion of a larger proportion of high-grade PCa in comparison 
to our series likely, reflected by a high rate of adverse repeat biopsy findings of 
40% at 1 year. Most contemporary AS protocols use more strict inclusion criteria, 
possibly leaving the added value of ADC less impressive while evaluating a more 
true low-risk population upfront. We aimed to correlate the DWI features of the 
AS participants with histopathology obtained at inclusion. Magnetic resonance 
guided biopsy has been established to more accurately sample prostate cancer 
Gleason grade compared to TRUS-guided biopsies (32) and therefore seems to 
be a more appropriate method to determine histopathological Gleason grade 
in AS candidates who are not undergoing radical prostatectomy. For this reason, 
we chose to obtain histopathological verification of our CSRs by MRGB in every 
participant. In the present series, we showed that ADC is able to differentiate tumor-
bearing CSRs from noncancerous CSRs with reasonable accuracy and should thus 
be considered in any MRI protocol used for identification of CSRs and targeting of 
biopsies in AS candidates.
The main limitation of our series is the lack of follow-up, leaving unrevealed how 
patients who are confirmed to harbor low-risk PCa by MP-MRI and MRGB do fare. It 
is, at this point, impossible to determine whether these patients are at a lower risk for 
progression during follow-up. However, a substantial proportion of the participants 
were identified as participants who have incorrectly stratified low-risk prostate 
carcinoma and were referred for definitive curative treatment after the MP-MRI, 
including DWI, and MRGB. Another methodological limitation of our series might 
be that the ROIs defined as contralateral normal were not sampled histologically 
by MRGB to confirm their benign character and might thus be harboring foci 
of low-volume/low-grade cancer in some cases. However, mADC was found to 
be a significant predictor of high-grade PCa upon MRGB in all participants. The 
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use of DWI as a single measure to identify and grade PCa is limited by the wide 
variability of ADC values between and within patients, making the identification 
of a threshold for (high-grade) PCa impossible. For this reason, DWI should always 
be part of a MP-MRI setting in which histopathological verification of the identified 
CSRs should be obtained. Within such a framework, DWI is a very valuable tool to 
guide targeted biopsies.
We conclude that DWI is a promising tool for risk stratification in patients eligible 
for AS upon clinical and TRUS-guided biopsy criteria and may aid in identification 
and targeting biopsy of PCa to determine true Gleason grade and identify patients 
subject to Gleason undergrading. Further prospective evaluation of our MRPRIAS 
cohort will be needed to establish whether incorporation of MP-MRI and MRGB at 
inclusion does lower the risk for Gleason upgrade at repeat biopsy by better risk 
stratification. Future series will need to address the question whether DWI does 
outperform or can be used in conjunction with established clinical parameters, 
such as PSA density and number of cores positive for PCa, in predicting adverse 
repeat biopsy findings (33). Its equivalence to an immediate restaging TRUS-biopsy 
session or saturation template biopsy also remains unclear. Ongoing prospective 
inclusion in and evaluation of our cohort will continue to further establish the value 
of DWI in the selection and monitoring of patients on AS for low-risk PCa through 
a more adequate prediction of biopathological behavior.
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Key Findings
Multiparametric MR imaging and MR guided biopsy in prostate 
cancer diagnosis
The first aim of this thesis was to evaluate 3T multiparametric MR imaging and 
MR guided biopsy for prostate cancer diagnosis. One of the studies, which was 
performed to investigate this purpose, was a retrospective multi-reader study for 
detection and localization of transition zone prostate cancer (Chapter 3). In this 
study multiparametric MR imaging did not improve detection and localization 
accuracy for transition zone cancers compared to T2-weighted MR imaging alone. 
Multiparametric MR imaging generally increased sensitivity, while decreasing 
specificity for transition zone cancer diagnosis compared with T2-weighted MR 
imaging. A decrease in specificity, i.e. an increase in false positive results may have 
been caused by varying quantitative parameters due to varying cellular densities 
in benign prostatic hyperplasia on diffusion weighted MR imaging and due to 
hypervascularity in benign prostatic hyperplasia on dynamic contrast-enhanced 
MR imaging (1,2). T2-weighted MR imaging alone may have been subject to less 
false-positive results, as differentiation of transition zone cancer from benign 
prostatic hyperplasia is not based on quantitative parametric differences only, but 
merely on general anatomical characteristics and patterns of transition zone cancer 
which differ from those of benign prostatic hyperplasia. T2-weighted MR imaging 
findings should therefore outweigh other functional techniques for evaluation of 
the prostate transition zone.
In a retrospective analysis, we aimed to evaluate the diffusion weighted MR 
imaging apparent diffusion coefficient for differentiation of transition zone cancer 
from non-cancerous transition zone and from prostatitis and for differentiation of 
transition zone cancer Gleason grades (Chapter 4). MR guided biopsy specimens 
were used as a reference standard in this study. We found that, despite overlap, 
apparent diffusion coefficient values can differentiate transition zone cancer from 
non-cancerous transition zone and from a degree1, and most cases of a degree 2 
prostatitis. However, due to substantial overlap, the apparent diffusion coefficient 
has a moderate accuracy (AUC 0.62) to distinguish between different primary and 
secondary Gleason grade cancer subcategories and cannot be used to differentiate 
between non-cancerous transition zone and degrees 1 to 2 of prostatitis.
In a prospective study, MR guided biopsy prostate cancer detection rates were 
investigated in patients with an elevated prostate specific antigen and one or more 
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cancer-negative previous TRUS biopsy sessions (Chapter 5). MR guided biopsy had 
a detection rate of 41%, mainly for clinically significant cancers (87%), based on i.a. 
prostate cancer Gleason score. Accurate multiparametric MR imaging localization 
accuracy (72-91%)(3-5) explains these high prostate cancer detection rates 
compared with systematic TRUS biopsies (≤18%) (6,7). Furthermore, MR guided 
biopsy detection rates for clinically significant cancer may be higher compared to 
detection rates for cancers with Gleason grade 4-5 components (0-29.8%) in the 
second to fourth repeat TRUS biopsy session (8). The high proportion of clinically 
significant cancers may have been attained by MR guided biopsy targeting areas 
with the lowest apparent diffusion coefficient of a presumed cancer suspicious 
region, which may harbour the highest local Gleason grade component (9,10).
Conclusions:
• 3T multiparametric MR imaging, consisting of T2-weighted imaging, diffusion-
weighted imaging ADC maps (b-values, 50, 500, and 800 sec/mm2), and dynamic 
contrast-enhanced MR imaging may not improve TZ cancer detection and 
localization accuracy compared with T2-weighted imaging alone (Chapter 3).
• Despite overlap, median apparent diffusion coefficient values can differentiate 
transition zone cancer from non-cancerous transition zone and froma degree 
1 and most cases of a degree 2 prostatitis. However, due to substantial overlap, 
apparent diffusion coefficient values had a moderate accuracy to distinguish 
between different primary and secondary Gleason grade cancer subcategories 
and cannot be used to differentiate between non-cancerous transition zone and 
degrees 1 to 2 of prostatitis (Chapter 4).
• In patients with elevated prostate specific antigen and one or more negative 
random systematic TRUS biopsy sessions, MR guided biopsy had a prostate 
cancer detection rate of 41% for predominantly clinically significant cancers (87%) 
(Chapter 5).
Multiparametric MR imaging and MR guided biopsy in risk- 
stratification of prostate cancer patients
An accurate prostate cancer diagnosis implies more than accurate cancer detection 
only. The established Gleason score, stage, multifocality and volume are of prognostic 
importance for patient risk stratification (11-14). Therefore, a second aim in this thesis 
was to investigate combined 3T multiparametric MR imaging and MR guided biopsy 
for risk-stratification in prostate cancer patients. To this end, a study was performed in 
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which concordance with radical prostatectomy specimen highest Gleason grade was 
evaluated for MR guided biopsy specimens highest Gleason grade in comparison 
to random systematic TRUS biopsy specimen highest Gleason grade (Chapter 6). 
For radical prostatectomy specimens containing cancers with a highest Gleason 
grade 4 and/or 5, concordance for MR guided biopsy specimens was 95% (21/22) 
versus 54% for TRUS biopsy specimens ((25/46), p=0.001). These results reflect that 
the established prostate cancer diagnosis and its corresponding risk stratification is 
significantly more accurate for MR guided biopsies compared with TRUS biopsies.
In order to clinically apply the MR guided biopsy advantages of increased prostate 
cancer detection rates (Chapter 4) and accurate prediction of highest prostate 
cancer Gleason grade (Chapter 6), a prospective multicentre sub-study was started 
in the existing PRIAS (Prostate Cancer Research International: Active Surveillance) 
trial (Chapter 7) (15). Our purpose was to evaluate 3T multiparametric MR imaging 
and MR guided biopsy for early risk re-stratification of prostate cancer patients on 
active surveillance. Multiparametric MR imaging and MR guided biopsy risk re-
stratified an additional 24% at 3 and 10% of patients at 12 months of follow-up. 
Multiparametric MR imaging cancer suspicious region (CSR) PI-RADS scores ≤2 had 
a high negative predictive value (84% and 100%), while PI-RADS scores ≥4 had a 
high sensitivity (75% and 92%) for detection of prostate cancer and Gleason grade 
(GG) 4-5 prostate cancer at subsequent MR guided biopsy in patients on active 
surveillance. Therefore, multiparametric MR imaging and MR guided biopsy may 
contribute in early identification of active surveillance patients with Gleason grade 
4-5 cancers, while also selecting active surveillance suitable patients based on 
cancer-negative MR guided biopsy specimens. An important finding in the latter 
study is the high number (48%) of cancer-negative MR guided biopsies, mainly 
caused by false-positive MR imaging results due to prostatitis. These false positives, 
however, may be partly caused by the low threshold we applied for biopsy in 
this study. False-positive results underline the importance of histopathology 
confirmation in multiparametric MR imaging cancer suspicious regions in active 
surveillance patients. Lack of targeted biopsies of MR imaging cancer suspicious 
regions may explain the poor results for MR-imaging as a predictive tool in other 
active surveillance studies (16-19).
A possible limitation of this study was that it was not designed as a randomized 
clinical trial to compare random systematic TRUS biopsies and MR guided biopsies 
in two separate arms. However, this comparison is rather difficult as both imaging 
techniques are fairly different and need a different approach. TRUS biopsies are 
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performed randomly, as over 40% of prostate cancers are iso-echogenic (20). The 
performance of random systematic TRUS biopsy has led to studies, which estimated 
the odds of diagnosing (clinically significant) cancer using both clinical criteria and 
random systematic TRUS biopsy outcome (13,21). On the other hand, MR guided 
biopsies, which are targeted to the most aggressive area of a presumed cancer 
suspicious region, can predict cancer presence and Gleason score ((22) and Chapter 
6 this thesis). Therefore, comparing both diagnostic tools for prostate cancer risk re-
stratification is possible to the extent of the detected Gleason score, however not 
for tumour volume or multifocality criteria.
The design of the latter study (Chapter 7) was used to determine whether 
diffusion-weighted MR imaging apparent diffusion coefficient values can be used 
to differentiate (high Gleason grade 4-5) prostate cancer in patients on active 
surveillance for presumed low-risk prostate cancer (Chapter 8). Diffusion weighted 
MR imaging apparent diffusion coefficient maps were used to evaluate biopsied 
cancer suspicious regions, which were pre-defined on multiparametric MR imaging. 
Mean median apparent diffusion coefficient values differed significantly for cancer 
suspicious regions with (1.04x10-3 mm2/s (SD±0.29) versus cancer suspicious 
regions without prostate cancer (1.26x10-3 mm2/s (SD±0.25; p<0.001) and for cancer 
suspicious regions with (0.84x10-3 mm2/s (SD±0.35)) versus without a cancer with a 
Gleason grade 4-5 component (1.09x10-3 mm2/s (SD±0.25; p<0.05)). An area under 
the receiver operating characteristic curve (AUC) of 0.73 was established (95% CI: 
0.61-0.84) for predicting the presence of prostate cancer in a cancer suspicious 
region by the median apparent diffusion coefficient. This moderate accuracy may 
be caused by variation of the apparent diffusion coefficient due to low prostate 
cancer volume percentages in biopsy core specimens and therefore due to 
inclusion of non-cancerous tissue in cancer-containing cancer suspicious regions.
Conclusions:
• Diffusion weighted MR imaging guided biopsies significantly improve pre-
treatment patient risk stratification, as MR guided biopsy specimen highest 
Gleason grade shows high concordance with radical prostatectomy specimen 
highest Gleason grade (Chapter 6).
• Multiparametric MR imaging and MR guided biopsy may contribute in early 
identification of active surveillance patients with cancers containing a Gleason 
grade 4 and/or 5, while also selecting active surveillance suitable patients 
(Chapter 7).
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• As part of a multiparametric MR imaging exam, diffusion weighted MR imaging 
apparent diffusion coefficient values may contribute in predicting prostate 
cancer presence in cancer suspicious regions identified by multiparametric MR 
imaging in patients deemed eligible for active surveillance (Chapter 8).
Clinical implications
Recommendation
This thesis have shown that combined multiparametric MR imaging and MR 
guided biopsy, in addition to improved prostate cancer detection, also include 
an accurate patient risk stratification (Chapters 4 and 6). Therefore, in men with an 
elevated prostate specific antigen, application of multiparametric MR imaging 
and MR guided biopsy should be recommended at least after one cancer-
negative TRUS biopsy session. Men with diagnosed prostate cancer can also 
benefit from improved risk stratification by multiparametric MR imaging and MR 
guided biopsy. Examples are prostate cancer patients with a clinical suspicion 
of TRUS biopsy undersampling and patients with presumed low-risk prostate 
cancer.
Volume and Gleason grade
The concept that a high Gleason grade, regardless of the existence of multifocality 
or the volume of tumour, is most likely to determine clinical prognosis, is important 
for the clinical application of prostate multiparametric MR imaging and MR guided 
prostate biopsy (23). This concept is supported by studies that disagreed with the 
idea of the index lesion (based on largest tumour volume) Gleason score as the 
most important predictive parameter (24,25). High Gleason grades, which also can 
be situated in lower volume tumours present in addition to the index lesion, may 
determine patient outcome in multifocal prostate cancer.
If a high prostate cancer Gleason grade would be the most important prognostic 
factor, the implementation of multiparametric prostate MR imaging and MR guided 
biopsy would be supported, as this combination may accurately predict the highest 
Gleason grade compared to radical prostatectomy specimens (Chapter 6).
Conversely, cancers with a lower Gleason grade, sparse growth patterns and small 
volumes are less frequently detected by MR imaging (26,27). The latter could be 
advantageous in preventing overdiagnosis in prostate cancer screening.
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Improving the application of MR guided biopsies
Obstacles for the widespread clinical application of MR guided biopsy are availability 
of the procedure, expertise and equipment as well as a relatively long procedure 
time if more than one lesion needs to be targeted. Current research focuses on 
improving these issues: developments of needle guide tracking sequences shorten 
examination time by reducing the time needed for manual adaptation of the 
sequence settings after needle guider re-positioning (28). Furthermore, investigation 
of robots, which enable remote control of movements of the needle guider, will 
further reduce examination time by cancelling the time for the examiner to walk 
into the scanner room in order to manually re-position the needle guider (29).
The availability of MR guided prostate biopsy will be enhanced by MR imaging-
ultrasound fusion, in which MR images are registered to the ultrasound data (30,31). 
Subsequently, ultrasound biopsy can be guided to lesions, which are accurately 
localized on multiparametric MR imaging. Fusion techniques aim to combine the 
accuracy of the MR imaging examination with the practicality, availability and speed 
of an ultrasound examination. Accurate image segmentation and registration are 
major challenges in image fusion. When intra-procedural motion corrections will 
be possible and the error in the actual fusion accuracy of images will be below 
millimetre level (1.9 mm), MR-ultrasound fusion will be a promising technique (32).
Use in active surveillance
An important clinical implication for the incorporation of multiparametric MR 
imaging in active surveillance protocols is that it should be performed in 
combination with MR guided biopsies of MR imaging cancer suspicious regions. As 
we found a substantial number of false-positive imaging results in our application of 
MR imaging and MR guided biopsy in active surveillance, it is of major importance 
that histopathological proof of a cancer suspicious region is obtained before it is 
to be further followed using MR imaging. Not performing biopsy may lead to poor 
results for MR imaging in predicting active surveillance outcome, due to inclusion 
of false-positive cancer suspicious regions (16,18,33). Only when ample experience 
and scientific evidence on the application of MR imaging and MR guided biopsies 
in active surveillance has been acquired, thresholds for performing MR guided 
biopsy could be increased.
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Future research
Patient tailored MR imaging and MR guided biopsy
To further evaluate the role of MR guided biopsies for prostate cancer diagnosis, 
future studies, which compare MR guided biopsy detection rates in homogeneous 
patient populations with identical previous TRUS biopsy protocols and a comparable 
numbers of previous biopsy sessions, should be performed. Due to inhomogeneous 
patient populations in current studies, conclusions on when to use MR imaging and 
MR guided biopsies after a certain type and/or amount of TRUS biopsy sessions 
cannot be made (Chapter 5). Furthermore, the added value of MR imaging should 
be measured in nomograms or predictive models, which also include other clinical 
patient parameters like PSA, clinical stage and prostate volume. These latter study 
designs will clarify how multiparametric MR imaging and MR guided biopsy can 
contribute to prostate cancer diagnosis in a specific patient with clinical and/or 
histopathological parameters. Studies investigating patient-specific added value 
of multiparametric MR imaging and MR guided biopsy may also enable accurate 
evaluation of cost-effectiveness of MR imaging and MR guided biopsy for different 
clinical scenarios.
Validation and implementation of MR guided biopsy prostate 
cancer diagnosis
MR guided biopsy specimens could be envisioned as a future surrogate for radical 
prostatectomy specimens. This may certainly hold true given the current shift from 
radical treatments involving the whole prostate gland to active surveillance or focal 
image guided therapies (34). Since MR guided biopsy specimen histopathology is 
image guided and image confirmed, it allows for accurate correlation of MR image 
parameters to local histopathology. Other advantages are objectivity and accurate 
delineation in image annotation, which may reduce inter-observer variability and 
other biases in image-histopathology correlation (35).
However, clinical patient parameters, MR guided biopsy specimen outcome and 
MR guided biopsy maximal cancer core length need to be studied as combined 
predictors of clinically significant cancers in radical prostatectomy specimens. 
Results of these investigations are needed to obtain more knowledge on the 
prognostic value of MR guided biopsy specimen outcome for a specific patient 
case. This evidence is not only important in the clinical setting of active surveillance, 
but also for focal therapy.
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Our findings on the accurate prediction of radical prostatectomy highest Gleason 
grade by MR guided biopsy highest Gleason grade should be more extensively 
studied for their application in prostate cancer screening and active surveillance. One 
could hypothesize that a more accurate prostate cancer patient risk stratification by 
multiparametric MR imaging and MR guided biopsy may reduce prostate cancer 
overdiagnosis in screening and may decrease overtreatment by improved risk 
stratification of low-risk prostate cancer patients on active surveillance.
Active surveillance
In order to evaluate effects of multiparametric MR imaging and MR guided biopsy 
on secondary active surveillance progression and intervention rates, more follow-
up is needed. If multiparametric MR imaging and MR guided biopsy appear to 
reduce secondary progression rates, cost-effectiveness studies and quality of life 
studies warrant further investigation. Further follow-up of multiparametric MR 
imaging and MR guided biopsy in active surveillance (Chapter 7) will also allow 
for investigation of the added value of an endorectal coil and of MR imaging 
pelvic node and bone staging. Frequently used pre-treatment nomograms 
(http://nomograms.mskcc.org) predict probabilities for extracapsular extension 
ranging from 12-26% and for lymph node invasion ranging from 1.9-2.0% (for a 
clinical stage cT1c to a cT2a) in a 60-year old man with a PSA of 10 ng/mL and a 
Gleason score 3+3 cancer in 2 out of 10 cores (36,37). These probabilities mainly 
reflect the need for accurate evaluation of extracapsular extension of an MR 
imaging cancer suspicious region in incorrectly included intermediate- to high risk 
prostate cancer patients on active surveillance.
However, as the majority of active surveillance patients will not undergo surgery 
and the risk of lymph node invasion is small, it should be investigated whether an 
endorectal coil and pelvic node and bone evaluation can be safely omitted in MR 
imaging of active surveillance patients.
Computer-aided diagnosis
Prostate tissue characteristics form a limitation in multiparametric MR imaging 
prostate cancer diagnosis, especially for the transition zone.
The transition zone includes benign prostatic hyperplasia, in which both glandular 
and stromal cell proliferation can be present with large variations of tissue cellular 
density and image signal intensity. Due to this inhomogeneity, prostate cancer 
differentiation based on quantitative parameters only will be insufficient (1,38). Other 
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pitfalls in prostate cancer diagnosis, which are inherent to the prostate structure 
itself, are differentiation of benign conditions, like prostatitis, which, despite the 
application of multiparametric MR imaging, may still lead to false-positive results. 
Finally, the lower detection rates of lower Gleason grade (26) or sparsely growing 
prostate cancers (27) and the inter-patient and intra-patient variability of apparent 
diffusion coefficient values are other examples of prostate-tissue-related challenges 
(39). Computer-aided diagnosis holds future promise in helping the radiologist 
with these pitfalls by combining quantitative parameters with shape and pattern-
recognition characteristics in order to differentiate prostate cancer from various 
benign conditions (40,41). Especially for prostate cancer diagnosis in the transition 
zone, the added value computer aided diagnosis using pattern recognition 
combined with tissue characteristics and quantitative MR imaging parameters 
needs to be a future object of study.
Safeguarding quality: standardization and education
Finally, all results in this thesis were performed in a Prostate Cancer Center of 
Excellence with highly developed techniques and sophisticated software for 
simultaneous interpretation. MR imaging data were subsequently read by highly 
experienced radiologists. The results in this thesis can therefore only become 
widely clinically applicable when a uniform quality level of the MR imaging 
techniques and their interpretation can be guaranteed on a larger scale. Multicentre 
trials, investigating improvement and standardization of prostate MR imaging 
techniques, are needed (42,43). Uniformity of the quality level of the technique and 
its interpretation, education of radiologists (44) and development of supporting 
techniques (40,41) are important requirements for a more general application of 
prostate MR imaging.
Recently published guidelines containing protocols and instructions to provide a 
minimal quality level of multiparametric MR imaging of the prostate are a first step 
in this direction (45). Next to providing technical imaging recommendations, PI-
RADS criteria for structured image interpretation were presented (45). The PI-RADS 
criteria represent an important first step in standardization of multiparametric 
prostate MR imaging interpretation, however, future studies on validation, inter-
observer variation and reliability of PI-RADS warrant further investigation.
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Table 3 PI-RADS scoring system
Score Criteria
A1. T2WI for the peripheral zone (PZ)
1 Uniform high signal intensity (SI)
2 Linear, wedge shaped, or geographic areas of lower SI, usually not well demarcated
3 Intermediate appearances not in categories 1/2 or 4/5
4 Discrete, homogeneous low signal focus/mass confined to the prostate
5 Discrete, homogeneous low signal intensity focus with extra-capsular extension/invasive behaviour or mass effect on the capsule (bulging),
or broad (>1.5 cm) contact with the surface
A2. T2WI for the transition zone (TZ)
1 Heterogeneous TZ adenoma with well-defined margins: “organised chaos”
2 Areas of more homogeneous low SI, however well marginated, originating from the TZ/BPH
3 Intermediate appearances not in categories 1/2 or 4/5
4 Areas of more homogeneous low SI, ill defined: “erased charcoal sign”
5 Same as 4, but involving the anterior fibromuscular stroma or the anterior horn of the PZ, usually lenticular or water-drop shaped.
B. Diffusion weighted imaging (DWI)
1 No reduction in ADC compared with normal glandular tissue. No increase in SI on any high b-value image (≥b800)
2 Diffuse, hyper SI on ≥b800 image with low ADC; no focal features, however, linear, triangular or geographical features are allowed
3 Intermediate appearances not in categories 1/2 or 4/5
4 Focal area(s) of reduced ADC but iso-intense SI on high b-value images (≥b800)
5 Focal area/mass of hyper SI on the high b-value images (≥b800) with reduced ADC
C. Dynamic contrast enhanced (DCE)-MRI
1 Type 1 enhancement curve
2 Type 2 enhancement curve
3 Type 3 enhancement curve
+1 For focal enhancing lesion with curve type 2–3
+1 For asymmetric lesion or lesion at an unusual place with curve type 2–3
D1. Quantitative MRS for 1.5 T. Diagram references [50, 70]
Eur Radiol (2012) 22:746–757 753
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Figure 1. The PI-RADS scoring system for presence of clinically significant prostate cancer on 
multiparametric MR imaging as presented by Barentsz et al. European Radiology 2012.
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2. Individual lesions being given a (PI-RADS) score.
3. Maximum dimension of the largest abnormal lesion.
Reviews of the literature show that Likert-like five-grade
scoring systems are often used to evaluate mp-MRI of the
prostate [28, 72–76]. In keeping with this, a recent consen-
sus meeting of prostate cancer experts used the UCLA-
RAND appropriateness method and recommended that a
five-point scale be used for the PI-RADS scoring:
Score 1 0 Clinically significant disease is highly un-
likely to be present
Score 2 0 Clinically significant cancer is unlikely to be
present
Score 3 0 Clinically significant cancer is equivocal
Score 4 0 Clinically significant cancer is likely to be
present
Score 5 0 Clinically significant cancer is highly likely
to be present.
The criteria for assigning scores to lesions identified by
each technique are not yet generally accepted. The most
developed is the quantitative evaluation of 1H-MRSI [57,
76]. Based on consensus opinion and literature evidence the
ESUR experts propose to use the PI-RADS classification,
which is presented in Table 3. In this scoring system every
parameter: T2WI (PZ and TZ different description), DWI,
DCE-MRI and MRSI is scored on a five-point scale. Addi-
tionally, each lesion is given an overall score, to predict its
chance of being a clinically significant cancer.
Table 4 Scoring of extra-
prostatic disease Criteria Findings Score
Extra-capsular extension Abutment 1
Irregularity 3
Neurovascular bundle thickening 4
Bulge, loss of capsule 4
Measurable extra-capsular disease 5
Seminal vesicles Expansion 1
Low T2 signal 2
Filling in of angle 3
Enhancement and impeded diffusion 4
Distal sphincter Adjacent tumour 3
Effacement of low signal sphincter muscle 3
Abnormal enhancement extending into sphincter 4
Bladder neck Adjacent tumour 2
Loss of low T2 signal in bladder muscle 3
Abnormal enhancement extending into bladder neck 4
Table 3 (continued)
Score Criteria
D2. Qualitative magnetic resonance spectroscopic imaging (MRSI)
1 Citrate peak height exceeds choline peak height >2 times
2 Citrate peak height exceeds choline peak height times >1, <2 times
3 Choline peak height equals citrate peak height
4 Choline peak height exceeds citrate peak height >1, <2 times
5 Choline peak height exceeds citrate peak height >2 times
In qualitative analysis, the relative peak heights of citrate and choline are visually compared (pattern analysis), rather than quantified. The criteria
apply for 1.5: for at least three adjacent voxels
Score 1 0 Clinically significant disease is highly unlikely to be present
Score 2 0 Clinically significant cancer is unlikely to be present
Score 3 0 Clinically significant cancer is equivocal
Score 4 0 Clinically significant cancer is likely to be present
Score 5 0 Clinically significant cancer is highly likely to be present
754 Eur Radiol (2012) 22:746–757
Figure 1. The PI-RADS scoring system for presence of clinically significant prostate cancer on 
multiparametric MR imaging as presented by Barentsz et al. European Radiology 2012.
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Summary
3T multiparametric MR imaging and MR guided biopsy: 
prostate cancer diagnosis and risk-stratification
Current epidemiologic studies show a high prevalence of prostate cancers. Many 
patients have low-risk cancers and do not develop clinical symptoms during their 
lifetime. As the majority of prostate cancers behaves as a chronic disease rather 
than as a lethal cancer, diagnostic tools, which involve an accurate patient risk-
stratification as part of a prostate cancer diagnosis are required. This thesis aims 
to evaluate multiparametric MR imaging and MR guided biopsy in prostate cancer 
diagnosis and in risk-stratification.
Chapter 2 presents a literature review on state-of-the-art multiparametric MR 
imaging for detection, localization and staging of prostate cancer. A combination 
of T1-and T2-weighted MR imaging with diffusion weighted or dynamic contrast-
enhanced MR imaging was suggested as a minimal protocol requirement for 
multiparametric prostate MR imaging. Literature generally shows that addition of 
functional multiparametric MR imaging to T2-weighted MR imaging may improve 
prostate cancer localization and staging accuracy. However, as multiparametric MR 
imaging studies were often incomparable, their reported diagnostic accuracies 
were inconsistent. Therefore, based on available literature, no definite conclusions 
on the diagnostic accuracies of (combined) multiparametric MR imaging techniques 
for a particular clinical prostate cancer problem can be made. In order to improve 
quality, uniformity, reliability and clinical applicability, guidelines on optimal 
imaging protocols and combinations of multiparametric MR imaging techniques 
for different clinical prostate cancer indications are needed.
In chapter 3 a multi-reader study on 3T multiparametric MR imaging versus T2-
weighted MR imaging for detection and localization of transition zone prostate 
cancers is described. Twenty-eight patients with transition zone cancer with a 
volume >0.5 cm3 in their radical prostatectomy specimen and a pre-prostatectomy 
endorectal 3T multiparametric MR imaging were retrospectively selected from 
197 consecutively performed radical prostatectomy specimens between January 
2007 and August 2011. Subsequently, thirty-five patients without transition zone 
cancer were randomly selected as a control-group. Four radiologists scored 
transition zone cancer suspicion on T2-weighted MR imaging and on different 
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multiparametric MR imaging protocols on a 5-point-scale in 6 regions of interest. 
Transition zone cancer detection accuracy did not differ significantly between 
T2-weighted- and multiparametric MR imaging for all (68% vs. 66% respectively, 
p=0.85), for Gleason grade 4-5 (79% vs. 73-75%, p=0.13) and for Gleason grade 2-3 
transition zone cancers (66% vs. 62-65%, p= 0.47). In receiver operating characteristic 
analysis, multiparametric MR imaging (AUC 0.70-0.77) did not significantly improve 
T2-weighted MR imaging transition zone cancer localization accuracy (AUC 0.72, 
p>0.05). This study shows that 3T multiparametric MR imaging, consisting of T2-
weighted, low-b-value (<1000 s/mm2) diffusion weighted apparent diffusion 
coefficient maps and dynamic contrast-enhanced MR imaging may not improve 
transition zone cancer detection and localization accuracy compared to 3T T2-
weighted MR imaging alone.
The evaluation of the diffusion weighted magnetic resonance (MR) imaging 
apparent diffusion coefficient (ADC) for differentiation of transition zone cancer 
from non-cancerous transition zone and from prostatitis and for differentiation of 
transition zone cancer Gleason grade is discussed in chapter 4. In this retrospective 
study, we included 52 patients with 87 transition-zone-cancer-containing MR 
guided biopsy core specimens and 53 patients with 101 non-cancerous transition 
zone MR guided biopsy core specimens. MR guided specimen core histopathology 
was used as a reference standard for median ADC. Median ADC was measured in 
annotated regions of interest (ROIs) on biopsy sampling locations of MR guided 
biopsy confirmation scans. In a linear mixed model analysis mean mADC differed 
significantly for transition zone cancer versus non-cancerous transition zone 
without and with degree 1-2 prostatitis (p<0.0001-0.05). Exceptions were mixed 
primary and secondary GG cancers versus a degree 2 of prostatitis (P = 0.06-0.09). 
No significant differences were found between subcategories of primary and 
secondary GG cancers (P = 0.17-0.91) and between a degree 1 and 2 prostatitis 
and non-cancerous transition zone without prostatitis (P = 0.48-0.94). Areas under 
the receiver operating characteristic curve were 0.84 for mADC to differentiate 
transition zone cancer versus non-cancerous transition zone, 0.84 and 0.56 to 
differentiate prostatitis from transition zone cancer and from non-cancerous 
transition zone. mADC had an AUC of 0.62 to differentiate a primary Gleason grade 
4 versus 3 cancer.
Our findings suggest that mADC can differentiate transition zone cancer from 
non-cancerous transition zone and from a degree 1 and most cases of a degree 
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2 prostatitis. However, due to substantial overlap, mADC has a moderate accuracy 
to distinguish between different primary and secondary Gleason grade cancer 
subcategories and cannot be used to differentiate between non-cancerous 
transition zone and degrees 1 to 2 of prostatitis.
The study in chapter 5 describes MR guided biopsy prostate cancer detection 
rates in a large prospective population of patients with an elevated prostate 
specific antigen and one or more cancer-negative TRUS biopsy sessions. Between 
March 2008 and February 2011, 438 patients, with a prostatic antigen >4 ng/ml 
and at least one previous negative TRUS guided biopsy session, were included. In 
265 of these patients, MR guided prostate biopsy was performed. Prostate cancer 
detection rates were 25% for all 438 patients and 41% for the 265 patients, who 
also underwent MR guided prostate biopsy. The majority of detected cancers 
were clinically significant (87%). Results of this study show that in patients with an 
elevated prostate specific antigen and one or more cancer-negative TRUS biopsy 
sessions, MR guided biopsy has higher prostate cancer detection rates compared 
to those reported for repeat TRUS biopsy. Furthermore, MR guided biopsy mainly 
detects clinically significant prostate cancers.
In the study in chapter 6 concordance between highest Gleason grade in MR 
guided biopsies and the highest Gleason grade in the radical prostatectomy 
specimen was determined. These concordance rates were compared to similar 
concordance rates of Gleason grade for random systematic 10 core TRUS biopsies. 
Between August 2006 and April 2009, 98 out of a total of 123 specimens of radical 
prostatectomy patients were included based on a prostate cancer diagnosis upon 
pre-prostatectomy MR guided biopsy (n=34) or upon pre-prostatectomy random 
systematic TRUS biopsy (n=64). MR guided biopsy was targeted to the lowest 
apparent diffusion coefficient in cancer suspicious regions on diffusion weighted 
MR imaging. MR guided biopsy overall highest Gleason grade concordance with 
radical prostatectomy specimens was significantly higher compared to TRUS biopsy 
(respectively 88% versus 55%, p=0.001). For highest Gleason grade 3 MR guided 
biopsy versus TRUS biopsy concordance rates were 100% versus 94% (p=0.41), for a 
Gleason grade 4 and 5 results were 91% versus 46% (p=0.02) and 73% versus 30% 
(p=0.01), respectively. In conclusion, MR guided biopsies significantly improve risk-
stratification for prostate cancer patients compared with a separate cohort of TRUS 
biopsies.
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In chapter 7, earlier findings of high MR guided biopsy detection rates of clinically 
significant prostate cancer (chapter 4) and the high concordance rate of MR 
guided biopsy highest Gleason grade to radical prostatectomy specimen Gleason 
grade (chapter 6), were clinically applied in prostate cancer patients on active 
surveillance. In 4 hospitals participating in Prostate Cancer Research International: 
Active Surveillance (PRIAS), we initiated a side-study (MR-PRIAS) in 66 of 82 
consecutively and prospectively included patients. Our purpose was to evaluate 
3T multiparametric MR imaging and MR guided biopsy for early risk re-stratification 
of patients on active surveillance for low-risk prostate cancer. MR imaging of pelvic 
lymph nodes and bones, prostate multiparametric MR imaging and MR guided 
biopsy were performed within 3 months after prostate cancer diagnosis. Follow-
up comprised repeat multiparametric MR imaging of the prostate, MR guided 
biopsy and repeat TRUS biopsy at 12 months after diagnosis. Multiparametric MR 
imaging and MR guided biopsy risk re-stratified 24% at 3 and 10% of patients at 
12 months of follow-up in addition to TRUS biopsy. Risk re-stratification was based 
on histopathologically proven node/bone metastases and/or MR guided biopsy 
Gleason grade 4 and/or 5 and/or a stage ≥ pT3 (MR guided biopsy specimen with 
cancer invading (peri-prostatic) fat or seminal vesicles) and/or cancer multifocality 
(≥ 3 foci, Gleason score ≤3+3 and stage ≤ T2). TRUS biopsy risk re-stratification 
criteria were according to risk re-stratification criteria used in the PRIAS study. A 
cancer-negative MR guided biopsy specimen had a negative predictive value of 
79% for risk re-stratification at repeat examinations. Furthermore, multiparametric 
MR imaging cancer suspicious region (CSR) PI-RADS scores ≤2 had a high negative 
predictive value (84% and 100%), while PI-RADS scores ≥4 had a high sensitivity 
(75% and 92%) for detection of prostate cancer and Gleason grade (GG) 4-5 prostate 
cancer at subsequent MR guided biopsy in patients on active surveillance. These 
initial results indicate that multiparametric MR imaging and MR guided biopsy 
may contribute in early identification of active surveillance patients with Gleason 
grade 4-5 cancers, while also improving the selection of active surveillance suitable 
patients.
Using the research design of chapter 7, we aimed to determine whether diffusion-
weighted MR imaging apparent diffusion coefficient (ADC) values can be used 
to differentiate (high Gleason grade 4-5) prostate cancer in patients on active 
surveillance for low-risk prostate cancer. This study is discussed in chapter 8. In 54 
consecutive patients, cancer suspicious regions were identified on multiparametric 
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MR imaging at active surveillance inclusion. MR guided biopsy was performed in 
all cancer suspicious regions to obtain histopathological verification. Regions of 
interest were annotated on MR guided biopsy apparent diffusion coefficient maps 
according to needle position. Median apparent diffusion coefficient (mADC) of 
annotations was related to MR guided biopsy specimen outcome. Upon receiver 
operating characteristic analysis, mADC had an area under the curve of 0.73 for 
predicting prostate cancer presence in a cancer suspicious region. Mean mADC 
in cancer suspicious regions with prostate cancer was 1.04 x 10-3 mm2/s (standard 
deviation (SD) ±0.29), whereas the cancer suspicious regions with no prostate 
cancer displayed a mean mADC of 1.26 x 10-3 mm2/s (SD±0.25; p<0.001). Cancer 
suspicious regions with a high-grade Gleason component (Gleason grade 4-5) 
displayed a mean mADC of 0.84 x 10-3 mm2/s (SD±0.35) versus a mean mADC for 
low-grade cancer suspicious regions of 1.09 x 10-3 mm2/s (SD±0.25; p<0.05). Our 
results suggest that diffusion weighted imaging may be a promising technique 
for risk stratification in patients deemed eligible for active surveillance and may aid 
in identification and biopsy targeting of prostate cancer on multiparametric MR 
imaging.
Results of individual studies regarding the value of 3T multiparametric MR imaging 
and MR guided biopsy in prostate cancer diagnosis and risk-stratification are 
discussed in chapter 9. Based on the scientific evidence presented in this thesis, 
the following conclusions can be made:
• 3T MR imaging, consisting of T2-weighted imaging, diffusion-weighted imaging 
ADC maps (b-values, 50, 500, and 800 sec/mm2), and dynamic contrast-enhanced 
MR imaging may not improve TZ cancer detection and localization accuracy 
compared with T2-weighted imaging alone (Chapter 3).
• Despite overlap, median apparent diffusion coefficient values can differentiate 
transition zone cancer from non-cancerous transition zone and from a degree 
1 and most cases of a degree 2 prostatitis. However, due to substantial overlap, 
mADC has a moderate accuracy to distinguish between different primary 
and secondary Gleason grade cancer subcategories and cannot be used to 
differentiate between non-cancerous transition zone and degrees 1 to 2 of 
prostatitis. (Chapter 4).
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• In patients with elevated prostate specific antigen and one or more negative 
random systematic TRUS biopsy sessions, MR guided biopsy of multiparametric 
MR imaging cancer suspicious regions had a prostate cancer detection rate of 
41% for predominantly clinically significant cancers (87%) (Chapter 5).
• Diffusion weighted MR imaging directed MR guided biopsies significantly 
improve pre-treatment patient risk stratification, as MR guided biopsy specimen 
highest Gleason grade shows high concordance with radical prostatectomy 
specimen highest Gleason grade (Chapter 6).
• Multiparametric MR imaging and MR guided biopsy may contribute in early 
identification of incorrectly selected active surveillance patients with Gleason 
grade 4-5 cancers. Conversely, low Multiparametric MR imaging PI-RADS scores 
and cancer-negative MR guided biopsy specimens may improve selection of 
active surveillance suitable patients (Chapter 7).
• As part of a multiparametric MR imaging exam, diffusion weighted MR imaging 
apparent diffusion coefficient values may contribute in predicting prostate 
cancer presence in cancer suspicious regions identified by multiparametric MR 
imaging in patients deemed eligible for active surveillance (Chapter 8).
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Samenvatting
De waarde van 3T multiparametrische MRI en MR geleide biopten 
voor de diagnose en risico-stratificatie van prostaatkanker.
Hedendaagse epidemiologische studies tonen een hoge prevalentie van klinisch 
insignificante prostaatkankers. Veel patiënten bij wie de diagnose laag-risico 
prostaatkanker is gesteld zouden tijdens hun leven geen symptomen ontwikkeld 
hebben. Prostaatkanker is zich meer gaan gedragen als een chronische ziekte dan 
als een dodelijke kanker. Dit vraagt om diagnostische instrumenten, welke een 
nauwkeurige risico-stratificatie van de patiënt een onderdeel laten zijn van de 
diagnose. Dit proefschrift heeft als doel om de waarde van multiparametrische 
MRI en MR geleide biopsie te evalueren voor de diagnose risico-stratificatie van 
prostaatkanker.
In Hoofdstuk 2 wordt een overzicht van de literatuur gegeven over state-of-the-
art multiparametrische MRI voor de opsporing, de lokalisatie en de stadiëring van 
prostaatkanker. Dit literatuuroverzicht resulteerde in een combinatie van T1- en 
T2-gewogen MRI met diffusie-gewogen of contrast versterkende MRI als minimale 
vereiste binnen een protocol voor multiparametrische prostaat-MRI. In het algemeen 
laat de literatuur zien dat toevoegen van functionele multiparametrische MRI aan 
T2-gewogen MRI de nauwkeurigheid voor prostaatkanker lokalisatie en stadiëring 
kan verbeteren. Echter, omdat studies waarin multiparametrische MRI geëvalueerd 
werd vaak onvergelijkbaar waren, waren de door deze studies gerapporteerde 
diagnostische nauwkeurigheden inconsistent. Derhalve kunnen op basis van de 
huidige beschikbare literatuur geen definitieve conclusies getrokken worden 
met betrekking tot de diagnostische nauwkeurigheden van (gecombineerde) 
multiparametrische MRI technieken voor een specifieke klinische probleemstelling 
bij prostaatkanker. Om de kwaliteit, de uniformiteit, de betrouwbaarheid en de 
klinische toepasbaarheid te verbeteren zijn er richtlijnen nodig voor optimale 
protocollen en combinaties van multiparametrische MRI technieken voor diverse 
klinische prostaatkankerindicaties.
In hoofdstuk 3 wordt een multi-reader studie beschreven waarin 3 tesla 
multiparametrische MRI wordt vergeleken met T2-gewogen MRI voor de 
detectie en lokalisatie van transitiezonecarcinoom van de prostaat. Achtentwintig 
patiënten met transitiezonecarcinoom met een volume >0.5 cm3 in hun 
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radicale prostatectomie-preparaat en een 3T endorectale multiparametrische 
MRI voorafgaand aan hun radicale prostatectomie, werden retrospectief 
geselecteerd uit 197 opeenvolgende preparaten van uitgevoerde radicale 
prostatectomiëen tussen januari 2007 en augustus 2011. Vijfendertig patiënten 
zonder transitiezonecarcinoom werden vervolgens willekeurig geselecteerd als 
controlegroep. Vier radiologen scoorden T2-gewogen MRI en multiparametrische 
MRI op een 5-punts schaal in zes aandachtsgebieden. De nauwkeurigheid voor 
het opsporen van transitiezonecarcinoom verschilde niet significant tussen T2-
gewogen- en multiparametrische MRI voor alle transitiezonecarcinomen (68% vs. 
66% respectievelijk, p=0.85). Dit was ook het geval voor voor Gleason graad 4-5 
(79% vs. 73-75%, p=0.13) en voor Gleason graad 2-3 transitiezonecarcinomen (66% 
vs. 62-65%, p= 0.47). In een receiver operating characteristic analyse verbeterde 
multiparametrische MRI de lokalisatie nauwkeurigheid voor transitiezonecarcinoom 
niet significant ten opzichte van T2-gewogen MRI (AUC respectievelijk 0.70-0.77 
versus 0.72, p>0.05).
Deze studie laat zien dat 3 tesla multiparametrische MRI, bestaande uit T2-
gewogen, apparente diffusiecoëfficiënt weergaven van diffusiegewogen-MRI 
met lage b-waarde (<1000 s/mm2) en dynamische contrastversterkende MRI, 
de nauwkeurigheid voor opsporing en lokalisatie van transitiezonecarcinoom 
waarschijnlijk niet kan verbeteren in vergelijking met T2-gewogen MRI alleen.
In hoofdstuk 4 wordt de waarde van de apparente diffusie coëfficiënt (ADC) van 
diffusie-gewogen MRI besproken voor het onderscheiden van transitiezonekanker 
van carcinoomvrije transitiezone en van prostatitis en voor het onderscheiden van 
de verschillende Gleason graden in transitiezonekanker. In een retrospectieve studie 
werden 52 patiënten met 87 MR geleide biopsie cores met transitiezonecarcinoom 
en 53 patiënten met 101 cores in de transitiezone zonder carcinoom ingesloten. 
De histopathologische uitslagen van de MR geleide biopten dienden als 
gouden standaard voor de mediane ADC (mADC). De mADC werd gemeten in 
geannoteerde “regions of interest” (ROIs) op de controle-MRI-opnamen voor 
de naaldpositionering van MR geleide biopten, precies op de plek van het met 
MR geleide biopsie weggenomen weefsel. In een linear mixed model analyse 
verschilde de gemiddelde mADC significant voor transitiezonecarcinoom versus 
carcinoom-vrije transitiezone zonder en met een graad 1-2 prostatitis (p<0.0001-
0.05). Uitzonderingen waren prostaatkankers met verschilende Gleason graad 
componenten versus een graad 2 prostatitis (P=0.06-0.09). mADC verschilde niet 
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significant tussen de diverse subcategorieen van primaire en secundaire Gleason 
graad carcinomen (P=0.17-0.91) en tussen een graad 1-2 prostatitis en kanker-vrije 
transitiezone zonder prostatitis (P=0.48-0.94).
In een receiver operator characteristics analyse was de “area under the curve” (AUC) 
0.84 voor mADC om transitiezonecarcinoom te onderscheiden van kanker-vrije 
transitiezone. Voor het onderscheid van prostatitis van transitiezonecarcinoom 
en carcinoom-vrije transitiezone waren AUCs respectievelijk 0.84 en 0.56. Voor het 
onderscheiden van een primaire Gleason graad 4 versus 3 transitiezonecarcinoom 
op basis van mADC was de AUC waarde 0.62. Deze bevindingen suggereren dat 
men met behulp van mADC waarden transitiezonecarcinoom kan onderscheiden 
van carcinoom-vrije transitiezone en van een graad 1, en in de meeste gevallen 
ook van een graad 2 prostatitis. Echter, ten gevolge van substantiële overlap tussen 
mADC waarden, heeft mADC een matige nauwkeurigheid voor het onderscheid 
tussen de verschillende primaire en secundaire Gleason graad subcategorien, in 
geval van kanker, en kan mADC niet gebruikt worden om onderscheid te maken 
tussen carcinoom-vrije transitiezone en graad 1-2 prostatitis.
De studie in hoofdstuk 5 beschrijft prostaatkanker detectiepercentages van 3-tesla 
MR geleide biopsie in een grote prospectieve populatie van patiënten met een 
verhoogd PSA en een of meer kanker-negatieve transrectale echografische biopsie 
sessies. Tussen maart 2008 en februari 2011 werden 438 patiënten met een prostaat-
specifiek antigeen >4 ng/ml en tenminste één negatieve eerdere transrectale 
echografische biopsie sessie geincludeerd. Bij 265 van deze patiënten werd MR 
geleide biopsie van de prostaat uitgevoerd. Prostaatkanker detectie-percentages 
waren 25% voor alle 438 patiënten en 41% voor de 265 patiënten die ook MR geleide 
prostaatbiopten ondergingen. Het merendeel van de opgespoorde kankers was 
klinisch significant (87%). De uitkomsten van deze studie laten zien dat bij patiënten 
met een verhoogd prostaat-specifiek antigeen en een of meer kanker-negatieve 
transrectale echografische biopsie sessies, prostaatkanker-detectie percentages 
van MR geleide biopten hoger zijn in vergelijking met die van eerder beschreven 
herhaalde transrectale echografische biopten. Bovendien worden er met MR 
geleide biopsie voornamelijk klinisch significante prostaatkankers gevonden.
In de studie in hoofdstuk 6 werd de overeenstemming bepaald tussen de hoogste 
Gleason gradering in MR geleide biopten en de hoogste Gleason gradering in radicale 
prostatectomie preparaten. Deze overeenstemming werd vergeleken met eenzelfde 
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soort overeenstemming voor Gleason gradering van willekeurige systematische 
10 core transrectale echografische biopten. Van augustus 2006 tot en met april 
2009 werden 98 van een totaal van 123 preparaten van patiënten die een radicale 
prostatectomie hadden ondergaan geincludeerd op basis van een prostaatkanker 
diagnose in MR geleide biopten (n=34) of in willekeurige systematische transrectale 
biopten (n=64). MR geleide biopten werden gericht op de laagste apparente 
diffusie coëfficiënt waarde van de voor prostaatkanker verdachte gebieden op 
MRI. De algehele overeenstemming voor hoogste Gleason gradering met radicale 
prostatectomie preparaten was significant hoger voor MR geleide biopten in 
vergelijking met transrectale echografische biopten (respectievelijk 88% versus 55%, 
p=0.001). Voor een hoogste Gleason graad 3 waren overeenstemmingspercentages 
voor MR geleide versus transrectale echografische biopten 100% versus 94% (p=0.41), 
voor een Gleason graad 4 en 5 waren de uitkomsten respectievelijk 91% versus 
46% (p=0.02) en 73% versus 30% (p=0.01). Concluderend leidt het uitvoeren van 
MR geleide biopten tot een significante verbetering van de risico-stratificatie voor 
prostaatkanker-patiënten in vergelijking met transrectale echografische biopten.
In hoofdstuk 7 werden eerdere bevindingen van hogere detectierates van 
klinisch significant prostaatcarcinoom met MR geleide biopsie (hoofdstuk 4) en 
een hoge overeenkomst tussen de hoogste Gleason graad in MR geleiden biopten 
en de hoogste Gleason graad in radicale prostatectomie preparaten (hoofdstuk 
6) klinisch toegepast bij prostaatkankerpatiënten onder actieve observatie. 
Binnen 4 in Prostate Cancer Research International: Active Surveillance (PRIAS) 
participerende ziekenhuizen werd een sub-studie uitgevoerd (MR-PRIAS) bij 66 
van 82 opeenvolgende en prospectief geincludeerde patiënten. De doelstelling 
was het evalueren van 3T multiparametrische MRI en MR geleide biopsie voor 
vroege risico-her-stratificatie van patiënten onder actieve observatie voor laag 
risico prostaatcarcinoom. Multiparametrische MRI van het bekken en van de 
lokale prostaat en MR geleide biopsie werden uitgevoerd binnen 3 maanden na 
prostaatkanker diagnose. Follow-up bestond uit herhaling van multiparametrische 
MRI, MR geleide biopsie en herhaling van de transrectale echografische biopten 
12 maanden na prostaatkankerdiagnose. Multiparametrische MRI en MR geleide 
biopsie her-stratificeerden een additionele 24% van de patiënten op 3 maanden 
en 10% van de patiënten op 12 maanden follow-up in vergelijking met transrectale 
echografische biopten. Risico-re-stratificatie werd gebaseerd op histopathologisch 
bewezen klier- of bot-metastasen en/of een Gleason graad 4 en/of 5 in MR geleide 
CHAPTeR 10
218
biopten en/of een stadium ≥pT3 (MR geleide biopsie preparaat: carcinoom met 
invasie van (peri-prostatisch) vet en/of de zaadblaasjes) en/of kanker multifocaliteit 
(≥ 3 foci, Gleason score ≤3+3 en stadium ≤T2). Her-stratificatie criteria van transrectale 
echografische biopten waren conform de PRIAS studie. Een carcinoom-vrije MR 
geleide biopsie had een negatief voorspellende waarde van 79% voor risico-her-
stratificatie bij herhaal-onderzoeken. Bovendien hadden prostaatkanker-verdachte 
gebieden met een PI-RADS score ≤2 op multiparametrische MRI een hoge negatief 
voorspellende waarde (84% and 100%), terwijl prostaatkanker-verdachte gebieden 
met een PI-RADS score ≥4 op multiparametrische MRI een hoge sensitviteit hadden 
(75% and 92%) voor het opsporen van prostaatkanker en Gleason graad (GG) 4-5 
prostaatkanker bij MR geleide biopsie in patiënten onder actieve observatie. Deze 
initiële resultaten tonen aan dat multiparametrische MRI en MR geleide biopsie 
kunnen bijdragen aan vroege identificatie van patiënten, die met een Gleason 
graad 4-5 carcinoom ten onrechte actief worden geobserveerd. Tegelijkertijd kan 
er met behulp van MRI en MR geleide biopsie ook verdere selectie plaatsvinden 
van patiënten die in aanmerking komen voor actieve observatie.
Gebruik makende van het onderzoeksdesign van hoofdstuk 7, beoogden we 
te onderzoeken of apparente diffusiecoëfficiënt (ADC) waarden van diffusie-
gewogen MRI kunnen worden toegepast om prostaatcarcinoom (met een 
hoge Gleason gradering 4-5) te kunnen onderscheiden in patiënten onder 
actieve observatie voor laag-risico prostaatkanker. Deze studie wordt besproken 
in hoofdstuk 8. In 54 opeenvolgende patiënten werden voor prostaatkanker 
verdachte gebieden (CSR) geïdentificeerd op multiparametrische MRI, welke 
werd uitgevoerd ten tijde van inclusie in actieve observatie. Van al deze CSRs 
werd MR geleide biopsie uitgevoerd ter histopathologische verificatie. Op de ADC 
beelden van de MRI geleide biopten werden “regions of interest” geannoteerd 
overeenkomstig met de naaldpositie van het weggenomen weefsel. De mediaan 
van de ADC (mADC) in de annotaties werd gerelateerd aan de histopathologische 
uitkomst van de MR geleide biopsie. In een receiver operating characteristic 
analyse had mADC een AUC van 0.73 voor het voorspellen van prostaatkanker in 
een CSR. De gemiddelde mADC voor de CSRs met prostaatkanker was 1.04x10-3 
mm2/s (standaard deviatie (SD) ±0.29), terwijl de carcinoom-vrije CSRs een 
gemiddelde mADC van 1.26x10-3 mm2/s (SD±0.25; p<0.001) lieten zien. CSRs met 
een hoge Gleason graad (4 of 5 component) toonden een gemiddelde mADC 
van 0.84x10-3 mm2/s (SD±0.35) versus een gemiddelde mADC van 1.09x10-3 mm2/s 
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(SD±0.25; p<0.05) voor CSRs met laaggradige prostaatkanker. Onze resultaten 
suggereren dat diffusie-gewogen MRI een veelbelovende techniek zou kunnen 
zijn voor risico-stratificatie van patiënten die geschikt worden geacht voor actieve 
observatie. Daarnaast kan diffusie-gewogen MRI bijdragen tot de identificatie 
van en tot het gericht aanprikken van prostaatkanker op MRI bij patiënten onder 
actieve observatie.
In hoofdstuk 9 worden de resultaten van de verschillende studies naar 
multiparametrische MRI en MR geleide biopten voor de diagnose en 
risicostratificatie van prostaatkanker besproken. Op basis van de in dit proefschrift 
gepresenteerde wetenschappelijke artikelen kunnen de volgende conclusies 
worden getrokken:
• 3T multiparametrische MRI, bestaande uit T2-gewogen MRI, apparente 
diffusiecoëfficiënt waarden afgeleid van diffusie-gewogen MRI (b-waarden 
50, 500, and 800 sec/mm2) en dynamische contrast-versterkende MRI, laat in 
vergelijking met T2-gewogen MRI geen verbetering zien voor wat betreft de 
nauwkeurigheid voor de opsporing en lokalisatie van transitiezonecarcinomen 
(Hoofdstuk 3).
• Ondanks overlap kan op basis van mediaanwaarden van de apparente 
diffusiecoëfficiënt transitiezonecarcinoom worden onderscheiden van 
carcinoom-vrije transitiezone en van graad 1 en meestal ook van een graad 2 
prostatitis. Echter, ten gevolge van substantiële overlap tussen mADC waarden, 
heeft mADC een matige nauwkeurigheid voor het onderscheid tussen de 
verschillende primaire en secundaire Gleason graad subcategorien, in geval van 
kanker, en kan mADC niet gebruikt worden om onderscheid te maken tussen 
carcinoom-vrije transitiezone en graad 1-2 prostatitis. (Hoofdstuk 4).
• Voor patiënten met een verhoogd prostaat-specifiek antigeen en een of 
meerdere negatieve willekeurige systematische transrectale echografische biopt 
sessies had MRI geleide biopsie van voor prostaatkanker verdachte gebieden op 
multiparametrische MRI een detectie-rate van 41% voor voornamelijk klinisch 
significante prostaatkanker (87%) (Hoofdstuk 5).
• Voorafgaand aan behandeling verbeteren MRI geleide prostaatbiopten op basis 
van diffusie-gewogen MRI de risico-stratificatie van prostaatkanker-patiënten 
met prostaatkanker significant, doordat de hoogste Gleason graad in MR geleide 
biopsie-preparaten hoge correlatie heeft met de hoogste Gleason graad in 
radicale prostatectomie preparaten (Hoofdstuk 6).
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• Multiparametrische MRI en MR geleide biopsie kunnen bijdragen aan een vroege 
identificatie van patiënten met een Gleason graad 4-5 carcinoom, die ten onrechte 
actief worden geobserveerd. Omgekeerd kunnen lage PI-RADS scores op 
multiparametrische MRI en carcinoom-vrije MRI geleide biopten de selectie van 
voor actieve observatie geschikte patiënten mogelijk verbeteren (Hoofdstuk 7).
• Apparente diffusiecoëfficiënt waarden kunnen, als deel van een 
multiparametrische MRI onderzoek, bijdragen aan het voorspellen van de 
aanwezigheid van prostaatkanker in voor prostaatkanker verdachte gebieden, 
welke gedefinieerd worden door multiparametrische MRI in patiënten die 
geschikt werden bevonden voor actieve observatie (Hoofdstuk 8).
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Abstract
• Twee recente onderzoeken naar screening op prostaatkanker lieten tegenstrijdige 
effecten van screening op de sterfte aan prostaatkanker zien.
• De huidige screeningsmethode van PSA-bepaling in combinatie met transrectale 
echografische biopten leidt tot een hoog aantal fout-positieve uitslagen en 
overbehandeling.
• Er is behoefte aan een screeningstest die het aantal onnodige prostaatbiopten 
vermindert en die minder agressieve vormen van prostaatkanker onderscheidt 
van agressievere vormen.
• Multiparametrische MRI detecteert prostaatkanker met een hoge specificiteit  en 
geeft informatie over de agressiviteit. De combinatie van PSA en multiparametrische 
MRI bij 1,5 tesla blijkt een redelijk nauwkeurige screeningstest te zijn.
• Multiparametrische MRI komt vanwege de hoge kosten en de beperkte 
beschikbaarheid niet in aanmerking als initiële screeningstest, maar zou kunnen 
dienen als vervolgonderzoek bij een afwijkende uitslag van de PSA test.
• Met multiparametrische MRI als vervolgtest bij prostaatkankerscreening kan 
men gerichter biopteren, onnodige prostaatbiopten voorkomen en het 
prostaatcarcinoom beter karakteriseren.
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Recent werden resultaten gepubliceerd van de twee grootste internationale 
studies naar prostaatkankerscreening middels prostaatspecifiek antigeen (PSA). De 
‘European randomized study of screening for prostate cancer’ (ERSPC), de grootste 
studie (n= 182.160 patiënten), liet een sterftereductie zien van 20% (1). De ‘Prostate, 
lung, colorectal and ovarian cancer screening trial’ (PLCO) bij 76.693 patiënten liet 
geen effecten zien van PSA-screening op de sterfte aan prostaatcarcinoom (2). 
Ofschoon nu positieve effecten van screening zijn aangetoond is er nog steeds 
geen consensus over het nut van prostaatkankerscreening (3).
Zowel de European Association of Urology (EAU)(4) als de Nederlandse Vereniging 
voor Urologie (NVU) hebben gereageerd op de genoemde studies (www.nvu.nl, 
klik op het logo voor het standpunt van de NVU d.d. 18 maart 2009). In hun reacties 
uiten ze de behoefte aan ontwikkeling van methoden om de minder agressieve 
vormen van prostaatkanker, waarbij de kans op overlijden heel laag is, te kunnen 
herkennen.
De huidige screeningsmethoden bestaan uit een PSA bepaling met een 
lage specificiteit (circa 60% fout-positieven) in combinatie met transrectale 
echografische (TRUS) biopten (5). Deze combinatie leidt tot een hoog aantal fout-
positieve uitslagen en differentieert onvoldoende tussen klinisch significante en 
insignificante carcinomen, dat wil zeggen: carcinomen met een relatief lage kans op 
progressie (6). Bij de invoering van PSA-screening in combinatie met TRUS-biopten 
zullen patiënten zonder kanker onnodig worden gebiopteerd en zullen patiënten 
met klinisch insignificante carcinomen onnodig worden bestraald of geopereerd. 
Deze overbehandeling kan leiden tot onnodige complicaties als impotentie en 
incontinentie (7).
In de ERSPC-studie was ook sprake van overbehandeling: om te voorkomen dat 
1 patiënt overleed ten gevolge van prostaatcarcinoom, moesten 1410 mannen 
gescreend worden en 48 van hen ook behandeld (1). De onderzoekers gaven 
aan dat men overbehandeling kan voorkomen door laag-risico carcinomen 
of indolente carcinomen niet of niet direct te behandelen. Er is dus behoefte 
aan een additionele test met een hoge specificiteit, die in combinatie met 
de PSA-test onnodige prostaatbiopten kan voorkómen en waarmee men de 
agressieve prostaatcarcinomen beter kan onderscheiden van de niet-agressieve. 
Multiparametrische MRI is een techniek die mogelijk in deze behoefte zou kunnen 
voorzien. In dit artikel beschrijven wij de mogelijke rol van multiparametrische MRI 
bij een eventuele screening op prostaatkanker.
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Figuur 1. Anatomische T2-gewogen MRI van de prostaat (a), vervaardigd met een endorectale 
spoel (transversale opname). De perifere zone (P) van de prostaat heeft een hogere intensiteit 
en is homogener dan de transitiezone (T) en de centrale zone (hier plat gedrukt door de 
transitiezone). In de linker perifere zone is een gebied zichtbaar met een lagere intensiteit (C); 
dit gebied is sterk verdacht voor prostaatcarcinoom. Het breidt zich door het kapsel heen uit 
in de linker neurovasculaire bundel (neurovasculaire bundels: rood omcirkeld). (b) Dynamische 
contrastversterkte MRI-opname op dezelfde plaats als (a). Het gebied dat voor tumor verdacht 
is vertoont verhoogde aankleuring met een gadoliniumhoudend contrastmiddel.(c)‘Apparent 
diffusion coefficient (ADC) map’ op basis van een diffusiegewogen MRI-opname van dezelfde 
plaats als (a). Met deze techniek heeft het voor tumor verdachte gebied op de kleurschaal 
duidelijk een zeer lage ADC-waarde (geel in de verklarende tekening). De gebieden in de 
transitiezone met een verlaagde ADC-waarde zijn niet verdacht voor prostaatcarcinoom (blauw 
in de tekening).
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Figuur 2. MR-spectroscopie van de prostaat. Het middelste deel van de figuur is een 
transversale T2-gewogen MRI-opname van dezelfde plaats als figuur 1a. De blauwe voxel (dit 
is een driedimensionale volume-eenheid) is genomen uit een niet-afwijkend gebied van de 
prostaat. Het spectrogram (links) vertoont een lage choline-concentratie (pijl a) en een hoge 
citraat-concentratie (pijl b). De rode voxel is genomen uit een voor tumor verdacht gebied 
met een lage signaalintensiteit op de T2-gewogen opname. Het spectrogram hiervan (rechts) 
vertoont een hogere choline-concentratie (pijl a) en een lagere citraat-concentratie (pijl b), met 
verhoging van de (choline + creatine)/citraatratio. Dit wijst op prostaatkanker.
R L
Figuur 3. Transversale doorsnede van het prostatectomiepreparaat van dezelfde patiënt 
als in figuur 1. In de linker perifere zone is een witgrijs gebied (groen in de tekening). Bij 
histopathologisch onderzoek bleek zich hier prostaatcarcinoom te bevinden. De Gleason score 
was 9 en er was sprake van kapseldoorgroei.
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Multiparametrische MRI
Multiparametrische MRI is een combinatie van een anatomische T2-gewogen 
MRI (figuur 1a) met meerdere functionele MRI-technieken zoals dynamische 
contrastversterkende MRI (DCE-MRI, figuur 1b), diffusie-gewogen MRI (DWI, 
figuur 1c), en proton-MR-spectroscopie (MRSI, figuur 2). DWI is een functionele MRI 
techniek waarbij gedurende enkele tienden van milliseconden de bewegingen 
van watermoleculen per voxel afgebeeld weefsel worden vastgelegd. Uit diverse 
diffusiemetingen wordt beeldcontrast verkregen door de ‘apparent diffusion 
coëfficiënt’ (ADC) te berekenen, een kwantitatieve maat voor de diffusie in 
weefsel (8). Uit onderzoek blijkt dat prostaatkanker op diffusiegewogen MRI 
significant lagere ADC-waarden toont dan goedaardig prostaatweefsel (vergelijk 
figuur 1c en figuur 3) (9). Een tweede functionele MRI-techniek, DCE-MRI, berust 
op het principe dat prostaatcarcinoom met een intraveneus gadolinium-
houdend contrastmiddel sterker aankleurt dan gezond prostaatweefsel, door 
een toegenomen microvascularisatie en vasculaire permeabiliteit (zie figuur 1b) 
(10). MRSI, een derde functionele MRI-techniek, geeft kwantitatieve informatie 
over de concentraties van citraat, creatinine en choline in het prostaatweefsel. In 
gebieden die prostaatkanker bevatten is de verhouding (choline + creatinine)/
citraat toegenomen (vergelijk figuur 2 en figuur 3) (11).
Onderzoek naar MRI bij screening op prostaatcarcinoom
In diverse studies is de combinatie van anatomische T2-gewogen MRI met 
functionele MRI-technieken onderzocht bij patiënten met een verhoogde PSA 
waarde. Het grootste recente screeningsonderzoek omvatte 225 patiënten 
(gemiddelde PSA concentratie: 11,5 ng/ml; uitersten: 0,4-133 ng/ml), die een T2-
gewogen MRI (1,5 tesla) in combinatie met MRSI ondergingen. Hiervan was de 
sensitiviteit voor de detectie van prostaatcarcinoom 72%, met bij een hoge 
specificiteit (93%) (12).
Andere studies waarbij anatomische MRI werd gecombineerd met functionele 
MRI-technieken, zoals DCE-MRI, MRSI of DWI(13,14,15,16), gaven betere resultaten 
dan alleen T2-gewogen MRI (tabel) (17,18). Voor de combinatie van T2-gewogen 
MRI met functionele MRI-technieken was de sensitiviteit 72-95%, de specificiteit 
74-93% en de ‘area under the curve’ (AUC), een maat voor het diagnostisch 
onderscheidingsvermogen, 0,71-0,86. Als alleen T2-gewogen MRI werd gebruikt, 
was de sensitiviteit 55-83%, de specificiteit 54-94% en de AUC-waarde 0,67-0,80.
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Combinatie PSA-bepaling en multiparametrische MRI
Multiparametrische MRI is niet geschikt als een eerste screeningstest, omdat 
deze techniek tijdrovend, te duur en niet overal beschikbaar is. Deze techniek 
zou prostaatkankerscreening wel kunnen ondersteunen als vervolgonderzoek bij 
patiënten met een verhoogde PSA waarde. Voordat een test als screeningsmethode 
kan worden ingevoerd, dient deze te voldoen aan de criteria van Wilson en Jungner 
(19). Een screeningstest moet met name effectief en vervolgens ook kosteneffectief 
zijn. Voor de multiparametrische MRI bij patiënten met een verhoogde PSA waarde 
moet dit nog onderzocht worden.
Volgens statistische besluitvormingsanalyses zijn bij screening op prostaatcarcinoom 
onder meer lage kosten, een maximale specificiteit bij een goede sensitiviteit 
en een lage interobserver-variabiliteit belangrijke testeigenschappen (20). Uit 
het eerder genoemde onderzoek bleek dat de combinatie van PSA-bepaling 
en multiparametrische MRI een hoge specificiteit hebben als men dit als één 
screeningstest beschouwt. Voor zover ons bekend is er nog geen onderzoek 
gedaan naar de intra- en interobserver- variabiliteit bij multiparametrische MRI van 
de prostaat.
Andere diagnostische technieken
Voor de detectie van prostaatkanker zijn naast MRI ook echografische technieken 
beschikbaar, zoals contrastechografie (CTRUS) en elastografie. CTRUS verhoogt 
detectiepercentages voor prostaatkanker; hierbij zijn veel minder biopten 
nodig dan met conventionele echografie (21). Echter, CTRUS heeft een lagere 
sensitiviteit (71%) en specificiteit (50%) dan multiparametrische MRI (22). De 
resultaten van elastografie zijn nog controversieel. Bij een groep patiënten met 
een Gleason score van 7 of hoger (een graderingsschaal voor prostaatcarcinomen) 
scoorde elastografie redelijk, met een sensitiviteit van 75% en een specificiteit 
van 77% (23). Echter, in een gerandomiseerd gecontroleerd onderzoek gaf de 
combinatie van elastografie met TRUS geen verbetering van de detectie van 
prostaatcarcinoom (24).
Mogelijke toepassingen multiparametrische MRI
Karakterisering prostaatkanker bij screening
In de eerste twee screeningsrondes van de ERSPC-studie had 69% van de 
gedetecteerde prostaatcarcinomen een Gleason score kleiner dan 7 (25). 
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Deze carcinomen hebben een laag risico op progressie. Met MRI zou men de 
waarschijnlijkheid van de diagnose ‘insignificant prostaatcarcinoom’, gesteld op 
basis van de Gleason score en volumecriteria, 6 verder kunnen vergroten.
Een MRI geeft informatie over de agressiviteit van een tumor, op basis waarvan 
men gericht prostaatbiopten kan nemen. Gericht biopteren kan zowel door fusie 
van MRI- en TRUS-beelden als door directe MR-geleide biopsie (26). Zo kan men 
het gebied aanprikken dat het meest verdacht is voor prostaatcarcinoom. Dit leidt 
mogelijk tot hogere detectiepercentages en representatievere prostaatbiopten, 
wat zal resulteren in adequatere risicostratificatie en een optimale therapiekeuze 
(27). De resultaten van het onderzoek naar de rol van multiparametrische MRI bij 
het voorspellen van insignificante prostaatkanker zijn tot op heden beperkt. Wel 
heeft incorporatie van MRI- en MRSI-informatie in nomogrammen het voorspellend 
vermogen voor insignificante prostaatkanker verbeterd (28). Overigens lijkt MRI 
insignificante tumoren minder goed te detecteren dan significante tumoren met 
een hogere Gleason score (29).
Door de heterogeniteit en de onregelmatige begrenzing van de tumoren geeft 
MRI geen nauwkeurige schatting van het prostaatkankervolume, een mogelijke 
maat voor de agressiviteit (30). Verder is onderzoek gedaan naar het verband 
tussen Gleason scores enerzijds en de signaalintensiteit op T2-gewogen MRI, de 
ADC-waarde in DWI en de metabole ratio’s in MRSI anderzijds (31,32,33), maar een 
absoluut afkappunt voor deze MRI parameters per Gleason score heeft men nog 
niet gevonden.
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Tabel 1. Overzicht van onderzoeken naar de detectie van prostaatcarcinoom met MRI (1,5 tesla) 
bij patiënten met een verhoogde PSA waarde
studie 
eerste auteur,
jaartal
Referentie-
test*
n PSA waarde 
in ng/ml; 
gemiddelde, 
tenzij anders 
aangegeven
techniek sensitiviteit
%
specificiteit
%
AUC
Langer, 200915 PR 25 5,0 (mediaan) T2, erc
DWI,erc
DCE,erc
-
-
-
-
-
-
0,673
0,689
0,592†
0,543‡
0,706§
Villeirs, 200812 TRUS of PR 225 11,5
uitersten: 0,4-
133.0
T2, erc
MSRI, erc
T2+MRSI
57
60
72
94
96
93
0,801
0,857
0,857
Tanimoto, 
200713
TRUS 83 ≥4,0 T2
T2+DWI
T2+DWI+DCE
73
84
95
54
85
74
-
-
-
Namimoto, 
199814
TRUS of PR 42 uitersten:
5-300
DCE
T2+DCE
79
82
-
-
-
-
Hara, 200516 TRUS 90 ≥ 2,5 DCE 76 83 -
Vilanova, 
200117
TRUS 81 4-10
10-20
4-20
T2, erc 55
83
70
80
65
76
-
-
-
Kubota,
200818||
TRUS 185 4,0-10,0 T2 79 59 -
PSA = prostaat specifiek antigeen; AUC = oppervlakte onder de ‘receiver operating characteristic’-curve, 
een waarde voor het diagnostisch onderscheidingsvermogen; PR = histopathologisch onderzoek van 
prostatectomie-preparaat; TRUS = histopathologisch onderzoek van een transrectaal prostaatbiopt, 
genomen onder geleide van echografie; T2 = anatomische T2-gewogen MRI; erc = met gebruikmaking 
van een endorectale coil om het MRI-signaal uit de prostaat op te vangen; DCE = dynamische 
contrastversterkende MRI; DWI = diffusiegewogen MRI; MRSI = proton-MR-spectroscopie; . = waarde niet 
bekend. *De referentietest is de gouden standaard aan de hand waarvan de sensitiviteit en specificiteit 
van de onderzochte test werd afgemeten. † AUC van Ktrans, een parameter van DCE-MRI. ‡ AUC van Ve, een 
parameter van DCE-MRI. § AUC van T2 + Ktrans (een parameter van DCE-MRI) + ADC, een parameter van DWI. 
|| Patiënten werden in dit onderzoek geïncludeerd voorafgaand aan het uitvoeren van transrectale biopten.
Vervolgtest bij screening op prostaatkanker
De combinatie van een PSA-bepaling en multiparametrische MRI (bij 1,5 tesla) is 
redelijk nauwkeurig als screeningstest. Er zijn echter een beperkt aantal studies 
met multiparametrische MRI als screeningsmethode verricht. Bij de meeste 
hiervan gebruikte men een suboptimale gouden standaard voor de detectie van 
prostaatkanker, namelijk TRUS-biopten in plaats van een prostatectomie-preparaat. 
Daarom dient prostatectomie de standaard te zijn bij toekomstig onderzoek naar 
de waarde van MRI als vervolgtest bij patiënten met een verhoogde PSA-waarde.
Aspecten als interobserver-variabiliteit en kosteneffectiviteit zijn onvoldoende 
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onderzocht om MRI nu te kunnen inzetten bij screening. Het verband tussen 
parameters op MRI-beelden en de agressiviteit van prostaatkanker is nog niet 
duidelijk genoeg. Ook dit vraagt om nader onderzoek.
De klinische praktijk is nog niet geheel rijp voor toepassing van multiparametrische 
MRI bij screening omdat apparatuur, software en ervaren personeel daarvoor 
te beperkt beschikbaar zijn. Momenteel hebben slechts enkele centra ervaring 
met multiparametrische MRI van de prostaat bij een veldsterkte van 1,5 tesla. In 
Nederland kan momenteel alleen het Universitair Medisch Centrum (UMC) St. 
Radboud het volledige arsenaal van DCE-MRI, DWI en MRSI bij een veldsterkte van 
3 tesla uitvoeren, maar technisch gezien kan men met de meeste MRI apparaten 
een goed multiparametrisch MRI onderzoek doen. Richtlijnen voor de uitvoering 
van functionele MRI bij verschillende specifieke klinische vraagstellingen zijn 
nog in ontwikkeling. Ook standaardisatie van de verslaglegging is belangrijk. Een 
MRI verslag is immers vrij subjectief, omdat de uitslag mede afhankelijk is van de 
ervaring van de radioloog.
Samengevat heeft multiparametrische MRI de volgende voordelen: gerichtere 
bioptering en vermindering van het aantal onnodige TRUS biopten, karakterisering 
van prostaatkanker en informatie over uitbreiding en stadiëring van de tumor. 
Hierdoor is een optimale therapiekeuze mogelijk. Echografie heeft het voordeel dat 
het beter beschikbaar is dan MRI en sneller een uitslag geeft, maar de sensitiviteit 
en specificiteit zijn lager dan die van multiparametrische MRI. Bovendien geeft 
echografisch onderzoek toegepast als screeningsmethode, geen bruikbare 
informatie over het stadium en de agressiviteit van prostaatkanker, in tegenstelling 
tot MRI.
Als uit de eindresultaten van de ERSPC- en de PLCO studie blijkt dat PSA-
screening effectief en kosteneffectief is, zou men multiparametrische MRI als 
een vervolgonderzoek op de screening kunnen overwegen. Deze techniek zou 
zowel het aantal onnodige TRUS biopten als de over- of onder-behandeling van 
prostaatkanker in gescreende populaties aanzienlijk kunnen beperken. Voordat 
MRI hiervoor kan worden ingezet dient men echter aspecten zoals prostaatkanker-
karakterisatie, kosteneffectiviteit en interobserver-variatie verder te onderzoeken.
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